National Cancer Institute

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Division of Extramural Activities

Annual Report 2005

1

2

3

4
A Vaccine To Prevent Cervical Cancer and 

Other Diseases Caused by HPV Infection

Research supported by the National Cancer Institute and other public sector agencies has shown that virtually all

cases of cervical cancer, which is the second most common cause of female deaths from cancer worldwide, are

attributable to persistent infection by a subset of human papillomaviruses (HPVs). The etiologic role of HPV implied

that an effective prophylactic vaccine might be able to prevent this disease and other benign and malignant conditions induced by HPV. The presence of viral oncogenes in HPVs and the difficulties associated with propagating

HPV suggested that a subunit vaccine approach would be preferred. The breakthrough observation in HPV 

vaccine development was that the viral L1 major capsid protein, when expressed in insect cells via a recombinant

baculovirus vector, could self-assemble into virus-like particles (VLPs) that morphologically resembled authentic 

virions and induced high titers of neutralizing antibodies, which are usually the cornerstones of prophylactic vaccines. In animal papillomavirus models, strong protection against viral challenge was induced by immunization with

L1 VLPs from the homologous virus, but not with denatured VLPs, which failed to induce neutralizing antibodies,

or with L1 VLPs of a heterologous virus. Immune IgG could transfer protection, further implicating neutralizing

antibodies as conferring protection. Human clinical trials indicated that L1 VLP vaccines were well tolerated and

conferred close to 100 percent protection, lasting at least 3.5 years, against persistent infection and disease

induced by the HPV types targeted by the vaccines. A commercial quadrivalent vaccine composed of L1 VLPs from

HPV6, 11, 16, and 18 (GardasilTM, manufactured by Merck) was licensed by the Food and Drug Administration

in 2006 for females 9–26 years old. HPV 16 and 18 account for about 70 percent of cervical cancer, but HPV6

and 11 account for about 90 percent of genital warts. Thus, the quadravalent vaccine has the potential to prevent a majority of cervical cancers, and an even higher proporton of genital warts. A bivalent commercial vaccine

composed of L1 VLPs from HPV16 and 18, which primarily targets cervical cancer and its precursors, is also in

phase III trials (CervarixTM, manufactured by GlaxoSmithKline). 

Cover Images: 1. Authentic bovine papillomavirus virions; 2. Bovine papillomavirus-like particles; 3. Human

papillomavirus-like particles; 4. 3-D reconstruction of cryo-electron micrograph of authentic papillomavirus virion

(blue) coated with neutralizing antibody (red). Images 1-3 courtesy of Drs. Doug Lowy and John Schiller, NCI.

Image 4 courtesy of Benes Trus, CIT, NIH, and Dr. John Schiller, NCI. Narrative: Courtesy of Dr. Doug Lowy, NCI.

References:

Kirnbauer R, Booy F, Cheng N, Lowy DR, and Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like 

particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-4.

Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, and Lowy DR.

Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV 

infection. J Virol 1995;69:3959-63. 

Suzich JA, Ghim S, Palmer-Hill FJ, White WI, Tamura JK, Bell J, Newsome JA, Jenson AB, and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA

1995;92:11553-7. 

Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad

FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci

L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, and Barr E. Prophylactic quadrivalent human papillomavirus

(types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre

phase II efficacy trial. Lancet Oncol 2005;6:271-8.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, and Barr E. Efficacy of

human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol

2006;107:18-27.

Harper DM, Franco EL, Wheeler C, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA,

and Dubin G. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types

16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
National Cancer Institute

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Division of Extramural Activities

Annual Report 2005

1

2

3

4
NCI/DEA Annual Report 2005

ii
Contents

Foreword .............................................................................................................................................v

Introduction ........................................................................................................................................1

Overview of the Division of Extramural Activities......................................................................................3

Special Activities in the Office of the Director, DEA ..................................................................................5

Program Coordination: A Resource for New Initiatives...............................................................................6

Grant Referral: A First Point of Contact for NCI Grantees and Applications..................................................7

Peer Review—The Next Step ..................................................................................................................9

Grant Funding Trends ..........................................................................................................................26

Supporting Peer-Review Consultants ......................................................................................................27

DEA’s Role in Advisory Activities...........................................................................................................29

Committee Management Activities ........................................................................................................33

Portfolio Tracking and Analysis .............................................................................................................35

Information Resources Management......................................................................................................37

Organizational Structure of the Division of Extramural Activities...............................................................40

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2005 Sorted by Date 

of Publication ....................................................................................................................53

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2005 Sorted 

by Division and Office ........................................................................................................53

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs), FY2005.................................54

Table 3a. Program Announcements (PAs) Published by the NCI in FY2005 Sorted by Date 

of Publication ....................................................................................................................54

Table 3b. Program Announcements (PAs) Published by the NCI in FY2005 Sorted 

by Division and Office ........................................................................................................55

Table 4. NCI Participation in Trans-NIH Program Announcements (PAs), FY2005 Sorted by

Date of Publication ............................................................................................................56

Table 5. Applications Received for Referral by the NCI/DEA (by Mechanism), FY2005............................57

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA 

(by Mechanism), FY2005....................................................................................................59

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs), 

FY2005............................................................................................................................61

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed for 

Each NCAB Meeting, FY2005.............................................................................................61

Table 9. Summary of Unsolicited P01 Applications Reviewed, Sorted by NCI Program Division, 

FY2005............................................................................................................................62

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA, FY2005 ......................................63

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA, FY2005 ........................................65

Table 12. Average Total Cost and Number of RPG† Awards by Division, 

FY2002-FY2005 ...............................................................................................................68

Table 13. Summary of NCI Grant Awards by Mechanism, FY2005.........................................................70

Table 14. NCI Special Interest Category (SIC) Dollars for FY2001-FY2005—Annual Percent Change ........73

Table 15. NCI Organ Site-Specific Dollars for FY2001-FY2005—Annual Percent Change ........................76

Table 16. Requests for Proposals (RFPs) Reviewed by NCI/DEA, in FY2005 ............................................78

Appendix A: Activities of the National Cancer Advisory Board ..............................................................80

Appendix B: Activities of the Board of Scientific Advisors.....................................................................82

Appendix C: List of Chartered Committees .........................................................................................85

Appendix D: NCI Initial Review Group Consultants ............................................................................103

Appendix E: NCI Grant Guidelines and Descriptions ..........................................................................147

Appendix F: Glossary of Acronyms .................................................................................................155

Appendix G: Cancer Information Sources on the Internet ...................................................................157

† Research Project Grant.

NCI/DEA Annual Report 2005

iii
NCI/DEA Annual Report 2005

iv
Foreword

Last year, for the first time since 1930 when collection of mortality 

statistics on cancer in the United States began, the number of cancer

deaths in the United States decreased. Though the decrease was 

modest, it was nevertheless an historic marker of our progress against

cancer. Years of dedicated intramural and extramural research sponsored by the National Cancer Institute (NCI) have greatly 

contributed to this progress. Such research has unearthed a combination of enhanced prevention strategies, earlier detection, and better

treatment once the disease has been diagnosed, which has led to the

first documented downturn in cancer deaths.

The NCI continues to promote and support such advances in research.

Our investment in scientists and their science through the peer review

system of individual grants allows for the flexibility and creativity that has yielded and will 

continue to yield great dividends. The Division of Extramural Activities (DEA) plays a crucial role

in supporting NCI’s goal of excellence in peer review. By coordinating the scientific review of 

extramural research prior to funding, and by providing systematic surveillance of that research after

awards are made, the DEA consistently provides the highest quality and most effective scientific peer

review and oversight of extramural research.

I offer my congratulations and gratitude to the many dedicated DEA staff that have contributed to

this annual report, as well as to the coordination of the extramural enterprise. 

John E. Niederhuber, M.D.

Director, National Cancer Institute

NCI/DEA Annual Report 2005

v
NCI/DEA Annual Report 2005

vi
Introduction

The Division of Extramural Activities (DEA) is centrally involved in establishing and disseminating

extramural policy and all aspects of grant development and tracking, from original conception of

research and training programs, to issuance of announcements of such programs, receipt and referral of incoming applications, review and final approval of the applications, coding and tracking

awards after disbursement of funds, and coordinating relevant advisory boards. In brief, the DEA

was established to:

Provide advice and guidance to potential and current applicants;

Coordinate and assist in the development and publication of extramural research funding initiatives;

Refer incoming grant applications to appropriate programs within the NCI;

Provide the highest quality and most effective scientific peer review and oversight of extramural grant and contract research;

Coordinate and administer advisory committee activities, such as the National Cancer Advisory

Board (NCAB) and Board of Scientific Advisors (BSA), as they relate to the various aspects of

the NCI mission;

Establish and disseminate extramural policies and procedures, such as requirements for inclusion of certain populations in research, actions for ensuring research integrity, budgetary limitations for grant applications, policies to expedite funding and changes to the application and

award processes; and

Track the NCI research portfolio (more than 7,000 research and training awards) using consistent, budget-linked scientific information to provide a basis for budget projections and to serve

as an NCI resource for the dissemination of information about cancer research.

In essence, the DEA is the organizational component of the NCI that coordinates the scientific and

merit review of extramural research by peer review groups and advisory boards before funding and

provides systematic surveillance of that research after awards are made. In this latter role, the DEA

assists the NCI in its goal of achieving a balanced portfolio of research in biology, behavior, epidemiology, and cancer control, prevention, detection, diagnosis, and treatment, as well as long-term survival/survivorship, rehabilitation, and end-of-life issues. In addition, the DEA serves as a focal point

for the development and dissemination of information about the NCI’s extramural policies. DEA

maintains a comprehensive Web site providing detailed information related to its overall responsibilities, such as grant and contract announcements for funding opportunities, application procedures,

portfolio overview, and advisory boards—see http://deainfo.nci.nih.gov/funding.htm.*†

This DEA annual report describes activities that occurred during Fiscal Year (FY) 2005 (October 1,

2004–September 30, 2005). Receipt, referral, and review of grant applications generally occur from

1 to 3 months prior to either January, May, or September NCAB meetings. Applications are therefore, normally reviewed in the fall, spring, or summer prior to a January, May, or September Board

meeting, respectively.

* See Appendix F for a glossary of acronyms used in this report. 

† A directory of Cancer Information Sources on the Internet, including selected DEA and NCI Web sites, is included in Appendix G.

NCI/DEA Annual Report 2005

1
NCI/DEA Annual Report 2005

2

Organizational Chart

Division of Extramural Activities

NCAB

BSA

Office of the Director

Director, Paulette S. Gray, Ph.D.

Deputy Director, Paulette S. Gray, Ph.D.

Assistant Director, Cedric W. Long, Ph.D.

Special Assistant to the Director, 

Patricia Marek, M.B.A.

Committee 

Management 

Office

Chief, Claire Harris

Office of Extramural Applications

Associate Director for Extramural Applications

Paulette S. Gray, Ph.D.

Applied Information Systems Branch

Chief, James W. Seach

Research Analysis and Evaluation Branch

Chief, Marilyn Gaston

Office of Referral, Review, and 

Program Coordination

Associate Director for Referral, Review, and

Program Coordination, Diane A. Bronzert

Research Programs Review Branch

Chief, Olivia T. Bartlett, Ph.D.

Resources and Training Review Branch

Chief, David Maslow, Ph.D.

Special Review and Logistics Branch

Chief, Kirt J. Vener, Ph.D.

Program Coordination and Referral Branch

Chief, Christopher L. Hatch, Ph.D.
NCI/DEA Annual Report 2005

3

Overview of the Division of Extramural Activities

An important part of DEA’s mission is to manage and coordinate the second level of review with the

National Cancer Advisory Board (NCAB) and the concept review of all new and reissued RFAs and

RFPs with the Board of Scientific Advisors (BSA) (see Appendixes A and B). In addition, the DEA

tracks new funding initiatives proposed by other NIH Institutes, Centers, and Federal agencies to

consider possible NCI participation. The success of this operation is dependent on the development

of clear Institute referral guidelines, also a DEA responsibility. Before the publication of an initiative, the DEA negotiates with the CSR, DEA review units, and other offices for the scheduling, timelines, and workloads. Concepts for PAs do not require BSA approval, but are considered instead by

the NCI Extramural Division Directors (EDD) Committee.

The Committee Management Office (CMO), an established NIH service center, provides oversight

of all NCI chartered advisory committee, working groups, task forces, chartered review groups, the

National Center for Complementary and Alternative Medicine Council, and a DHHS chartered advisory committee. The CMO ensures that the NCI and client Institutes operate within the appropriate

Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines. The CMO supports Institute staff by being readily available to provide guidance and assistance as needed.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, PAs, Notices, and RFPs, and, finally, through the peer

review of grant applications and contract proposals. The Office of Referral, Review, and Program

Coordination (ORRPC) with four branches was established within the DEA for coordination of

grant referral, for development and issuance of NCI program initiatives, and for the management of

review activities. Review activities include the organization and management of peer review for all

RFAs, research and development RFPs, and Program Announcements with Special Receipt (PARs)

using specialized research grant and cooperative agreement mechanisms. The program coordination

responsibilities of the DEA, in cooperation with NCI Extramural Program Divisions and Offices,

extend to the development of all new extramural program guidelines and funding opportunities. 

Another program coordination activity is the development and maintenance of referral guidelines for

assignment of grant applications to the NCI. These guidelines, included in the Referral Guidelines

for Funding Components of PHS, are critical to the development of program initiatives across the

NIH, as well as to the prompt referral of unsolicited grant applications to the NCI. These guidelines

differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas. 

The Research Analysis and Evaluation Branch works closely with the NCI Office of Budget and

Financial Management to provide budget linked portfolio data. In doing so, the Institute has the

capability of responding expeditiously to congressional and other inquiries. This Branch has historical budget linked portfolio data from the 1930s.
The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to staff, advisory groups, and

applicants. To facilitate this evaluation, the Office of Extramural Applications (OEA), through the

Applied Information Systems Branch (AISB) maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of

approved concepts, listings of active PAs and recently published RFAs, and policies related to the

clearance of new program initiatives. This information is provided in both public Internet

(http://deainfo.nci.nih.gov/funding.htm) and NCI limited-access Intranet versions.

NCI/DEA Annual Report 2005

4
NCI/DEA Annual Report 2005

5

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA

Office of the Director (OD) is a focal point and repository of information related to various funding

mechanisms for grants, staff and awardee responsibilities, eligibility requirements, receipt dates for

all granting mechanisms, and special programs. The OD is, for example, the coordinating center for

submission of applications for special NIH-wide awards, such as the James A. Shannon Director’s

Award, the Institutional Development Awards (IDeAs), and the Research Enhancement Awards

Program (REAP).

The DEA OD ensures that NCI meets the congressional mandate to promote increased participation

of women, children, and members of minority and medically underserved populations in the research

areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of

1993 mandates that women and members of minority groups be included as subjects in each research

project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect

to the health of the subject or the purpose of the research. Administrative procedures allow NCI staff

to resolve inclusion problems after initial review of applications that are otherwise highly meritorious. In the event that a grantee believes the proposed study does not warrant or require inclusion of

women or minority groups, he or she can apply for a waiver of this requirement. The DEA Director

has the authority to grant this waiver. In FY2005, 27 applications with preliminary bars to award

were received by the DEA. Through corrective action, all were brought into compliance before

award decisions were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies

concerning extramural research integrity and serves as a resource to all NCI staff with questions in

this area. In this role, the DEA OD works to address concerns about extramural research misconduct,

misuse of human and animal research subjects, financial mismanagement, and financial conflict of

interest involving NCI-supported research. Thus, the DEA Director functions as the NCI Research

Integrity Officer and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2005, eight cases of alleged research misconduct were opened by the Office of Research Integrity, DHHS, and referred to the Director, DEA.

Four cases were closed, and none of the cases were found to involve misconduct. The other cases

are open, pending resolution.
Program Coordination: A Resource for New Initiatives

As the NCI plans new strategic initiatives, the DEA performs critical functions for the NCI and its

“customers” by providing expert assistance to NCI program staff members as they work to develop

and publish funding opportunity announcements (FOAs) for scientific initiatives (also called

Requests for Applications [RFAs] and Program Announcements [PAs]). In providing this service,

members of the Program Coordination and Referral Branch (PCRB) work with the NCI program

directors to appropriately write, organize, format, and edit their FOAs. To maintain consistency and

completeness, all new NCI FOAs and guidelines are centrally edited and cleared through the DEA

before being forwarded to the NIH Office of Extramural Research for approval and publication in

the NIH Guide for Grants and Contracts. The services provided by the PCRB in preparing such

announcements materially ensure accuracy, clarity, quality control, and timeliness throughout the

development and publication processes. PCRB staff members also facilitate the dissemination of

operating policies and procedures pertaining to extramural programs.

Tables 1a and 1b show the variety of RFAs issued by the NCI in Fiscal Year (FY) 2005, and Table 2

lists RFAs issued by other NIH institutes or centers that the NCI has joined as a participating partner. Tables 3a and 3b show the variety of PAs issued by the NCI in FY 2005, and Table 4 lists PAs

issued by other NIH institutes or centers that the NCI has joined as a participating partner. 

In 2005, the NIH began the process of transitioning to the electronic (instead of paper-based) submission of grant applications through Grants.gov (http://www.grants.gov), which is the Federal

Government’s online grant application submission portal of the Federal Government. The DEA will

have the lead role in helping the NCI and its customers transition to the electronic submission of all

types of grant applications over a 2-year period (i.e., from October 2005 through October 2007).

During 2005, PCRB staff members were heavily involved in the reissuance of ongoing initiatives

and the development of FOAs to accept the first electronic submissions of conference grant (R13)

applications and the small business innovation research (SBIR) and small business technology transfer research (STTR) grant applications submitted in December 2005.

NCI/DEA Annual Report 2005

6
Grant Referral: A First Point of Contact for NCI Grantees 

and Applications

In Fiscal Year (FY) 2005, the NCI received more than 12,000 grant applications for referral (see

Table 5). These included applications for 50 different types of funding award mechanisms (see

Appendix E), including the Investigator-Initiated Research Project (R01), Career Development

Awards (K series), Research Program Project (P01), Cancer Center Support Grant (CCSG, P30),

Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03),

Exploratory/Developmental Project (R21); Phased Innovation Project (R21/R33); Small Business

Technology Transfer (STTR) Grant (R41/42), Small Business Innovation Research (SBIR) Grant

(R43/44), and U-series (Cooperative Agreements) mechanisms. The past 5 years have seen a significant increase in grant applications coming to the NCI for referral. The increase in all applications

has been 50 percent, while increases in R01, R21, and R03 have been 40 percent, 130 percent, and

103 percent, respectively (see Figure 1). 

NCI/DEA Annual Report 2005

7

12,185 12,848

11,144

9,346

8,544

6,276 5,655 5,783

5,078

4,469

2,089 1,961 1,532

909 1,017

228 230 287 419 463

0

800

1,600

2,400

3,200

4,000

4,800

5,600

6,400

7,200

8,000

8,800

9,600

10,400

11,200

12,000

12,800

13,600

2001 2002 2003 2004 2005

* All Applications Received and Referred by NCI

Total R01 Applications

Total R21 Applications

Total R03 Applications

Fiscal Year

Grant Applications Received and Referred

Figure 1. Receipt and Referral of NCI Applications*

FY2001–2005

* Includes NCI Primary applications received and referred.
All applications submitted to the National Institutes of Health (NIH) are assigned to an Institute or

Center (IC). The IC in turn has a structure in place to address internal assignments. Within the NCI,

DEA’s Program Coordination and Referral Branch (PCRB) is responsible for receipt, referral,

and assignment of applications, as well as for program (i.e., scientific initiative and funding opportunity) development functions. Upon receipt of primary and secondary assignments of applications

to the NCI by the NIH Center for Scientific Review (CSR), the PCRB Referral Officers (ROs): (1)

assign all incoming applications to one of the 45 NCI extramural research program areas; (2) track

program acceptance; and (3) whenever necessary, negotiate transfers of grant applications to and

from other NIH institutes and centers (and even other DHHS research funding agencies, such as the

Agency for Healthcare Research and Quality [AHRQ] and the Centers for Disease Control and

Prevention [CDC]). In 2005, PCRB referral staff members, in conjunction with program staff persons in virtually all of the NCI extramural research program areas, accomplished a complete revision and update of the NCI Internal Referral Guidelines.

The PCRB distributes all of the applications that are to be directly reviewed by peer review groups

managed by the DEA for the NCI. These applications include those for P01 Program Projects, P30

Cancer Centers, P20 Planning Grants, P50 Specialized Centers, R13 Conference Grants, R03 Small

Grants, certain R21/R33 Phased Innovation Grants, T32 Training Grants, certain R01 Research

Project Grants, and U-series Cooperative Agreement awards.

The PCRB is often the first point of contact for applicants. It is the receipt point for the recipient of

Letters of Intent (L01) from potential applicants for multiproject Program Grants (P01) and

Conference Grants (R13). It is also the information and coordinating center for the submission of

applications for the Academic Research Enhancement Award (AREA, R15) grants for research at

institutions and organizations that have little or no current NIH grant award support; applicants contact PCRB for information about the program at the NCI, their eligibility to apply, the relevance of

their proposed research to the missions of the various NCI programs, and the names and contact

information of NCI program staff members who might be interested in their research and able to

guide them in the application process.

The ROs serve as primary NCI contact persons for members of the extramural scientific community in need of information on a broad range of subjects, including application information (e.g.,

opportunities, mechanisms, policies, processes, procedures), new initiatives announced as RFAs or

PAs (i.e., FOAs), and the review process. In addition, the ROs assist members of the extramural community in navigating NIH and NCI Web pages to obtain current information, forms, and guidelines.

NCI/DEA Annual Report 2005

8
Peer Review—The Next Step

Once applications are referred to the NCI and the appropriate program, they must be reviewed. The

high caliber of NCI-sponsored research is maintained through peer review and a quality control

process in which experts in the field review and score applications and proposals for research. The

peer-review mechanism helps ensure that the NCI uses its resources wisely and funds research that

has the potential to make a significant contribution to science and medicine. The NCI’s extramural

programs and activities are funded primarily through peer-reviewed grants and cooperative agreements. Programs that are funded through research contracts are also subject to peer review, including contract-supported projects conducted within the intramural research program.

The dual peer-review system of the NIH consists of two sequential levels of review mandated by

statute. The first level of review of grant applications assigned to the NCI is performed by either an

NIH CSR study section, an NCI Initial Review Group (IRG) subcommittee, or NCI Special

Emphasis Panel (SEP) whose primary purpose is to review and evaluate the scientific merit of

research grant and cooperative agreement applications. The second level of review for program relevance is conducted by the National Cancer Advisory Board (NCAB).

Most investigators are familiar with the NIH CSR study sections, which have primary responsibility for managing the peer review of investigator-initiated Research Project (R01) grants and fellowships. It is less widely known, however, that grant applications representing more than 50 percent of

the NCI’s extramural budget are reviewed by chartered peer review groups that are directly formed

and managed within the NCI by the DEA. Peer review by either the CSR or the DEA is usually

decided by the choice of grant mechanism.

The NCI has no direct input into the selection of peer reviewers who serve on CSR study sections.

In contrast, members of the NCI IRG are selected by DEA review staff, with suggestions from program staff. All chartered DEA review subcommittee members are approved by the Director, NCI,

based on their knowledge of the various disciplines and fields related to cancer. There are nine NCI

IRG specialized review subcommittees; for example: Subcommittee A reviews Cancer Centers;

Subcommittee D reviews Clinical Program Projects; and Subcommittee H reviews Clinical

Cooperative Groups. (The current charter and membership of subcommittees may be found in

Appendix C and at the following Internet address: http://deainfo.nci.nih.gov/advisory/irg.htm.)

IRG members are appointed for varying terms of service, which may be up to 4 years. DEA SEPs

may be formed to review grant applications received in response to RFAs or Program

Announcements with Special Receipt (PARs) or other special applications. Members of such panels

are selected on a one-time, as-needed basis to review specific grant applications, cooperative agreement applications, or contract proposals. (Additional information about NCI SEPs can be accessed

at the following Internet address: http://deainfo.nci.nih.gov/advisory/sep.htm.)

Both the SEPs and the IRG advise the Director, NCI, on the scientific and technical merit of applications for research and research training grants, cooperative agreements, and contract proposals

relating to scientific areas relevant to cancer. Government-employed SRAs within the DEA manage

the scientific review of applications, including the selection of peer reviewers and the overall administration of the peer review process.

NCI/DEA Annual Report 2005

9
NCI/DEA Annual Report 2005

10

Fiscal Year

Grants & Contracts Reviewed

Figure 2. DEA Review Workload*

FY2001–2005

* Withdrawn applications are not included.

** There were 31 applications reviewed by the NCI for the NIAID.

2,903

1,884 1,956

3,347

2,505

1,316

1,918

1,177

1,425

1,234

925

436

395 269

690

471

392

143

78

420

0

250

500

750

1000

1250

1500

1750

2000

2250

2500

2750

3000

3250

3500

2001 2002 2003 2004 2005

DEA Grant and Contract Reviews**

PA/PAR Reviews

RFA Reviews**

DEA Contract Reviews

Review Workload

In FY2005, the DEA organized, managed, and reported the review of a total of 2,401 grant and 

cooperative agreement applications assigned to NCI, 31 applications reviewed by the NCI for

NIAID (see Table 6) and 471 NCI contract proposals (see Table 16). There were 444 fewer grant

and contract proposals reviewed in FY2005 as compared with FY2004 (see Figure 2). The FY2005

change may be attributed to a decrease in the number of new RFA initiatives and transfer of several

PARs involving imaging technology and SBIR/STTR applications to CSR for review (see Figure 5).

Although the number of grant applications decreased, the actual workload remained at a similar level

because of a doubling in complex multi-project applications (see Figure 3). Table 7 provides a summary of the applications reviewed by NCI IRG subcommittees and Special Emphasis Panels.

Twenty-four meetings of the NCI IRG subcommittees were convened to review and evaluate grant

applications of various types. In addition, there were 84 SEP meetings for review of grants or contracts, and 125 site visits (47 SEP and 78 IRG meetings). Approximately 2,000 reviewers served 

on either the parent IRG subcommittees or SEPs in FY2005 (see Appendixes C and D). Members

were selected because they are authorities in relevant fields of biomedical research or because they

represent informed consumer perspectives.
FY2005 Bypass Budget Goals and Initiatives*

Research Initiatives Bypass FOA†

A. Core Scientific Areas # of RFAs/PARs

1. Genes and the Environment none

2. Signatures of the Cancer Cell and Its Microenvironment 27/0

3. Molecular Targets of Prevention, Diagnosis and Treatment 29/0

4. Cancer Imaging and Molecular Sensing 6/1

B. Areas of Public Health Emphasis

5. Tobacco and Tobacco-Related Cancers none

6. Energy Balance 2/0

7. Quality of Cancer Care 4/0

8. Cancer-Related Health Disparities 10/0

9. Aging and Cancer 2/0

10. Cancer Survivorship 2/0

C. Platforms for Discovery, Development, and Delivery

11. Investigator-Initiated Research 14/1

12. Centers, Networks, and Consortia 7/0

13. Clinical Trials Program 8/4

D. Enablers of Discovery, Development, and Delivery

14. Bioinformatics 10/3

15. Communication 1/0

* See Tables 10 and 11 for RFA, PAR, and PA titles, respectively linked to the above Bypass Budget Initiatives. A single RFA may

include multiple bypass initiatives or research areas. For example, the National Cooperative Drug Discovery Groups for the

Treatment of Cancer (see Table 10) includes elements of four initiatives identified above: 3, 4, 12, and 13.

† Funding Opportunity Announcement.

NCI/DEA Annual Report 2005

11

Bypass Budget Goals and Initiatives

Each year, the NCI identifies several broad priority categories that serve as the framework for strategic planning and budget development. In 2005, those categories were integrated to more closely

align the research initiatives of the Institute with the mission of improving discovery, development,

and delivery of health care to cancer patients. To that end, the Institute has divided its initiatives into

four areas. These include: A. Core Scientific Areas; B. Areas of Public Health Emphasis; 

C. Platforms for Discovery, Development, and Delivery; and D. Enablers of Discovery,

Development, and Delivery. As shown below, in FY2005 the Bypass Budget Initiatives translated

into a variety of Funding Opportunity Announcements (FOAs), RFA, PA, or PAR initiatives, not

only for academic research centers, but also for the small business community. These initiatives represent new research opportunities and areas of special emphasis for investigators. See Tables 10 and

11 for the list of RFAs, PAs and PARs, number of applications reviewed by DEA in FY2005, and

those initiatives that were linked to specific Bypass Goals.
Highlights From Initiatives Reviewed by NCI in FY2005

Nanotechnology RFAs

During FY2005, the DEA coordinated the review of applications received in response to three

Requests for Applications in the area of nanotechnology. In November and December, 2004, the NCI

published RFAs for multidisciplinary U54 Centers of Cancer Nanotechnology Excellence, R01

Cancer Nanotechnology Platform Partnerships, and F32/F33 applications for Multidisciplinary

Career Development in Cancer Nanotechnology Research. Because of the complexity of the RFAs,

including specific eligibility and review criteria, DEA staff participated with NCI program staff in

the NCI Office of Technology and Industrial Relations, which issued the RFAs, in a pre-application

briefing for potential applicants. The briefing was held at the NIH Natcher Conference Center in

February 2005. See Table 10 for more information. 

The review of the Centers for Cancer Nanotechnology Excellence applications (28 U54 applications)

represented a unique peer review challenge due to the number and size of the applications, the

diverse nature and complexity of the proposed research, and the very compressed receipt and review

schedule. The applications averaged 600 pages in length and contained an average of seven projects

and six core resources; in total, there were more than 400 separate components to review. The large

number of potential assignments (approximately 900) necessitated the recruitment of 96 reviewers

with expertise in multiple scientific disciplines. An invaluable collaboration was established between

the Research Programs Review Branch and the Research Analysis and Evaluation Branch to facilitate the identification of potential reviewers with appropriate expertise and the planning of review

logistics. In addition, staff in the Special Review and Logistics Branch (SRLB) played a major role

in the development and implementation of several computer-based tools for identification of reviewer conflicts and assignment of reviewers. The review plan included coordination of teleconference

calls for orienting reviewers to the initiative-specific goals and review criteria and a separate teleconference to triage poor applications. The actual review meeting began with a joint session with the

entire panel to score one application for the purpose of standardizing scoring behavior among all

reviewers. The panel was then divided into two equivalent groups for concurrent review sessions for

the remaining 27 applications. 

Loan Repaymant Plan

Another highlight of DEA reviews for FY2005 includes the Loan Repayment Program (LRP). The

LRP is a Congressionally mandated program funded through the contract mechanism that is intended to forgive outstanding loan balances for clinician scientists who intend to pursue careers in general clinical or pediatric research. Contract proposals are submitted electronically to the NIH Loan

Repayment Office, which then sends the applications to the Center for Scientific Review for referral of the proposals to the individual Institutes. This initiative is unique in that all of the proposals

are submitted electronically and are classified as contracts. Instead of conducting a face-to-face

meeting to review these proposals, staff conducted a three-part virtual meeting in which assigned

reviewers submitted their evaluations electronically and those evaluations were then made available

to all reviewers, and the applications were scored electronically. A total of approximately 300 potential reviewers were contacted, and 145 actually served. As shown in Table 16 of the 471 proposals

reviewed, 276 proposals responded to the Clinical Research RFP and 85 proposals responded to the

Pediatric Research RFP. As a result of the review, 170 proposals were funded.

NCI/DEA Annual Report 2005

12
Early Detection Research Network

An important initiative for the NCI over the past several years has been the identification of 

biomarkers of cancer at its earliest stages so that treatment may be started early in the disease process to

maximize the possibility of a favorable outcome. The EDRN (Early Detection Research Network)

program was established in 1999 to lead the effort in identifying and testing new biomarkers. In

2005, DEA reviewed the following major initiatives as a part of this activity. As shown in Table 10,

these were: Early Detection Research Network: Clinical Epidemiology and Validation Centers

(CA-05-005); Early Detection Research Network: Biomarkers Reference Laboratories (CA-05-009);

Early Detection Research Network: Biomarkers Development Laboratories (CA-05-023); and Early

Detection Research Network: Data Management and Coordinating Center (CA-05-501). These four

initiatives, which involved the peer review of 71 applications, required the SRLB staff to contact

315 potential reviewers before 70 consultants finally agreed to participate in one of the four review

meetings. The NIH Director noted in his 2007 NIH Budget Request that the EDRN has identified a

number of biomarkers that allow for the earlier detection of breast, prostate, colon, lung, and other

cancers.

Cancer-Related Health Disparities Research

Cancer-related health disparities have been a major focus for the NCI. There are significant cultural, demographic, and other issues that continue to contribute to poor outcomes in minority cancer

patients. Thus, the NCI has emphasized this research area through eight RFA initiatives reviewed in

2005, each of which had a slightly different focus (see Table 10). The Comprehensive Minority

Institution/Cancer Center Partnership (CA-05-021) has been a very successful program in supporting collaborative research between minority institutions and established cancer centers. The

Planning Grant for Minority Institution/Cancer Center Collaboration (CA-05-020) and Cooperative

Planning Grant for Comprehensive Minority Institution/Cancer Center Partnership (CA-05-022) also

have provided funds to develop new collaborations and partnerships. Other initiatives relevant to

health disparities include: Community Networks to Reduce Cancer Disparities Through Education,

Research and Training (CA-05-012); Reducing Barriers to Effective Symptom Management and

Palliative Care (CA-05-013); Minority-Based Community Clinical Oncology Program (CA-05-015):

Patient Navigator Program (CA-05-019); and Breast Cancer Surveillance Consortium (CA-05-502).

In 2005, 165 reviewers ultimately participated in the review of 205 applications. In addition, a

Resources and Training Review Branch SRA served on the NCI Committee on Cancer Health

Disparities and also was on the Planning Committee for the Workshop entitled, “Enhancing

Interactions to Reduce Cancer Health Disparities.”

Trans NIH Initiatives

The NCI conducted the review of a major biodefense initiative, RFA-AI-04-45, for the establishment

of Centers for Medical Countermeasures Against Radiation (CMCR). Because of the historical relationship between the NCI and the study of radiation effects, NCI’s assistance (both program and

review) was solicited by the National Institute of Allergy and Infectious Diseases (NIAID), which is

the lead NIH Institute for support of bioterrorism-related research. In the summer and fall of 2005,

SRLB staff discussed the review approach to be used for these centers (the total cost maximum for

one application for 1 year is $5 million). Two SRAs were assigned the full-time task of managing

NCI/DEA Annual Report 2005

13
the review of these applications. Thirty-one multi-component center applications were submitted

that were composed of 149 research projects and 171 cores. The SRAs shared recruitment of the

panel, and split the responsibilities by dividing the application and panel members to conduct

reviewer assignments and mailing of the review materials. Due to the breadth of the science that was

submitted, 95 reviewers (including 10 mail reviewers) were recruited to perform the review. The

review plan included coordination of teleconference calls for orienting reviewers to the initiativespecific goals and review criteria. The review staff completed summary statements from the June

20-22, 2005, meeting in time for the NIAID Council meeting on August 8, 2005.

Peer Review Functions

The DEA Office of Referral, Review, and Program Coordination (ORRPC) is responsible for the

coordination and management of review of grants, cooperative agreements, and contracts for the

Institute, and it includes three review branches. The review branches are responsible for organizing,

managing, and reporting the scientific peer review of applications for a wide variety of grant mechanisms and topics. Reviews are conducted by one of the nine subcommittees of the NCI Initial

Review Group (IRG) or by specially convened Special Emphasis Panels (SEP) as shown in Table 7. 

Specifically, the Resources and Training Review Branch (RTRB) has primary responsibility for

review of applications for cancer centers, cancer training and career development, and cancer clinical trials, as well as for managing the corresponding six subcommittees of the NCI Initial Review

Group (IRG). The Research Programs Review Branch (RPRB) has primary responsibility for

review of unsolicited applications for program project grants (P01s), for Specialized Programs of

Research Excellence (SPOREs, P50s) in various organ sites, and for conference grants (R13s). The

RPRB also manages the three subcommittees of the NCI IRG that are responsible for review of program project grant applications and the NCI R13 Review Committee, which is composed of NCI

extramural scientific staff from all four program Divisions and the DEA. RTRB and RPRB are primarily responsible for the peer review of a variety of unsolicited multiproject and career development grant applications (see Table 6) and together manage the nine subcommittees of the NCI IRG

(see Appendix C). The Special Review and Logistics Branch (SRLB) organizes and manages peer

review primarily for grant applications in response to most of NCI’s specific RFAs, Program

Announcements with special receipt dates and involving Institute-managed review (PARs), and contract proposals submitted in response to Requests for Proposals (RFPs); all of these reviews are conducted by the Special Emphasis Panels (SEPs). Review units prepare the summary reports of the

evaluations and recommendations for each site visit or review committee meeting and distribute

these reports to program officials, the NIH data management system, and NCI’s Records

Management Center. Details of the summary statements also are provided to the NCAB, as required.

Each primary applicant receives a report in the form of the summary statement.

Many of the reviews conducted by the RPRB and the RTRB involve complex, multidisciplinary

applications. The review format for some of these applications, including the Cancer Center Support

Grants (P30), Cooperative Clinical Trials Grants (U10), and Program Project Grants (P01), involves

a two-tier review process. The first tier of the review involves either a site visit to the applicants’

NCI/DEA Annual Report 2005

14
NCI/DEA Annual Report 2005

15

institution, an applicant interview in the Washington, DC, area, or a teleconference by an expert

review panel; these review formats provide an opportunity for the reviewers to question the applicants directly to clarify issues in the application, thereby enhancing the review process. The review

panel members prepare a draft review report, which is then considered, along with the application,

by the relevant subcommittee of the NCI IRG. Six of the nine NCI subcommittees of the NCI IRG

serve as the “parent committees” for final scoring of applications after expert panel reviews:

Subcommittee A is the “parent committee” for Cancer Center Support Grant (P30) applications;

Subcommittees C, D, and E are the “parent committees” for Program Project (P01) grant applications; and Subcommittee H is the “parent committee” for review of Cooperative Clinical Trials (primarily U10) applications. The other four subcommittees of the NCI IRG, Subcommittees F, G, I, and

J, review all of the career development, training, education, and Population and Patient-Oriented

Training grant applications submitted to the NCI.

Applications Reviewed by NCI IRG and SEPs

During FY2005, the nine subcommittees of the NCI IRG reviewed a total of 824 applications using

33 different grant and cooperative agreement mechanisms with requests for a total of $528,360,392

in direct costs for the first year, and more than $2,699,012,741 for all years (see Tables 6 and 7).

The FY2005 IRG workload was very similar to the FY2004 workload (824 versus 830). In addition,

during FY2005 a variety of Special Emphasis Panels (SEPs) were responsible for reviewing a total

of 1,577 applications submitted in response to RFAs or applications otherwise unique to the NCI,

with requests for a total of $848,259,279 in direct costs for the first year, and $4,041,740,642 for all

years (see Table 7). This represented a 13 percent decrease in applications reviewed by SEPs compared to FY2004.

Research Programs Review Branch

Program Project Applications (P01)

A significant proportion of the effort of the RPRB during FY2005 was associated with the review of

unsolicited P01 applications. The SRAs in the RPRB organized and managed the review of 134 new,

recompeting, amended, and supplemental P01 applications (see Table 8), continuing the high level

of P01 workload that the NCI has seen since FY2002, as shown in Figure 3. Fifty percent of the

applications were amended. The 134 applications requested $303 million in total costs for the first

year (see Table 9). IRG Subcommittees C, D, and E reviewed 123 program project applications,

while 11 were reviewed by Special Emphasis Panels, due to IRG member conflicts. 

During FY2005, the RPRB continued the “cluster” review process, which was begun during 

FY 2004, for the first tier of review for P01 applications. In this review process, two to four P01

applications on closely related topics were reviewed together by one review panel with expertise in

all of the applications, rather than constituting a separate review panel for each individual application. The cluster review panel members met to discuss the applications and via teleconference asked

key questions of applicants prior to scoring each component of the application. 
NCI/DEA Annual Report 2005

16

During the summer of 2005, RPRB staff did a formal analysis of the P01 cluster review format. The

rationale for implementing the cluster review format during FY 2004 had been to reduce time and

effort required by reviewers and NCI staff for review of P01 applications, reduce the total number

of reviewers required, promote scoring consistency and spreading of scores, and reduce NCI costs

associated with P01 review. To determine if these goals were achieved, data from three NCAB

rounds involving cluster review (September 2004, January 2005, and May 2005) were compared to

data from the three NCAB rounds just prior to implementing the cluster review format (September

2003, January 2004, and May 2004), which had an individual review panel for each P01 application.

For the three cluster review rounds, there was a significant decrease in the total number of review

panels required (56 vs 125) as well as the number of reviewers on those review panels (969 vs 1398)

compared to the previous three review rounds. However, the number of reviewers assigned to each

application actually rose slightly, from 11 to 12 per application, due to “cross assignment” of reviewers on each cluster review panel to more than one application. The total number of reviewers at each

of the “parent” committee meetings also fell 14 percent, from 371 to 319, since fewer “reporters”

were required from each cluster review panel. A decrease in the number of review panels and number of reporters also resulted in an increase in the consistency of the review process for the P01 applications. There was also some broadening in the pattern of priority scores for P01 applications as a

result of the cluster review process, and a slight increase in the mean score.

134

122

135 131

94

21

28

49 49

30

63

40

65

72

5

25

45

65

85

105

125

145

165

185

2001 2002 2003 2004 2005

Total P01 Applications

Total SPORE (P50) Applications

Multi-project Applications (P50, P30, U19 & U54)** 

Fiscal Year

Number of Grant Applications

Figure 3. P01, P50 (SPORE) and Other Multi-Project Research Applications Reviewed* 

FY2001–2005

* Withdrawn applications are not included.

** There were 31 applications reviewed by the NCI for the NIAID.
NCI/DEA Annual Report 2005

17

Feedback was received from approximately 600 of the reviewers who participated in cluster review

panels during the September 2004, January 2005, and May 2005 NCAB review rounds. The reviewers indicated that there was a good match between their expertise and their review assignments, that

all necessary expertise was present on the cluster panels, that the grouping of the applications into

clusters according to science was appropriate, and that all applications received a complete, fair, and

appropriate review. Initial issues with the teleconference equipment and arrangements were

addressed by RPRB staff. Nevertheless, many reviewers felt that the cluster review process was

highly repetitive and that the teleconference with the applicants did not add significant value to the

review. 

Cost analysis showed that, despite inflation from 2004 to 2005, implementing cluster reviews for

P01 applications had saved the NCI approximately $220,000. Most of this savings was in the NCI

RMS budget, due to decreased NCI review and program staff travel. There was also a significant

decrease in costs for reviewer travel, honorarium and per diem, and a decrease in costs for teleconferences. The costs for reviewer lodging and for meeting rooms increased somewhat, since the

Washington, DC, metropolitan area is a high-cost area. 

Based on this analysis, NCI DEA reconvened the NCI P01 Working Group, which included representatives from the DEA and the four NCI extramural program Divisions, to make recommendations

on ways to further streamline P01 review. Although cost savings were not a driving force behind the

initial implementation of the cluster review format, NIH-wide changes in the way review costs are

managed were implemented October 1, 2005, which made cost savings more important. 

The NCI P01 Working Group endorsed continuation of cluster reviews for P01 applications, elimination of the teleconference with the applicants, and streamlined review (i.e., “triage” and unscoring) of very weak applications. The Working Group also recommended implementing a single tier,

“paper only” review process for P01 applications, similar to the review process that is used for P50

SPORE applications and applications received in response to Requests for Applications (RFAs), in

which 6 to 10 P01 applications in a broad topic area, such as molecular mechanisms of cancer, would

be reviewed together by one review panel. 

As FY 2005 drew to a close, the NCI Extramural Division Directors approved these recommendations, and RPRB P01 review staff began preparations to implement this new P01 review process. 

During FY2005, the RPRB also continued several other initiatives to improve review procedures for

program project applications, which included holding joint orientation sessions for new members of

the three P01 “parent” subcommittees and plenary sessions of all committee members. The plenary

session included exercises designed to help the reviewers establish consistent scoring calibration

standards that are applicable across the three committees, regardless of scientific discipline. The

outcome of the plenary session was more consistent review practices and scoring patterns across

the three subcommittees and, therefore, better information for NCI program staff to base funding

decisions for program project applications. 
NCI/DEA Annual Report 2005

18

Specialized Centers of Research Excellence (P50)

During FY2005, the RPRB also had responsibility for the peer review of the applications received

for the NCI Special Programs of Research Excellence (SPORE) program. These large, complex multidisciplinary P50 research center applications focus on translational research directly applicable to

human disease in various organ sites. During FY2005, the RPRB organized and managed Special

Emphasis Panels for the review of a total of 21 SPORE applications for research in Myeloma (1),

Genitourinary (3), Breast (12), Ovarian (2), and Gynecologic (3) cancer (see Figure 3). These 21

applications requested almost $38.4 million in direct costs for the first year of support and total direct

costs of more than $237 million for all years of support. As shown in Figure 3, the number of

SPORE applications reviewed by the RPRB continued to decrease in FY2005 as the SPORE program reached its target number of awards, and the NCI has implemented a new policy of receiving

applications for an organ site only when there will be competing renewals. The SRAs who organize

the SPORE reviews routinely conduct orientation conference calls with all of the reviewers before

the applications are sent to the reviewers to explain the special features of the SPORE program and

the special review criteria for SPORE applications. Two RPRB SRAs also were key participants,

with SPORE program staff in the NCI Organ Systems Branch, in planning and facilitating the annual SPORE Investigators Workshop. 

Conference Grants (R13)

During FY2005, the RPRB also continued to conduct the reviews for unsolicited R13 applications

to support a wide variety of scientific conferences. The Chief of the RPRB organized the review of

75 applications by the NCI R13 Review Committee, which is composed entirely of NCI extramural

staff. This committee uses an innovative “virtual review” format to accomplish an accelerated review

of the conference grant applications, so that conference organizers can plan more effectively.

Resources and Training Review Branch

The RTRB, which administers six NCI IRG subcommittees (A, F, G, H, I, and J), has the responsibility for review of applications for multidisciplinary cancer centers, cooperative clinical trials, institutional training and education, and career development awards. Staff members from this branch also

participate in the reviews of other funding mechanisms within the DEA. 

The reviews conducted by the subcommittees within RTRB are of two types. First, for the complex,

multidisciplinary applications, such as cancer center support grants (P30s) and multi-institutional

clinical trial cooperative group statistical center cooperative agreements (U10s), the review format

generally involves a two-step initial review. The first step of the review has involved a site visit to

the applicant institution. Each group of experts serves as a fact-finding body to clarify any issues or

information related to the application through discussion with the applicants. This first committee

prepares a draft report that is presented, together with the full application, for discussion, evaluation,

and final scoring by the appropriate parent subcommittee: NCI IRG Subcommittee A for cancer centers and Subcommittee H for clinical trials. Second, the U10 applications for support of the operational aspects of the clinical trial cooperative groups are reviewed by applicant interview at the parent subcommittee meeting, which eliminates a separate trip for reviewers and, thus, reduces the

reviewer burden. Scoring by a parent subcommittee provides for a more uniform evaluation of applications than scoring by individual review teams.
NCI Cancer Centers

Shortly after his appointment as NCI Director, Dr. von Eschenbach established a P30/P50 Working

Group composed of leaders of the cancer research community to study the P30 Cancer Center

Support Grant (CCSG) and the P50 SPORE award to determine how to continue supporting these

important methods for funding translational research in a more restricted budget environment. Based

on the final report presented to the NCAB in February 2003, new Guidelines were prepared with

considerable input from DEA staff, especially in those areas affecting application preparation and

peer review. They were approved in September 2004, and the first applications to be reviewed using

these new Guidelines were received in February 2005. The DEA prepared documents to assist

reviewers in the transition to the new Guidelines, including a list of major changes and a summary

of review criteria and their appropriate component for evaluation of consortia and partnerships.

RTRB review staff members instituted modifications of the review process, such as use of poster 

sessions for shared resource presentations, limited time for program presentations, staff selection of

protocols for review, and simplified review of budgets, which have reduced the burden on peer

reviewers. SRAs involved in CCSG review will continue to interact with staff of the Cancer Centers

Branch on the implementation of these new Guidelines and on the format to be used in future

Summary Statements. During FY2005, Subcommittee A reviewed 12 CCSG applications.

Training and Career Development

There was continued growth in the number of individual career development applications reviewed

by RTRB in FY2005 (see Figure 4) albeit at a slower rate. Between 2001 and 2004, the number of

career development applications reviewed in the DEA increased by 55 percent (339 to 525); in 2005

the number reviewed was 562, an increase of 7 percent for just that year. In contrast, the number of

institutional training grant applications, which had increased from 181 to 198 between 2001 and

2004 (9 percent), was 201 in 2005, an increase of 1 percent. The increases over the last 5 years are

due, in part, to the increased number of mechanisms available and to the increased information disseminated about them. Recently, several factors have led to a severe increase in the workload for

reviewers of training and career development applications. For example, reduced success rates have

increased the number of amended applications each round, increases in the number of basic scienceoriented applications, increases in applications proposing research in population and clinical areas, and

additional work from newly approved K99/R00 career development awards, all contributed to

increases in the review workload of the existing subcommittee. After discussions with the leadership

and staff of the Cancer Training Branch, a new subcommittee was created to share the review responsibilities in these disciplines. One subcommittee will review the K07 and K23 applications and those

K22 applications with clinical or prevention emphases, and the other subcommittee will review the

R25, K05, and K24 applications and the once-yearly submission of K12 applications. This distribution will be monitored over the first year to ensure an equitable division of review load across the

subcommittees. Because both subcommittees will have expertise in clinical and population research

areas, there should be no need to create SEPs to ensure fair reviews of applications that are in 

conflict with members on one of the subcommittees. The new Subcommittee J was officially 

chartered in July 2005, although it met as an SEP throughout 2005. 

NCI/DEA Annual Report 2005

19
Clinical Cooperative Groups

The SRA for Subcommittee H (Clinical Cooperative Groups) continues to work closely with the staff

of the Clinical Investigations Branch of the NCI Clinical Trials Evaluation Program (CTEP) to

update the Clinical Trials Cooperative Group Program Guidelines. This work is in the final stages

with the addition of the Clinical Trials Working Group (CTWG) initiatives. The SRA has started

work on the inclusion of the CTWG initiatives in the development of a Clinical Cooperative Groups

Grant Application Review Guide. The piloted new review format for the Clinical Cooperative

Groups has met with great success. Most of the site visits have been replaced by applicant interviews

at the parent subcommittee meeting. The new review format has gained approval of all of the

Cooperative Group Chairs and CTEP staff and is now considered to be the standard operating procedure. The new format has been written into the Draft Clinical Trials Cooperative Group Program

Guidelines. During FY2005, two competitive Clinical Cooperative Groups were reviewed and two

Clinical Cooperative Groups competed for supplemental funds to their Operations Office award. The

subcommittee also evaluated a large U24 cooperative resource, the International Breast Cancer

Study Group. The SRA for Subcommittee H has been actively involved in a cross-branch initiative,

DEA Checklist Working Group, to assess training workflow and efficiency between SRAs and

DEAS staff. The SRA for Subcommittee H also has been involved in a trans-NIH initiative, Peer

NCI/DEA Annual Report 2005

20

562

339

397

411

525

198 201

167 160 181

100

150

200

250

300

350

400

450

500

550

600

2001 2002 2003 2004 2005

Total CD Applications

Total T&E Applications

Fiscal Year

Number of Grant Applications

Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed*

FY2001–2005

CD mechanisms: K01, K05, K07, K08, K22, K23, K24, K25.

T&E mechanisms: R25, T32, K12.

* Withdrawn applications are not included.
Review JAD, to improve the IMPAC II Peer Review Module. In this capacity, she has assisted in

other review-related activities. She also has assisted the Research Programs Review Branch (RPRB)

in review activities during this time period.

Other RTRB Activities

To assist reviewers in preparing for their participation in peer review, Reviewer Guides were being

prepared for all of the application types reviewed by the RTRB. This was especially helpful for 

the subcommittees that evaluate training and career development grant applications, because each

subcommittee and most reviewers review several types of applications. The Reviewer Guides will

contain general information on peer review and NIH rules on use of human subjects, as well 

as specific instructions for each of the mechanisms to be reviewed by that subcommittee. These

mechanism-specific guides have been completed for all education, training, and career development

types of applications that are reviewed in the RTRB, and for the cancer centers and clinical group

applications that are evaluated by Subcommittees A and H.

Special Review and Logistics Branch

The SRLB has a prominent role in the outcome of NCI initiatives tied to the Bypass Budget indicated on page 11, since this branch organizes and manages peer review primarily for grant applications

submitted in response to specific NCI RFAs, contract proposals submitted in response to specific

Requests for Proposals (RFPs), and Program Announcements with special reviews (PARs). These

reviews are conducted with SEPs and involve recruiting the appropriate scientific expertise for each

review meeting. At the January, May, and September 2005 NCAB meetings, 22, 19, and 17 DEAreviewed initiatives directly related to the Bypass Budget were recommended for funding. Most of

the RFA initiatives were reviewed by SRLB staff.

Following approval by the NCI Executive Committee and BSA, program staff, assisted by the DEA

staff, prepare the initiatives for publication in the NIH Guide for Grants and Contracts.* In an RFA,

a specific, published dollar amount is set aside by the Institute, whereas for an Institute PAR

(Institute Reviewed Program Announcement), there is no dollar set-aside and no requirement for

BSA review. Table 10 lists the RFAs reviewed by DEA in FY2005. Table 11 represents those applications submitted in response to PAs or PARs, the review of which is shared by SRLB, RPRB, and

RTRB. In Tables 10 and 11, the title of the initiative is tied to one of the specific emphasis areas

identified on page 11. Contract proposals that were submitted in response to RFPs and reviewed by

SRLB and PCRB during FY2005 are shown in Table 16.

Technology Research Applications

The NCI developed a grant mechanism, the R21/R33 phased application awards, for the support of

innovative exploratory/developmental studies, which can rapidly move to proof-of-principle

research studies if the stated milestones are met. This grant mechanism is well suited for technology development, and the number of program announcement grant submissions for these initiatives

has greatly expanded in the past 7 years. In FY2005, 324 technology R21/R33 and R01 grant applications were reviewed under seven RFAs, which was a growth rate of 50 percent as compared to

NCI/DEA Annual Report 2005

21

* Because of the importance of allowing adequate time for the applicant community to respond to NCI’s initiatives, it is to be 

expected that some initiatives may be funded (or reviewed by the NCAB) in subsequent fiscal years.
Multi-Component Research Applications

Figure 3, which describes the historic and current workload for multi-component applications,

demonstrates a 113 percent increase in FY 2005 when compared to FY 2004. This “spike” is due to

three major initiatives. First, 2005 was the year that the National Cooperative Drug Discovery

Groups (NCDDG) for the treatment of cancer were recompeted. This initiative accounted for 37

applications. Second, as described on page 13, the DEA assisted another IC, NIAID, by performing

the review of 31 U19 applications that were submitted in response to a Bioshield Initiative, “Centers

for Medical Countermeasures against Radiation.” Finally, 28 applications submitted in response to

NCI/DEA Annual Report 2005

22

FY2001 (see Figure 5). In 2005, there was a major change in the review of SBIR applications (R41,

R42, R43, R44). This change involved a decision to not renew one PAR and to move several major

program announcements from NCI to CSR review. These announcements included: Flexible System

to Advance Innovative Research for Cancer by Drug Discovery (FLAIR), Cancer Prognosis and

Prediction, and Development of Novel Technologies for In Vivo Imaging. Together, these three initiatives accounted for 322 of the 410 SBIR applications reported in the DEA FY2004 Annual Report.

The program announcements issued for the Innovative Technology for the Molecular Analysis 

of Cancer (IMAT) were converted to Requests for Applications and review of SBIR applications for

the IMAT initiatives remained with the DEA. Overall, the change in the review locus to CSR 

for three initiatives resulted in a significant drop in SBIR applications reviewed by DEA in FY 2005

(see Figure 5). 

215

204

352

324

197

148

410

235

197

99

30

60

90

120

150

180

210

240

270

300

330

360

390

420

450

2001 2002 2003 2004 2005

 Technology Applications**

SBIR/STTR Applications

Fiscal Year

Number of Grant Applications

Figure 5. Technology Initiatives Applications Reviewed* 

FY2001–2005

* Withdrawn applications are not included.
the RFA, “Centers for Nanotechnology Excellence,” were reviewed. These three initiatives account

for 96 applications of the 134 multi-component applications that were reviewed in 2005. Because

multi-component applications may include projects, cores, training, and developmental projects,

each application may be the equivalent of reviewing 10-12 R01s. Thus, the increase in workload

related to multi-component applications more than offset the decrease in SBIR/STTR applications

in FY2005.

Small Grant Programs

Several recurring initiatives are stimulating increased interest in the applicant community. The small

grant (R03) PARs include programs in cancer prevention (PAR02-176, PAR04-147), cancer epidemiology (PAR03-010), and behavior research in cancer control (PAR04-020). These initiatives

support many new investigators and pilot studies. In FY2003, those announcements attracted 166

applications (Division of Extramural Activities Annual Report 2003). In FY2005, those same initiatives attracted 400 applications, an increase of 141 percent. The first-year funding request for the

FY2003 application cohort was approximately $12.4 million; for FY2005, the first-year funding

request was approximately $60 million (see Table 11). 

Research and Development Contract Proposals

The DEA reviewed 471 research and development (R&D) contract proposals (including 361 Loan

Repayment Program applications) in response to 31 RFPs. Twenty three of those 31 RFPs were part

of the Omnibus Solicitation for Small Business Innovation Research (SBIR) published each fall (15

Phase I Topics and 8 Phase II topics) (Table 16). During review, several elements of each proposal

are individually evaluated and scored, with the combined score indicating the overall merit. After

negotiations, contract awards result from the RFP solicitation. Phase II SBIR proposals can only be

submitted at the request of the IC. To facilitate the contract review process, the SRLB has been working with the staff of the Applied Information Systems Branch to develop a series of Web-based documents to be used for contract peer review.

SRLB Teamwork, Communication, and Other Activities

The SRLB has continued to emphasize the importance of team work and communication in the management of its review activities. First, branch staff participate in pre-application meetings that are

organized by the NCI program staff. During the pre-application meeting, review staff respond to

questions relating to the review process. Prior to the receipt of applications, program staff participate

in the review planning process to ensure that all relevant issues are discussed. After the review committee is assembled, review and program staff conduct a pre-review orientation conference call so

that all reviewers understand the intent of the initiative and any special criteria that are relevant. The

latter process has been exceptionally valuable in helping to provide a consistency of approach on the

part of the review panel members.

In addition, the SRLB, acting in collaboration with the PCRB or the NCI Office of Acquisitions,

often serves as a resource to program staff during the drafting of initiatives. Review staff members

are consultants for critically reading the document with suggestions for editing, and with regard to

applying review policy in the formation of initiative-specific review criteria. Notably in FY2005,

SRLB staff provided support to program staff for the reissuance of the Innovative Molecular

NCI/DEA Annual Report 2005

23
Analysis Technologies (IMAT) RFAs and the NCI Nanotechnology initiatives, as well as attending

the annual IMAT meeting.

The SRLB formed partnerships with several other DEA branches in accomplishing its mission 

during FY2005. Initiatives for Medical Countermeasures Against Radiation and Nanotechnology

benefited from support of the RAEB for the identification of prospective reviewers. Members of the

RPRB partnered with a SRLB SRA in conducting the nanotechnology reviews, and a member of the

PCRB led the review of Loan Repayment Program applications using methods developed in SRLB. 

SRLB staff are active in working with NCI staff across all of the Divisions through working groups

and participating in research meetings. An SRLB staff member was an active member of the NCI

Integration and Implementation Imaging Committee and the NCI R21/R33 Working Group. SRLB

staff regularly participate in the Extramural Advisory Board and the Small Business Program

Managers monthly meetings. Other activities include participation by the SRLB Branch Chief in the

NCI Breast Pre-Malignancy Steering Committee and the NCI Strategic Plan Committee.

Other Extramural Review Activities

Several DEA staff participated in three training sessions organized by the NCI Office of Liaison

Activities (OLA) to train patient advocates in NCI’s Consumer Advocates in Research and Related

Activities (CARRA) program on peer review. The 21⁄2-day-long training sessions were held in April,

July, and October 2005, and included about 25 CARRA members at each session. The training

focused on preparing CARRA members to participate in scientific peer review of clinical research

applications and represent the perspective of the human subject populations involved in the research.

Staff members from the Research Programs Review Branch, the Special Review and Logistics

Branch, and the Resources and Training Review Branch advised OLA staff and their training contractors on the curriculum, prepared materials for handouts, and taught sections of the course related to: deciding to participate in peer review; understanding the expectations of CARRA members

during the review process; describing the “anatomy” of a grant application; explaining the peer

review criteria; and preparing critiques. Each training session culminated in a mock peer review, during which scientists from local Washington, DC, area universities “play-acted” as reviewers, a DEA

staff member “play-acted” as the SRA, and CARRA members “play-acted” as consumer/patient

advocate reviewers and thus had opportunities to practice their new skills in simulated situations that

mimicked real peer reviews.

In FY2005, the DEA was very active in the design and implementation of the Peer Review Module

of the central NIH extramural database, called IMPAC II, and an RPRB SRA served on the task force

to upgrade a new Internet-assisted review module that is part of the NIH Commons. This module

allows reviewers to log in through the NIH eRA Commons and post their preliminary critiques and

preliminary scores on a secure Web site prior to the review meeting. 

DEA staff are involved in the transition from paper to electronic grant submissions representing the

NCI on NIH committees. The Chief, PCRB, was a member of the NIH SF424 Electronic Grant

Applications Working Group for the purpose of keeping the NCI fully involved in the development,

NCI/DEA Annual Report 2005

24
implementation, and anlysis of the transition to and use of electronic grant applications by applicants, reviewers, and NIH/NCI staff. An RPRB SRA served on an NIH working group to identify

review and programmatic issues in converting from Form 398 to Form 424. 

The Chief, PCRB, was also a member of an NIH Guide Process Working Group that was commissioned in 2005 by the NIH Extramural Policy Management Committee (EPMC) for the purpose of

improving the publication processes for Early Notices, Notices, PAs, and RFAs. Their recommendations to EPMC and to the NIH OD Office of Extramural Research were approved and implemented,

and the implemented changes quickly yielded improvements in the efficiency and timeliness of publication processes for funding opportunity announcements. 

The Chief, RPRB, also represented the NCI on the NIH Review Policy Committee (RPC), and on

the RPC steering committee. The Associate Director, ORRPC, represented the NCI on the NIH

Locus of Review Working Group charged with providing greater consistency across the NIH on the

assignment of specific grant mechanisms to CSR or IC review. The Chief, RPRB, served on a transNIH committee to consider ways to shorten the NIH review cycle. This committee was charged by

the CSR Director with devising a way to decrease the traditional 9–10 month NIH receipt and review

schedule to allow applicants to resubmit applications that missed the payline for the very next NIH

receipt date. The committee recommended a pilot of a significantly shortened review cycle for unsolicited research project grant (R01) applications from new investigators (R01* applications). This

pilot was announced in the NIH Guide for Grants and Contracts on November 30, 2005. The NCI

also is conducting a pilot with the behavior small grant PAR.

The Chief, SRLB, chaired a NIH Grant Appendices Working Group charged with making recommendations on the submission of appendix material. Recommendations included allowing the electronic submission of appendix material with special initiatives and including only a publication list

with links to the publicly available online journal for electronic grant submissions. 

The Associate Director, ORRPC, served as one of the NCI representatives on the NIH Clinical

Workforce Steering Committee, a subcommittee of the NIH Roadmap committee for Re-engineering the Clinical Research Enterprise. She also served on the NIH Multiple PI Working Group that

is piloting the first initiatives using multiple PIs this year. The committee issued a Request for

Information (RFI) asking the research community to provide input on implementation plans for multiple PI applications in July 2005. The results of the RFI survey are available on the Multiple PI Web

page: http://grants2.nih.gov/grants/multi_pi/. 

An RPRB SRA also was on the trans-NIH committee to organize the first NIH-wide SRA education

and training retreat in almost 10 years. The retreat was held in the NIH Natcher Conference Center,

and focused on improving the peer review process and recent changes in review policies and

processes. 

The Chief, RTRB, served on the NIH Division of Quality Assurance Advisory Committee in support

of the NIH Division of Extramural Activities Support (DEAS). The Director, DEA, served as the

NCI representative on the NIH DEAS Advisory Committee.

NCI/DEA Annual Report 2005

25
Grant Funding Trends

In Table 12, a comparison is made of the average cost and number of NCI R01, P01, R03, R13, R21,

P30, P50, U01, U10, and U19 grants awarded in FY2002 through FY2005 according to the extramural division and office. Table 13 presents a summary for FY2005 of total funding of NCI grant

awards by mechanism. Trends in grant funding according to scientific discipline and organ site are

described on page 35 and in Tables 14 and 15. Some grant awards made during a fiscal year may

have been for grant applications reviewed in a prior fiscal year. 

NCI/DEA Annual Report 2005

26
NCI/DEA Annual Report 2005

27

Supporting Peer-Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and

contract proposals requires an efficient administrative support system. The DEA’s Scientific Review

and Evaluation Award (SREA) unit, residing within the NCI Committee Management Office

(CMO), supports the NCI peer-review process by compensating consultants for their services on the

NCI IRG subcommittees or SEPs and by reimbursing them for their travel and other expenses (see

Appendixes C and D). The SREA staff also approves and processes payments for other activities

related to review, including contract-supported ticketing services. During FY 2005, 4,909 consultant

reimbursement vouchers and 470 nonconsultant vouchers for travel ticketing, meeting room rental,

and teleconferences were authorized, and a total of 5,379 checks were processed to reimburse consultants and pay for meeting rooms and other expenses. 

During the last quarter of FY2005, the Committee Management Officer served as a member of the

SREA Transition/Implementation Team charged with developing and implementing the changes to

the new Scientific Review Evaluation Actvities program. The CMO was responsible for providing

advice on current FACA rules and regulations as well as the best options for reimbursing peer review

members and establishment of new IMPAC II processes. 

The Team made recommendations to the NIH Deputy Director for Management on the following:

CCR/DUNS implementation and developed detailed instructions for the entire NIH Peer Review

Community; analyzed current reimbursements costs across ICs and recommended a flat rate for

reviewers modeled after the National Science Foundation and the Department of Defense; analyzed

several different prong approaches regarding use of a logistics contractor, payment of airline tickets,

hotel lodging and OFM and reviewer reimbursement; and analyzed the impact of these changes on

the NIH Peer Review Community and Extramural staff. Additionally, the Team developed the

Standard Operating Procedures and the CMO gave detailed presentations to the following: NCI C,

D, E Cluster Meetings Reviewers, DEA SRA and DEAS Staff, NIH Committee Management

Officers, and developed a detailed NCI DEA SOP and provided training to DEA SRAs and DEAS

staff. This ultimately helped to introduce the new system to the NIH and NCI peer review community. 

The SREA Office oversaw the major effort of closing out the SREA Chairman’s Grant Award during the last quarter of FY2005. This entailed coordination of staff to review more than 3,000 outstanding vouchers to determine whether reimbursement was needed. 

Additionally, during the first half of FY2005, SREA staff continued to serve on the NIH SREA

Coordinating Committee. This group held bimonthly meetings to discuss SREA procedures and

streamline processes. In addition, the SREA staff advises consultants, NCI staff, and the SREA

trustee on policies and procedures; performs the administrative tasks related to setting up, managing,

monitoring, and closing out accounts; and prepares expenditure reports, including those required by

the NIH Office of Financial Management for 1099 tax forms and those requested by the CMO for

the NCI FOP, consultant services, and financial management reports for the IRG, SEP, and SREA.

The SREA administrative function was critical to the success of the peer-review system because any

error, inconvenience, or delay in reimbursement that reviewers experience is likely to discourage

their future service. Excellent customer service has remained a constant goal of the NCI SREA staff.
NCI/DEA Annual Report 2005

28

NCI Advisory Boards

NCAB Members

Retiring NCAB Chair, Dr. John Niederhuber, with Drs. von Eschenbach and Von Hoff

PCP Chair, Dr. LaSalle Leffall, Jr., and Dr. von Eschenbach

Continued on page 32.
NCI/DEA Annual Report 2005

29

DEA’s Role in Advisory Activities

Beyond its central role in coordinating the peer review and referral of grants, perhaps the most farreaching role the DEA plays across the NCI is the coordination and administration of NCI’s nine

chartered Federal advisory committees (see Appendix C). The activities and membership of these

advisory bodies are coordinated by the Office of the Director, DEA, and the Committee Management Office, DEA. A primary responsibility of the DEA is coordination of the activities of the

NCAB, whose members are appointed by the President and whose responsibilities include conducting the second-level review of grants and cooperative agreements, as well as advising the NCI

Director on policy for the conduct of the National Cancer Program. The DEA also coordinates

administration of the BSA, the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI. As such, the DEA plays a major role in the development

and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI.

The DEA Director serves as Executive Secretary to the NCAB and to the BSA. (See Appendixes A

and B for highlights of the activities of these Boards in FY 2005.)

Each year, the NCI relies on thousands of individuals with special expertise to advise and support

staff in its mission to win the war against cancer. These individuals provide advice and guidance to

NCI staff on countless research projects, scientific concepts, and programmatic and administrative

issues relating to its research initiatives and priorities. During FY2005, more than 2,200 consultants

were asked to serve as standing, temporary, and ad hoc members on NCI’s chartered advisory 

committees, panels, site visits, and work groups. Under the various chartered committees, working

groups were formed to address several important areas of cancer research related to clinical trials,

diverse populations, and cancer advocacy, treatment, prevention, communication, and education.

(See Appendix C for a list of chartered committee members and Appendix D for a list of 

consultants.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board. NCI’s principal advisory body is the Presidentially appointed NCAB.

The Board advises the Department of Health and Human Services (DHHS) Secretary and the NCI

Director on issues related to the entire National Cancer Program and provides a second level of

review for grant applications referred to the NCI.

Board of Scientific Advisors. The BSA represents the scientific community’s voice in NCI-supported

extramural science. The Board, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future

direction of the Institute’s Extramural Research Program. The Board evaluates NCI extramural programs and policies and reviews ideas for new research opportunities and solicitations, to ensure that

a concept is meritorious and consistent with the Institute’s mission.

The BSA believes it is important to interact with and receive feedback from the clinical, population

science, and laboratory research communities that are affected by NCI policies. To this end, the NCI

has established BSA-sponsored “NCI Listens” sessions at national association meetings (see

Appendix B). BSA members and NCI staff invite conference participants to join them for these sessions. A brief presentation is given by NCI staff emphasizing the status of grant funding, the Bypass

Budget, and the status of several new initiatives. The brief presentation is followed by an open question-and-answer period. The NCI is committed to providing a written response to the scientific soci-
NCI/DEA Annual Report 2005

30

ety hosting the meeting concerning issues raised during the session. The BSA hopes that conference

participants will take advantage of this opportunity to raise their concerns.

Boards of Scientific Counselors (Basic Sciences, and Clinical Sciences and Epidemiology). In FY2005, the

NCI received approval to establish the subcommittees under the BSC as two separate Federal advisory committees. The BSCs, managed through the Office of the Director (OD), NCI, advise the

Institute leadership on the progress and future direction of NCI’s Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics

(DCEG). These groups of scientific experts from outside the NCI evaluate the performance and productivity of NCI staff scientists through periodic site visits to intramural laboratories and provide

evaluation and advice on the course of research for each Laboratory and Branch. 

President’s Cancer Panel. The PCP consists of three members appointed by the President, who by

virtue of their training, experience, and background are exceptionally qualified to appraise the

National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer advocate. 

The Panel monitors the development and execution of the activities of the National Cancer Program,

and reports directly to the President. Any delays or hindrances in the rapid execution of the Program

are immediately brought to the attention of the President.

Advisory Committee to the Director, NCI. The ACD advises and makes recommendations to the

Director, NCI, for the oversight and integration of various planning and advisory groups serving 

the broad programmatic and institutional objectives of the Institute. The Committee serves as the

official channel through which the findings and recommendations emerging from these groups 

are submitted to the NCI. The Committee may consider the reports of the various review groups as

informational, advisory, or as recommendations, and provides the NCI with assistance in identifying

opportunities to be pursued within the areas of cancer research that cut across the intramural and

extramural programs. 

The Committee consists of the Director, NCI as Chair; Chair, NCAB; Chair, PCP; Chairs of the

BSCs (Basic Sciences, and Clinical Sciences and Epidemiology); Chair, BSA; and Chair, DCLG.

Nonvoting ex officio members include NCI Deputy Directors and the Director, Division of

Extramural Activities, NCI. 

Director’s Consumer Liaison Group. The DCLG advises and makes recommendations to the Director,

NCI, from the perspective and viewpoint of cancer consumer advocates on a wide variety of issues,

programs, and research priorities. The Committee serves as a channel for consumer advocates to

voice their views and concerns. The Committee may assemble ad hoc working groups; convene conferences, workshops, or other activities; and seek advice from special consultants. The members are

consumer advocates who are involved in cancer advocacy and experience, representing a constituency they communicate with on a regular basis.

NCI Initial Review Group. The IRG, composed of nine subcommittees, reviews grant and cooperative

agreement applications for centers, research projects, and research training activities in the areas of

cancer cause, diagnosis, treatment, and prevention, as well as contract proposals relating to all facets

of cancer. Members may be appointed as standing committee members with overlapping terms of up

to 4 years, or as “temporary” members with all the rights and obligations of committee membership,
NCI/DEA Annual Report 2005

31

including the right to vote on recommendations in which the individual fully participated as a

reviewer for a specific meeting. Consultants also may be invited to serve as special experts or ad hoc

members, to provide information or advice. These individuals generally serve in site visit groups,

providing critical information to the chartered advisory subcommittees responsible for initial peer

review.

NCI Special Emphasis Panels. The SEPs advise the Director, NCI, and the Director, DEA, regarding

research grant and cooperative agreement applications, contract proposals and concept review 

relating to basic and clinical sciences, and applied research and development programs of special 

relevance to the NCI. Membership of an SEP is fluid, with individuals designated to serve for individual meetings rather than for fixed terms. These individuals have all of the rights and obligations

of committee membership, including the right to vote on recommendations.

Other Advisory Groups

Program Review Groups. As part of an ongoing process of review and revitalization, the NCI instituted a series of external reviews to guide it in strengthening major research support programs. Program

Review Groups, coordinated by the DEA as an activity of the BSA, examine the NCI extramural programs and their infrastructures to evaluate whether changes are necessary for the Institute to be in a

position to effectively guide and administer the needs of the science in the foreseeable future. (See

http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/bsaprgr.htm). 

Progress Review Groups. As part of its overall responsibilities for committee management functions

and coordination of advisory groups, the DEA assists other NCI offices with additional types of oversight activities. Progress Review Groups, managed by the Office of Science Planning and

Assessment within the OD, NCI, are created to provide their expertise, biomedical research information, and assistance to NCI chartered advisory committees in defining and prioritizing the national research agenda for particular concerns by: (1) identifying new or unmet scientific opportunities;

(2) reviewing current research programs; (3) providing expert opinions to address research opportunities and hasten progress. These groups report to the NCI through a chartered Federal advisory committee (see http://deainfo.nci.nih.gov/advisory/pog/progress/index.htm).
NCI Advisory Boards (Continued)

NCI/DEA Annual Report 2005

32

Retiring BSA Member, Dr. Tom Curran, with 

Drs. von Eschenbach and Young

Retiring BSA Member, Dr. David Abrams, with

Drs. von Eschenbach and Young

Retiring BSA Member, Dr. William Kaelin, Jr., with 

Drs. von Eschenbach and Young

Retiring BSC Chair, Dr. Frederick Alt, with 

Dr. von Eschenbach

BSA Members
NCI/DEA Annual Report 2005

33

Committee Management Activities

The Committee Management Office (CMO) coordinates the general administration of NCI’s chartered Federal advisory committees and serves as a Service Center to the DHHS Secretary’s Advisory

Committee on Genetics, Health, and Society and the National Center for Complementary and

Alternative Medicine (NCAAM) Council. The CMO provides advice related to the provisions of the

Federal Advisory Committee Act (FACA) and other Federal, DHHS, and NIH regulations governing

the actions of NCI staff who manage advisory committees. It coordinates the activities of advisory

committees across the NCI and ensures that NCI staff comply with Federal advisory committee policy. Additionally, the Office of the Director (OD), DEA, and the CMO provide guidance and information to staff and external groups on specific NIH policies related to the operation of working

groups and ad hoc consultants operating under the direction of some of NCI’s chartered Federal advisory committees. NCI working groups provide scientific expertise through chartered committees to

the NCI Director and Division Directors on a range of matters related to the National Cancer

Program. The Office works closely with the other DEA offices to coordinate activities with NCI

advisory committees; implements policies and procedures designed to avoid conflicts in the nomination and selection of board members; implements policies and procedures to ensure compliance

with DHHS and NIH regulations governing the operation of chartered advisory bodies; advises on

issues related to conflicts of interest, selection and recruitment of viable committee members, and

management of committee records; provides logistical support for NCAB and BSA meetings; and

facilitates committee-related travel.

CMO staff members continue to actively participate in various NIH-wide Information for

Management, Planning, Analysis, and Coordination (IMPAC II) software application user group

meetings, such as the CM Users Group (CMUG) and pilots, and provides advice on the redesign of

the Committee Management Web Module. The IMPAC II Module is being redesigned as a Webbased application and will be a more user-friendly and intuitive system. In FY2005, the CMO continued to provide in-house IMPAC II training to DEA staff on Coding Meeting Attendees in IMPAC

II. The user-friendly booklet the CMO created for the training includes screen shots from the CMO

Module and step-by-step instructions on how to code the various types of meeting attendees (i.e.,

mail reviewers, ad hoc reviewers, temporary members, regular members, telephone reviewers).

Additionally, the guide continues to be the recommended tool that is used in the training of DEAS

staff and new ESAs, SRAs, and CMOs. The Office of Federal Advisory Committee Policy (OFACP)

also recognized the guide as an outstanding tool for all IMPAC II users. As a result, the guide is

accessible on OFACP’s Web Site.

As a result of a new Office of Federal Advisory Committee Policy on the Membership and

Management of Subcommittees of National Advisory Councils, Program Advisory Committees, and

Board of Scientific Counselors, the CMO pursued the establishment of the BSC as two separate

Federal advisory committees. Approval was received by the DHHS to establish the BSC subcommittees as separate entities. 

The recommendations of the National Cancer Advisory Board Clinical Trials Working Group called

for an advisory body to advise on the NCI clinical trials enterprise. The CMO met with OFACP staff

to convey NCI’s need for the establishment of a clinical trials advisory committee and ensured

approval would be sought expeditiously at the Department and GSA. The CMO developed the

Clinical Trials Advisory Committee charter so that the NCI can effectively put in place an advisory

body that will make recommendations on the conduct, oversight, and implementation of clinical trials across the Institute. 
NCI/DEA Annual Report 2005

34

Additionally in FY2005, the CMO helped with the reorganization of NCI IRG Subcommittee G—

Education and the establishment of NCI IRG Subcommittee J—Population and Patient-Oriented

Training.

CMO and SREA staff gave presentations to NCI staff on management of Federal Advisory

Committees and the Scientific Review and Evaluation Award and participated in the following NCI

and NIH committees:

CM Web Module—This committee provided advice on the development of new business practices for the CM Web Version of the Module.

OFACP Service Center Committee—This committee developed standard operating procedures

for NIH Committee Management Service Centers to follow.

SREA Standard Operating Procedures Committee—This committee developed the new standard operating procedures for all ICs at the NIH to follow.

SREA Transition/Implementation Team—This team developed and implemented changes to the

new Scientific Review Evaluation Activities Program.

As a Committee Management Service Center, the CMO continues to provide exceptional committee

management service to the Office of Biotechnology Activities (NIH Office of the Director) for the

Secretary’s Advisory Committee on Genetics, Health, and Society. This committee reports to the

DHHS Secretary. 

In concert with the automation of the NIH-wide committee management functions, the CMO continued to work closely with other DEA staff to streamline general committee management and

review procedures related to member travel, vouchering, mail review, and teleconference reimbursements. The same procedures were used to facilitate more effective management of all other NCI

chartered advisory committees.

In addition, the DEA CMO continued to conduct briefings with the NCI Divisions, the NCI Offices

of Liaison Activities, and NCI senior management on the use of working groups associated with

chartered committees. Specifically, briefings were held to discuss the implementation of the NCAB

Clinical Trials Working Group recommendations and establishment of the Translational Research

Working Group. Consultation with NCI Senior staff included providing advice on FACA, editing 

of numerous documents describing the formation of new clinical trials implementation groups to

ensure FACA language was being used appropriately, and analyzing documents on the creation of

implementation committees, steering committees, and disease-specific committees.
NCI/DEA Annual Report 2005

35

Portfolio Tracking and Analysis

The DEA’s Research Analysis and Evaluation Branch (RAEB) is the officially designated contact

for scientific information on NCI-supported research. The NCI needs consistent budget-linked scientific information across all of its scientific programs to analyze the Institute’s portfolio, make

budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of

the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the

broader NIH community, and requesters nationally and worldwide. The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all institute programs.

These capabilities are based on a sophisticated system of indexing, in which research documentation

staff analyze grant applications to classify each project for its degree of relevance to Special Interest

Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way

the major scientific disciplines that are of stated or growing interest to the NIH, DHHS, Congress,

and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding between FY2001 and FY2005 for selected SIC Codes and organ sites are presented in Tables 14 and 15.

RAEB staff act as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives.

These groups and committees deal with various aspects of NIH grants and contracts or tracking and

reporting on areas of special interest to the NIH, NCI, or Congress. In 2005, the RAEB assumed

responsibility for bi-annual reporting of NCI compliance with Congressional Health Disparities

reporting requirements, and served as the NCI liaison for the NIH Knowledge Management for

Disease Coding Initiative.

FY2005 Highlights include:

(1) Major review and update of Special Interest Categories, adding new SICs at the request of the

Department and NIH for:

Biomedical Computing

Cost Effectiveness

Effectiveness Research

Ethics

Fertility

Genetic Testing Research, Human

Genomics

Health Literacy

Healthcare Delivery

Math Models

Metabolomics

Molecular Imaging

Pharmacogenetics

Proteomics

Registries
NCI/DEA Annual Report 2005

36

(2) In addition,

RAEB conducted a comprehensive update of Radiology categories.

RAEB scientific staff evaluated more than 8,000 funded and unfunded applications.

RAEB coordinated with FMB to update and align budget reporting categories between DEA and

FMB reporting systems.

RAEB assumed responsibility for bi-annual reporting of NCI compliance with Congressional

Health Disparities reporting requirements.

RAEB assisted DEA Review Branches in finding qualified scientists to serve as reviewers for

high-profile and multi-project RFAs that cover broad areas of science, as well as assisted in the

management of the review activities.

RAEB was appointed as the NCI liaison for the NIH Knowledge Management for Disease

Coding Initiative. 
NCI/DEA Annual Report 2005

37

Information Resources Management

The Applied Information Systems Branch (AISB) provides integrated computer support, applications, and information systems development to the DEA. The AISB monitors the DEA Web Site,

supports the Division’s Intranet server, designs and maintains Division-specific software applications, provides oversight of hardware and connectivity, and serves as liaison with the Center for

Information Technology (CIT) and NCI central units. Its mission is critical to the future of the

Division in communicating both internally and externally current information technology activities

and new developments with all components of the NCI, NIH, and reviewer and applicant communities.

All of the Division’s Information Technology and Information Systems contracts are consolidated

under the AISB. The AISB has a computer support team to track staff requests, manage the

Division’s computer equipment inventory, and provide computer-related training, as needed.

Specific projects utilizing the technologies and services provided by the AISB are described under

the appropriate functions of the DEA throughout this report. For FY2005, the following specific

accomplishments are highlighted:

Collaborated with NCI’s ISCS (Information Systems and Computer Services) to prepare and

transfer main DEA file servers to the NCI, and prepare for network domain migration by performing migration tests to verify user permissions, login scripts, and file share locations.

Created a Web application to assist in the verification of RFA/PA data that will be published on

DEA’s Internet site.

Developed enhanced user authentication for DEA applications using NIH network login, and

implemented user role management, which enables various levels of capabilities and permissions for DEA applications.

Consolidated the NCI Committee Management Office online reporting tools into one Web

application.

Created ECARES (Extramural Customer Assistance Request System) quarterly reports for each

of the four DEA branches.

Performed enhancements, upgrades, and maintenance on the following production systems:

 DEA Internet and Intranet:

– Updated DEA’s Web searching capability provided by FirstGov.gov to take advantage of

the latest features.

– Divided the Board of Scientific Counselors Web Site into separate sites to provide more

distinct information: (1) Board of Scientific Counselors for Basic Sciences; and (2)

Board of Scientific Counselors for Clinical Sciences and Epidemiology. 

– Created “SRA Resources” Web Site with a collection of nine sub-sections to provide a

comprehensive source of information for the Scientific Review Administrators (SRAs).

– Implemented Cascading Style Sheet (CSS) technology for all newly developed Web

sites.
NCI/DEA Annual Report 2005

38

 Enhanced both segments of the Standard Docs/RPDU Web-based application. The

Standard Docs portion is an application for DEA review staff to enable the merging of

IMPAC II data into MS Word or Corel WordPerfect documents and labels. The RPDU

(Mailroom) portion provides the means to assemble lists of grant applications received by

the DEA for referral and archiving purposes.

 Enhanced and upgraded the Fiscal-Linked Analysis of Research Emphasis (FLARE) application by adding new features that included: 

– Ability to code grants at the Subproject level.

– Functionality to automate the mapping of RAEB FLARE SIC (Special Interest

Category) and organ site codes to NIH Office of Budget disease category.

– Began to convert historical data (1990 back to 1937) into the FLARE database.

– Enhanced the procedures of distributing FLARE data to various NCI groups.

FLARE provides the functionality allowing the RAEB staff to consistently input disease coding data,

search for disease-related data, and respond to requests from various sources, both internal and external to the NCI. The system provides a basis for budget projections and serves as a resource for the

dissemination of information about cancer. It disseminates information on cancer by distributing the

disease coding data in various configurations to sources internal and external to NCI via various Web

sites, centralized databases, and other means.

Implemented an advanced utility to improve the search engine for searching text and key words in

the NCI Funded Research Portfolio Application. This application enables various user groups to

search information regarding the NCI funded grants.

Enhanced and upgraded the Reviewer CD application by implementing administrative controls over

the operation of jobs; added support to include several new types of documents; and implemented a

tabbed user interface for logical grouping of operations and more efficient navigation. Also, installed

and configured an additional and more advanced CD burning appliance that operates in parallel with

the existing one. This addition allows multiple job requests to be routed to different destinations,

which reduces completion time. Reviewer CD is a Web-based application that allows review staff to

create customized CDs (Compact Discs) containing grant applications and other related materials for

the grant reviewers.

Continued to support the Program Coding application and initiated the design and development of

the next version with several new features such as: optimized batch coding; implementing coding

rules; implementing roll forward for coding; implementing expiration of codes and code types; and

providing additional options for system administration functions. Currently, the new version is in a

testing environment. Program Coding is a Web-based application that allows users to code or index

grants using an NCI organization’s scientific codes.

AISB staff are involved with many NCI and NIH information systems and information technology

groups and organizations, including:

NCI Office of Information Systems and Computer Services

NCI Institute Information Systems Advisory Group

NCI Change Management Group

NCI Knowledge Management for Disease Coding (KMDC)—Working Group
NCI Intranet Advisory Board

NCI Leadership Focus Group

eRA Technical Coordinators Group

IMPAC II Joint Applications Development and Critical Design Review Groups

NIH Electronic Council Book and Query View Reporting Steering Committee

NIH Architecture Review Board

NIH Automatic Data Processing Extramural Coordination Committee

NIH A-76 Preplanning Teams

NIH A-76 Requirements Document Committees

NIH Knowledge Management for Disease Coding (KMDC)—Technical Advisory Group (TAG)

NCI/DEA Annual Report 2005

39
NCI/DEA Annual Report 2005

40

Organizational Structure of the Division of Extramural Activities

Office of the Director

Directs and administers the operations of the Division, including those activities relating to

grant review and administration and contract review, as well as Advisory Committee and Board

activities.

Directly coordinates and manages the NCAB and the BSA.

Coordinates coding of NCI’s grant portfolio.

Initiates, coordinates, and implements Institute policies and procedures relating to grants and

contracts review.

Coordinates the NCI’s Committee Management Office.

Implements NCI policies regarding extramural research integrity.

Represents the NCI on extramural policy issues to the NIH.

Advises the Executive Committee, NCI, on extramural guidelines, review, advisory activities,

and implementation strategies.

Coordinates NCI extramural staff training requirements with the NIH.

Represents the NCI on the NIH Institute-wide Extramural Program Management Committee

(EPMC) with responsibility for development of extramural policy and procedures across all

NIH Institutes and Centers.

Paulette Gray, Ph.D. .............................Director

Deputy Director and Associate Director, 

Extramural Applications

Diane Bronzert......................................Associate Director, 

Referral, Review, and Program Coordination

Cedric Long, Ph.D. ...............................Assistant Director

Patricia Marek, M.B.A. .........................Special Assistant to the Director

Carlene Neil-Allman*..............................Program Analyst

Carolyn Craig* ....................................Program Analyst

Bernadette Monacelli .............................Secretary

Wendy Jones*.......................................Secretary

Lisa Verikios .........................................Secretary

Barbara Hider† ......................................Secretary

Joshua Rhoderick ..................................Receptionist

* Left in 2005.

† Joined in 2005.
NCI/DEA Annual Report 2005

41

Committee Management Office, OD

Coordinates functionally related advisory activities across the Institute and manages a DHHS

committee to ensure that appropriate policies and procedures are in place to conduct its mission

and ensure the synthesis, integration, and documentation of these activities.

Provides committee management services to the Office of Biotechnology Activities, Office of

the Director, NIH, and is an established NCI Service Center.

Provides consultation services to NCI staff on administrative and technical aspects of Federal

Advisory Committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and

recruitment of board members; implements CM IMPAC II guidelines and procedures to ensure

that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, DHHS, and NIH; provides logistical support for NCAB and BSA meetings, subcommittees, and work groups; and

facilitates NCAB and BSA committee-related travel.

Provides administrative support for the peer-review system by compensating consultants for

their services on NCI IRG subcommittees and SEPs; reimburses consultants for travel and other

expenses; and approves and processes payments for other activities related to review, such as

meeting room rental and teleconferencing.

Claire Harris .........................................Committee Management Officer

Andrea Collins.......................................Deputy Committee Management Officer

Earline Jackson*....................................Program Analyst

David Alperin........................................Program Analyst

Linda Coleman* ....................................Committee Management Specialist

Hing Lee ..............................................Committee Management Specialist 

Kerry Peasland* ....................................Committee Management Specialist

Lisa Rustin............................................Committee Management Specialist

Malaika Staff† .......................................Committee Management Specialist

Linda Southworth ..................................Committee Management Specialist

* Retired in 2005. 

† Joined in 2005. 
Office of Referral, Review, and Program Coordination, OD

Coordinates program concept development; publication functions; and receipt, referral, and

assignment of all NCI applications.

Coordinates review activities of the SRLB, RTRB, RPRB, and PCRB.

Diane Bronzert......................................Associate Director

Catherine Battistone ..............................Program Analyst

Linda Brown**......................................Program Specialist

Angela Collick*.....................................Program Specialist

* Left in 2005.

** Transferred from RAEB to ORRPC in 2005.

NCI/DEA Annual Report 2005

42
Special Review and Logistics Branch

Plans, manages, and assists in the scientific merit review of special grant and cooperative agreement applications (RFAs and PAs) and the technical merit review of contract proposals (RFPs).

Arranges for and participates in onsite assessments of the research capabilities and facilities of

selected applicants.

Identifies and recommends appropriate review committee members and site visitors, as required

for the review of assigned applications and proposals.

Provides the SRA and other support staff for the technical review committees.

Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.

Provides input and advice on grant and contract review policy and procedures, application and

proposal patterns, and research trends and other related information, as required.

Coordinates secondary-level review activities of the NCAB with staff of other NCI Divisions,

other Branches of the Division, the Research Contracts Branch, and the Grants Administration

Branch.

Provides logistical support for primary- and secondary-level review activities in support of other

Division and Institute units.

Kirt Vener, Ph.D....................................Chief

Special Review Unit

Thomas Vollberg, Ph.D...........................Deputy Chief

Kenneth Bielat, Ph.D. ............................Scientific Review Administrator

Juana Diaz* .........................................Program Support Assistant

Sherwood Githens, Ph.D. .......................Scientific Review Administrator

C. Michael Kerwin, Ph.D., M.P.H. ...........Scientific Review Administrator

Gerald Lovinger, Ph.D............................Scientific Review Administrator

Timothy Meeker, M.D. ...........................Scientific Review Administrator

Lalita Palekar, Ph.D. ..............................Scientific Review Administrator

Joyce Pegues, Ph.D. ..............................Scientific Review Administrator

Phuong Pham .......................................Program Analyst

Marvin Salin, Ph.D.† ..............................Scientific Review Administrator

Mary Jane Slesinsky, Ph.D......................Scientific Review Administrator

* Left in 2005.

† Joined in 2005.

NCI/DEA Annual Report 2005

43
Review Processing and Distribution Unit

Adrian Bishop .......................................Mail and File Clerk

Robert Kruth.........................................Mail and File Clerk

Clara Murphy .......................................Program Assistant

NCI/DEA Annual Report 2005

44
Program Coordination and Referral Branch

Serves as the information and coordinating point within the NCI for the development, clearance,

publication, and tracking of all NCI extramural program initiatives, which include all RFAs,

PAs, and Notices submitted for publication in the NIH Guide for Grants and Contracts, and as

of November 2005, for the SBIR and STTR mechanisms, also on Grants.gov (which is a

Federal-wide online portal for electronic submission of grant applications).

Coordinates the development and periodic revision of referral guidelines within the NCI for

both external and internal use.

Coordinates the development of shared (referral) interest statements with other NIH Institutes

and Centers (ICs) so that grant applications of possible or real mutual interest can be properly

assigned for receipt, review, and/or funding. 

Serves as liaison to the CSR, NIH, to ensure the appropriate referrals (i.e., assignments) of grant

applications to the Institute and the transfers of grant applications between the NCI and other

NIH Institutes and Centers.

Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI

Internal Referral Guidelines that define the program interests of each of the 45 cancer activity

areas (which typically represent program branches in the NCI extramural divisions).

Semi-automatically refers amended and competing continuation (Type 2) applications to the

cancer activity area that accepted the previously submitted application (with quality control

measures performed to ensure the accuracy of referrals).

Coordinates requests from program staff for application status changes (including corrections of

application assignments and numbers, which is done in collaboration with NCI program staff,

CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant

assignments.

Serves as the NCI contact point and liaison to involved parties at the NIH (including the NCI

program staff members, the relevant NCI Division Directors, the Chief of the NCI Office of

Grants Administration, the Chief of the NCI Office of Acquisitions, and the NIH OD Office of

Extramural Research) for approval of the use of cooperative agreement mechanisms and for

conversion of grants to cooperative agreements.

Works with NCI program and review staff and with NIH referral liaisons to address unresolved

referral and review issues with the CSR and other NIH Institutes and Centers.

Receives and distributes advance copies of applications for Program Project (P01) grants, applications for conference (R13) grants, and applications submitted in response to RFAs and PAs,

and coordinates this information with review and program staff.

Receives Letters of Intent from applicants (principal investigators) intending to submit large

budget grants (including, but not limited to, program projects and cooperative agreements for

clinical trials) and also from prospective R13 (conference grant) applicants.

NCI/DEA Annual Report 2005

45
Coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual

conference (R13) grant applications.

Processes Awaiting Receipt of Application (ARA) request forms through the NCI Online

Workplace (NOW) system to the CSR so that applications with large (greater than $500,000

first-year direct costs) budgets and applications of high-priority programmatic interest can be

assigned to the NCI for consideration.

Maintains database records of prospective large budget grant and conference grant applications

for each council round.

Serves as the primary NCI information referral point for the extramural scientific community

on a broad range of subjects, including grant guidelines, application information, new initiatives

announced as RFAs or PAs, and the review process.

Serves as the primary point of contact and assistance at the NCI for applicants who wish to

apply for an Academic Research Enhancement Award (i.e., the NIH R15 grant mechanism).

Manages the peer reviews of the large numbers of NIH Loan Repayment Program (contract)

proposals that are received each year and assigned to the NCI (currently about 400 proposals

per year).

Assists the extramural community in navigating the NIH and NCI Web pages to help users

obtain current information, forms, and guidelines.

Directs applicants to the appropriate Program Directors and SRAs for information regarding the

status of the review and award of their grant applications.

Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.

Provides data and data analyses on funding opportunities and on the receipt and referral of grant

applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D. ...................Chief, CSR Referral Liaison

David Contois.......................................Referral Officer

Leota Hall.............................................Referral Officer, CSR Referral Liaison

Natacha P. Lassègue ..............................Program Analyst

Kimberly Morris ...................................Program Support Assistant

Sonya Roberson, Ph.D.* ........................RFA/PA Coordinator, Scientific Review Administrator

Bratin Saha, Ph.D.† ...............................Referral Officer, Scientific Review Administrator

* Transferred to RTRB in 2005. † Joined PCRB in 2005.

NCI/DEA Annual Report 2005

46
Research Programs Review Branch

Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by chartered review committees and

Special Emphasis Panels.

Arranges for and participates in onsite assessments of the research capabilities and facilities of

selected applicants.

Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.

Provides input and advice on grant review policy and procedures, application patterns, research

trends, and other related information, as required.

Coordinates grant review activities with staff of other NCI Divisions and other DEA Branches.

Olivia Bartlett, Ph.D..............................Chief

Virginia Wray, Ph.D. .............................Deputy Chief

Shakeel Ahmad, Ph.D. ...........................Scientific Review Administrator

Ashley Church*.....................................Office Automation Clerk

Mary Fletcher, Ph.D* ............................Scientific Review Administrator

Monica Green§ ......................................Program Specialist

Tiffany Jenifer* .....................................Program Specialist (Instructor)

Willie Johnson*................................Program Specialist

Wlodek Lopaczynski, M.D., Ph.D.** .......Scientific Review Administrator

William Merritt, Ph.D.............................Scientific Review Administrator

Hasnaa Shafik, M.D., Ph.D. ...................Scientific Review Administrator

Michael Small, Ph.D. .............................Scientific Review Administrator

Shamala Srinivas, Ph.D. ........................Scientific Review Administrator

Barbara Thompson*...............................Program Support Assistant

Claudio Dansky Ullman, M.D.*...............Scientific Review Administrator

Peter Wirth, Ph.D..................................Scientific Review Administrator

Brian Wojcik, Ph.D.* .............................Scientific Review Administrator

Sunghan Yoo, Ph.D. .............................Scientific Review Administrator

* Left in 2005.

§ Transferred from NIH OD OER DEAS to RPRB in 2005.

**Joined in 2005.

NCI/DEA Annual Report 2005

47
Resources and Training Review Branch

Plans, coordinates, and manages the scientific merit review of cancer center, clinical cooperative group, training, and education grant and cooperative agreement applications by chartered

review committees and Special Emphasis Panels.

Arranges for and participates in onsite assessments of the research capabilities and facilities of

selected applicants.

Identifies and recommends appropriate review committee members and site visitors, as

required, for the review of assigned applications.

Provides input and advice on grant review policy and procedures, application patterns, and

research trends and other related information, as required.

Coordinates grant review activities with staff of other NCI Divisions, other DEA Branches, and

the Center for Scientific Review.

David E. Maslow, Ph.D. ......................... Chief 

Lynn Amende, Ph.D. ............................. Scientific Review Administrator

Robert Bird, Ph.D.................................. Scientific Review Administrator

Gail Bryant, M.D. ................................. Scientific Review Administrator

Deborah Jaffe, Ph.D.............................. Scientific Review Administrator

Ilda McKenna, Ph.D. ............................. Scientific Review Administrator

Isla Norwood†....................................... Program Specialist

Raymond Petryshyn, Ph.D...................... Scientific Review Administrator

Sonya Roberson, Ph.D* ......................... Scientific Review Administrator

* Transferred from PCRB to RTRB in 2005.

† Joined in 2005.

NCI/DEA Annual Report 2005

48
Research Analysis and Evaluation Branch

Serves as the Institute’s officially designated, centralized source of scientific information and

science-based budget information on NCI-supported research.

Analyzes and classifies the science content of all Institute-supported research projects.

Analyzes the distribution of funds among research areas; these analyses serve as a basis for

budget projections.

Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded

research, including research grants, center grants, training grants, and research contracts.

Maintains liaisons with other organizations involved in related classification activities.

Documents the need for proposed RFAs by comparing RFA concepts with existing NCIsupported research and with unsolicited applications.

Marilyn Gaston .....................................Branch Chief

Edward Kyle..........................................Deputy Branch Chief

Research Documentation 

Analyzes and indexes grants and contracts for the Branch’s computerized systems.

Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.

Ensures that terms and categories for indexing are updated and reflect current trends in cancer

research, and maintains a thesaurus of term definitions.

Maintains liaison with other offices within the Institute to ensure consistent reporting of data.

Monitors the results of Institute grant-supported research. 

Assists other NCI organizations by indexing NCI research projects for attributes other than SICs

and Sites, for example, CSO Codes, AIDs Categories, and so on.

Edward Kyle ......................................... Lead Biologist

Bethany Buschling†................................ Biologist

Catherine Carneal*................................ Biologist

Lisa Krueger ......................................... Biologist

Bernard Whitfield .................................. Biologist

Tyrone Wilson ....................................... Biologist

* Left in 2005.

† Joined in 2005.

NCI/DEA Annual Report 2005

49
Technical Operations, Inquiry and Reporting

Provides specialized data querying, archiving, and reporting functions for the Division, the

Financial Management Branch, and the Institute.

Coordinates Institute data reporting with the NCI Financial Data Branch, NIH Population

Tracking and Inclusion Committee, and others.

Answers inquiries from Congress, the public, the press, and others concerning any phase of

Institute-supported work.

Conducts in-depth analyses of extramural research data, including trends analysis.

Identifies emerging priority areas for data collection and analysis.

Manages RAEB’s FLARE grants documentation and indexing database, ensuring reliability and

completeness of its contents. Maintains and updates archival document files.

Works with contractors and the AISB to refine RAEB’s computer applications to meet the

Branch’s needs, and resolve FLARE computer application problems for the Branch.

Manages RAEB’s personnel support functions.

Gail Blaufarb.........................................Lead Biologist

Stacy Harper-Avilla.................................Biologist

Clarissa Douglas† ..................................Program Specialist

Linda Brown* .......................................Computer Assistant

* Left in 2005 to join ORRPC.

† Joined in 2005.

NCI/DEA Annual Report 2005

50
Applied Information Systems Branch

Satisfies the information technology (IT) requirements of the Division; coordinates information

resources management (IRM) activities with other relevant NCI and NIH units; and provides

high-quality information analysis, design, development, and coordination of applications in support of Divisional business processes.

Serves as the focal point for the Division in the development, deployment, and application of

specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.

Serves as the liaison with the NCI Information Services Technology Branch (ISTB); other NCI

computer professionals; other NCI units charged with execution of extramural IRM functions;

other trans-NIH functional units such as the CSR, Office of Policy for Extramural Research

Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and

eRA (Electronic Research Administration) systems.

Supports resources and Internet and Intranet applications connectivity and design.

Establishes, administers, and monitors contracts to provide design, production, and maintenance

for microcomputer equipment and information storage and retrieval systems not covered by the

NCI’s Core Services.

Formulates DEA-specific office automation policy.

Provides staff/lead users with technical support and training for DEA IT applications.

Coordinates general user support and training with NCI or NIH services.

Provides Division-specific applications of video teleconferencing and audiovisual services in

support of review and Board activities.

Provides management with recommendations for establishing and implementing policies for

conducting Divisional computer-assisted presentations, as necessary.

Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

James W. Seach.....................................Chief

Application Development and Operations Team

Analyzes and coordinates life-cycle development of software for the Division; develops and

designs applications to support the Division’s business practices, including user guides.

Develops, administers, and monitors contracts for acquisition, support, and maintenance of

database systems.

NCI/DEA Annual Report 2005

51
Administers office automation contracts as well as DEA-wide Blanket Purchase Agreements for

microcomputer equipment maintenance and supplies.

Formulates office automation policy, system development, and IMPAC II operations.

Coordinates internal user groups and the provision of training for specific DEA applications and

the use of office automation equipment technology.

Gregory Fischetti ..................................Team Leader

Deborah Buranich ................................Information Technology Specialist

Charles Conley......................................Information Technology Specialist

Lauren Lawson......................................Information Technology Specialist

Teresa Park ..........................................Information Technology Specialist

Hector Reyes ........................................Information Technology Specialist

Information Management Team

Designs and maintains the Division’s Intranet and Internet, and identifies documents to be

placed on the NCI Web Site to make Division information more accessible to the public.

Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information

throughout the NCI.

Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.

Works with DEA staff to ensure the current utility and linkages of documents placed on the

Web.

Amir Sahar-Khiz.....................................Team Leader

Kichelle Green.......................................Management Assistant

Lorrie Smith..........................................Information Technology Specialist

Elaine Taylor ........................................Information Technology Specialist

NCI/DEA Annual Report 2005

52
Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2005 

Sorted by Date of Publication

Date of Division

Publication RFA Mechanism Title and Office

11/2/2004 CA05-021 U54 Comprehensive Minority Institution/Cancer Center 

Partnership OCTR

11/3/2004 CA05-022 U56 Cooperative Planning Grant for Comprehensive 

Minority Institution/Cancer Center Partnership OCTR

11/30/2004 CA05-026 R01 Cancer Nanotechnology Platform Development OTIR

12/1/2004 CA05-025 F32, F33 Multidisciplinary Career Development in Cancer 

7/13/2005 CA06-010 Nanotechnology Research OTIR

12/2/2004 CA05-024 U54 Centers of Cancer Nanotechnology Excellence OTIR

12/6/2004 CA06-005 R41, R42, Innovative Technologies for Molecular Analysis 

R43, R44 of Cancer (SBIR/STTR) OTIR

12/8/2004 CA06-004 R21, R33 Innovations in Cancer Sample Preparation OTIR

12/9/2004 CA06-002 R21, R33 Innovative Technologies for the Molecular Analysis of Cancer OTIR

12/9/2004 CA06-003 R21, R33 Applications of Emerging Technologies for Cancer Research OTIR

12/16/2004 CA06-006 R41, R42, Applications of Emerging Technologies for Cancer Research 

R43, R44 (SBIR/STTR) OTIR

12/16/2004 CA06-007 R41, R42, Innovations in Cancer Sample Preparation (SBIR/STTR) OTIR

R43, R44

2/14/2005 CA06-502 R01, R21 AIDS Malignancy Clinical Trial Consortium DCTD

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2005 

Sorted by Division and Office

Division Date of

and Office RFA Mechanism Title Publication

DCTD CA06-502 R01, R21 AIDS Malignancy Clinical Trial Consortium 2/14/2005

OCTR CA05-021 U54 Comprehensive Minority Institution/Cancer

Center Partnership 11/2/2004

OCTR CA05-022 U56 Cooperative Planning Grant for Comprehensive 

Minority Institution/Cancer Center Partnership 11/3/2004

OTIR CA05-026 R01 Cancer Nanotechnology Platform Development 11/30/2004

OTIR CA05-025 F32, F33 Multidisciplinary Career Development in Cancer 12/1/2004

CA06-010 Nanotechnology Research 7/13/2005

OTIR CA05-024 U54 Centers of Cancer Nanotechnology Excellence 12/2/2004

OTIR CA06-005 R41, R42, Innovative Technologies for Molecular Analysis of Cancer 

R43, R44 (SBIR/STTR) 12/6/2004

OTIR CA06-004 R21, R33 Innovations in Cancer Sample Preparation 12/8/2004

OTIR CA06-002 R21, R33 Innovative Technologies for the Molecular Analysis of Cancer 12/9/2004

OTIR CA06-003 R21, R33 Applications of Emerging Technologies for Cancer Research 12/9/2004

OTIR CA06-006 R41, R42, Applications of Emerging Technologies for Cancer Research 

R43, R44 (SBIR/STTR) 12/16/2004

OTIR CA06-007 R41, R42, Innovations in Cancer Sample Preparation 

R43, R44 (SBIR/STTR) 12/16/2004

NCI/DEA Annual Report 2005

53
Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs),

FY2005

Sorted by Date of Publication

Date of Division

Publication RFA Mechanism Title and Office

10/26/2004 DK04-013 R01, R21 Site Specific Approaches to Prevention or Management 

of Pediatric Obesity DCCPS

10/29/2004 OD05-001 K07 Strengthening Behavioral and Social Science in 

Medical Schools DCCPS

11/19/2004 AI05-001 U01 Leadership for HIV/AIDS Clinical Trials Networks DCTD

2/10/2005 AI05-002 U01, U19 Units for HIV/AIDS Clinical Trials Networks DCTD

5/5/2005 HD05-025 U01 Global Network for Women’s and Children’s Health Research DCCPS

6/30/2005 NR-06-001 R01 Research on Research Integrity DCP

9/8/2005 HG05-007 U01 Completion of a Comprehensive Mouse Knockout Resource DCB

9/20/2005 DK05-014 R01, R21 The Obese and Diabetic Intrauterine Environment: Long-Term 

Metabolic or Cardiovascular Consequences in the Offspring DCP

Table 3a. Program Announcements (PAs) Published by the NCI in FY2005 

Sorted by Date of Publication

Date of Division

Publication PA Mechanism Title and Office

11/2/2004 PAR05-011 K22 NCI Transition Career Development Award to OCTR/ 

Promote Diversity CMBB

11/22/2004 PA05-017 R01, R21 Decision Making in Cancer: Single-Event Decisions DCCPS

2/17/2005 PAR05-042 P50 Specialized Programs of Research Excellence (SPOREs) OCTR/

in Human Cancer for Year 2005-2006 OSB

3/3/2005 PA05-062 R01, R21 Correlative Studies with Specimens from Multi-Site Trials DCTD

3/8/2005 PAR05-065 R25 Cancer Education Grant Program OCTR/ 

TR

5/20/2005 PAR05-114 R21 Quick Trials for Imaging and Image-Guided Interventions: 

Exploratory Grants DCTD

5/26/2005 PA05-116 R03, R21 Pilot Studies in Pancreatic Cancer DCTD

6/20/2005 PA05-125 R01, R21 Diet-Induced Changes in Inflammation as Determinants 

of Colon Cancer DCP

7/13/2005 PA05-138 P01 Etiology, Prevention, and Treatment of Hepatocellular Carcinoma DCB

7/28/2005 PAR05-145 K05 Established Investigator Award in Cancer Prevention & Control OCTR/ 

TR

8/18/2005 PAR05-156 P50 Specialized Programs of Research Excellence (SPOREs) OCTR/

in Human Cancer for Year 2006 OSB

9/16/2005 PA05-165 R21 Exploratory Studies in Cancer Detection, Diagnosis, 

and Prognosis DCTD

NCI/DEA Annual Report 2005

54
Table 3b. Program Announcements (PAs) Published by the NCI in FY2005

Sorted by Division and Office

Division Date of

and Office PA Mechanism Title Publication

DCB PA05-138 P01 Etiology, Prevention, and Treatment of Hepatocellular 

Carcinoma 7/13/2005

DCCPS PA05-017 R01, R21 Decision Making in Cancer: Single-Event Decisions 11/22/2004

DCP PA05-125 R01, R21 Diet-Induced Changes in Inflammation as Determinants 

of Colon Cancer 6/20/2005

DCTD PA05-062 R01, R21 Correlative Studies with Specimens from Multi-Site Trials 3/3/2005

DCTD PAR05-114 R21 Quick Trials for Imaging and Image-Guided Interventions: 

Exploratory Grants 5/20/2005

DCTD PA05-116 R03, R21 Pilot Studies in Pancreatic Cancer 5/26/2005

DCTD PA05-165 R21 Exploratory Studies in Cancer Detection, Diagnosis, 

and Prognosis 9/16/2005

OCTR/CMBB PAR05-011 K22 NCI Transition Career Development Award to 

Promote Diversity 11/2/2004

OCTR/OSB PAR05-042 P50 Specialized Programs of Research Excellence (SPOREs) 

in Human Cancer for Year 2005-2006 2/17/2005

OCTR/OSB PAR05-156 P50 Specialized Programs of Research Excellence (SPOREs) 

in Human Cancer for Year 2006 8/18/2005

OCTR/TR PAR05-065 R25 Cancer Education Grant Program 3/8/2005

OCTR/TR PAR05-145 K05 Established Investigator Award in Cancer Prevention 

and Control 7/28/2005

NCI/DEA Annual Report 2005

55
Table 4. NCI Participation in Trans-NIH Program Announcements (PAs),

FY2005

Sorted by Date of Publication

Date of Division

Publication PA Mechanism Title and Office

10/18/2004 PA05-004 R01, R21 Symptom Clusters in Cancer and Immune Disorders DCP

12/10/2004 PA05-027 R01 Research on Mind-Body Interactions and Health DCCPS

12/17/2004 PA05-029 R01 Social and Cultural Dimensions of Health DCCPS

1/24/2005 PA05-041 R41, R42, Small Business Innovation Research (SBIR) and Small 

R43, R44 Business Technology Transfer (STTR) to Improve the 

Chemistry and Targeted Delivery of RNAi Molecules DCTD

3/30/2005 PAR05-080 R01 Tools for Zebrafish Research DCB

4/11/2005 PAR05-085 R01, R03, R21 Understanding and Treating Tuberous Sclerosis Complex DCB

4/15/2005 PA05-090 R01, R03, R21 Methodology and Measurement in the Behavioral and 

Social Sciences DCCPS

5/6/2005 PA05-103 R21 Pilot and Feasibility Program Related to the Kidney DCB

6/30/2005 PAR05-133 T15 Short-Term Courses in Human Embryonic Stem Cell 

Culture Techniques DCB

7/14/2005 PAR05-140 D43 AIDS International Training and Research Program DCTD

7/15/2005 PA05-141 R01, R15, R21 Basic and Preclinical Research on Complementary DCP/

and Alternative Medicine (CAM) OCCAM

7/20/2005 PA05-142 R01, R21 Biobehavioral Methods to Improve Outcomes Research DCCPS

7/22/2005 PA05-143 K23 Mentored Patient-Oriented Research Career OCTR/

Development Award TR

8/10/2005 PAR05-152 R21 CAM at Minority or Health Disparities Research Centers DCP

8/18/2005 PA05-155 R01, R21 The Secretory Pattern of Senescent Cells DCB

NCI/DEA Annual Report 2005

56
NCI/DEA Annual Report 2005

57

Table 5. Applications Received for Referral by the NCI/DEA 

(by Mechanism), FY2005*†

Applications by Board

Activity Totals 

Mechanism Code by Activity Jan May Sep

International Training Grant in Epidemiology (Fogarty International Center) D43 6 0 6 0

Predoctoral Individual National Research Service Award (NRSA) F31 83 0 48 35

Postdoctoral Individual National Research Service Award F32 502 110 218 174

National Research Service Award for Senior Fellows F33 7 1 4 2

National Research Service Award for Senior Fellows F34 1 0 1 0

Resources Project Grant (NLM) G08 1 0 0 1

Research Scientist Development Award—Research and Training K01 179 58 57 64

Research Scientist Development Award—Research K02 1 0 0 1

Research Scientist Award K05 11 5 3 3

Academic/Teacher Award K07 175 50 35 90

Clinical Investigator Award K08 142 50 51 41

Physician Scientist Award (Program) K12 13 12 1 0

Career Transition Award K22 73 24 29 20

Mentored Patient-Oriented Research Development Award K23 57 14 25 18

Midcareer Investigator Award in Patient-Oriented Research K24 20 10 5 5

Mentored Quantitative Research Career Development K25 19 5 9 5

Research Program Project P01 146 46 51 49

Exploratory Grant P20 32 0 0 32

Center Core Grant P30 37 9 24 4

Biotechnology Resource Grant Program P41 2 1 1 0

Specialized Center P50 28 11 12 5

Research Project R01 6,276 1,906 2,224 2,146

Small Research Grant R03 463 129 186 148

Conference R13 124 28 50 46

Academic Research Enhancement Awards (AREA) R15 100 39 38 23

(Continued)

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications and withdrawn applications. Does not inlcude 747

applications received for referral but not accepted for review.

† FY2005 includes receipt, referral, and review activities occurring between October 1, 2004, and September 30, 2005.
NCI/DEA Annual Report 2005

58

Applications by Board

Activity Totals 

Mechanism Code by Activity Jan May Sep

Exploratory/Developmental Grants R21 2,089 615 753 721

Resource-Related Research Project R24 1 0 0 1

Education Project R25 98 26 39 33

Exploratory/Developmental Grant Phase II R33 82 22 39 21

Clinical Trial Planning Grant R34 1 0 1 0

Method to Extend Research in Time (MERIT) Award R37 19 11 6 2

Small Business Technology Transfer (STTR) Grant—Phase I R41 192 61 59 72

Small Business Technology Transfer (STTR) Grant—Phase II R42 39 10 18 11

Small Business Innovation Research Grant (SBIR)—Phase I R43 940 325 305 310

Small Business Innovation Research Grant (SBIR)—Phase II R44 338 112 116 110

James A. Shannon Director’s Award R55 2 2 0 0

High Priority, Short Term Project Award R56 4 2 2 0

Minority Biomedical Research Support—(MBRS) S06 3 0 3 0

Research and Institutional Resources Health Disparities 

Endowment Grants—Capacity Building Grant S21 5 0 0 5

Research and Student Resources Health Disparities 

Endowment Grant—Educational Program S22 1 0 0 1

Continuing Education Training Program T15 2 0 2 0

Institutional National Research Service Award T32 105 48 38 19

Research Project (Cooperative Agreement) U01 263 110 142 11

Cooperative Clinical Research (Cooperative Agreement) U10 40 32 1 7

Research Program (Cooperative Agreement) U19 49 39 1 9

Resource-Related Research Project (Cooperative Agreement) U24 18 17 0 1

Specialized Center (Cooperative Agreement) U54 49 0 14 35

Exploratory Grants—Cooperative Agreement U56 10 0 0 10

Total 12,848 3,940 4,617 4,291

Table 5. Applications Received for Referral by the NCI/DEA 

(by Mechanism), FY2005*† (Continued)
Applications by Board

Activity Totals 

Mechanism Code by Activity Jan May Sep

Postdoctoral Individual National Research Service Award F32 4 0 0 4

National Research Service Award for Senior Fellow F33 1 0 0 1

Research Scientist Development Award—Research and Training K01 169 56 55 58

Research Scientist Award K05 8 3 3 2

Academic/Teacher Award K07 122 48 35 39

Clinical Investigator Award K08 118 39 45 34

Physician Scientist Award (Program) K12 13 12 1 0

Career Transition Award K22 73 24 29 20

Mentored Patient-Oriented Research Development Award K23 42 8 19 15

Midcareer Investigator Award in Patient-Oriented Research K24 15 8 3 4

Mentored Quantitative Research Career Development K25 15 4 6 5

Research Program Project P01 134 44 46 44

Exploratory Grant P20 32 0 0 32

Center Core Grant P30 12 3 5 4

Specialized Center P50 27 10 12 5

Research Project R01 139 2 52 85

Small Research Grant R03 400 120 137 143

Conference R13 70 17 27 26

Exploratory/Developmental Grant R21 276 62 152 62

Education Project R25 93 24 38 31

Exploratory/Developmental Grants—Phase II R33 58 14 30 14

Small Business Technology Transfer (STTR) Grant—Phase I R41 8 3 1 4

Small Business Technology Transfer (STTR) Grant—Phase II R42 3 0 3 0

Small Business Innovation Research Grant (SBIR)—Phase I R43 77 21 25 31

Small Business Innovation Research Grant (SBIR)—Phase II R44 11 6 3 2

Continuing Education Training Program T15 1 0 1 0

(Continued)

NCI/DEA Annual Report 2005

59

Table 6. Grant and Cooperative Agreement Applications Reviewed by the

NCI/DEA (by Mechanism), FY2005*

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications. Withdrawn applications have been subtracted from

the total count. Of the 2,401 applications reviewed during the year, 101 applications were withdrawn, 700 were not recommended

for further consideration by initial review committee, and an additional 828 received scores in the bottom 33 percent and were not 

submitted for NCAB action. Does not include 31 applications reviewed by the NCI for the NIAID.
Applications by Board

Activity Totals 

Mechanism Code by Activity Jan May Sep

Institutional National Research Service Award T32 95 45 31 19

Research Project (Cooperative Agreement) U01 233 107 124 2

Cooperative Clinical Research (Cooperative Agreement) U10 40 32 1 7

Research Program (Cooperative Agreement) U19 37 37 0 0

Resource-Related Research Project (Cooperative Agreement) U24 17 16 0 1

Specialized Center (Cooperative Agreement) U54 48 0 13 35

Exploratory Grant (Cooperative Agreement) U56 10 0 0 10

Total 2,401 765 897 739

NCI/DEA Annual Report 2005

60

Table 6. Grant and Cooperative Agreement Applications Reviewed by the

NCI/DEA (by Mechanism), FY2005*(Continued)
Table 7. Applications Reviewed by NCI IRG Subcommittees and 

Special Emphasis Panels (SEPs), FY2005*

Total Costs

NCI IRG Types of Applications Number of Requested Requested

Subcommittee Reviewed Applications First Year All Years

A—Cancer Centers P30 12 $69,650,903 $374,837,484

C—Basic and Preclinical P01, R01 47 85,161,202 444,319,719

D—Clinical Studies P01, R01 63 144,853,273 737,493,146

E—Cancer Epidemiology, 

Prevention and Control P01, R01, U01, U24 36 76,616,061 372,274,603

F—Manpower and Training K01, T32 252 52,391,309 293,436,402

G—Education K01, K05, K07, K22, 

K23, K24 195 26,185,334 130,340,716

H—Clinical Trials R01, U10 12 45,267,194 226,395,319

I—Career Development F32, F33, K01, K08, K22, 

K23, K25, R13, T15 207 28,235,116 119,915,352

J—Population and Patient-Oriented 

Training† 0 00

Subtotal-NCI IRG Subcommittees 824 $528,360,392 $2,699,012,741

All SEPs K05, K07, K08, K12, K22, 

K24, P01, P20, P50, R01, 

R03, R13, R21, R25, R33, 

R41, R42, R43, T32, U01, 

U10, U19, U24, U54, U56 

Subtotal SEPs 1,577 $848,259,279 $4,041,740,642

IRG & SEP Totals 2,401 $1,376,619,671 $6,740,753,383

* Source: IMPACII. There were 101 withdrawn applications subtracted from the total count.

† Formed in late FY2005.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed 

for Each NCAB Meeting, FY2005

Applications by Board

Type of Application January 2005 May 2005 September 2005 FY 2005 Total

New 7 13 13 33

New Amended 11 13 12 36

Recompeting 14 8 4 26

Recompeting Amended 10 9 13 32

Supplement 1 3 2 6

Supplement Amended 1 1

Total 44 46 44 134

NCI/DEA Annual Report 2005

61
Table 9. Summary of Unsolicited P01 Applications Reviewed by NCI in

FY2005

Sorted by NCI Program Division

Total Costs

Number of First Year Requested Total Costs for

Program Division Applications Total Costs Requested Period

Division of Cancer Biology (DCB) 41 $77,365,558 $403,170,677

Division of Cancer Control and Population Sciences (DCCPS) 6 14,872,698 73,792,716

Division of Cancer Prevention (DCP) 9 19,944,408 104,255,341

Division of Cancer Treatment and Diagnosis (DCTD) 78 191,163,794 986,030,563

Total 134 $303,346,458 $1,567,249,297

NCI/DEA Annual Report 2005

62
Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA,

FY2005*

Applications by NCAB Round Total Costs

Bypass RFA Activity Requested Requested

Title of Initiative Initiative Number Codes Totals Jan May Sept First Year Total Years

NCI/DEA Annual Report 2005

63

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications. There were 54 withdrawn applications subtracted from the total count.

U01 25 25 0 0 $55,992,790 $282,219,462

U19 37 37 0 0 45,420,337 225,776,438

R21 91 26 40 25 19,512,321 39,267,705 

R33 22 3 10 9 13,166,874 31,616,307

R21 82 26 32 24 16,014,981 115,963,399 

R33 28 8 17 3 16,632,963 48,960,969

R21 28 10 13 5 4,965,961 24,594,813 

R33 8 3 3 2 27,707,021 7,861,422 

U01 14 14 0 0 16,858,834 90,473,238 

U24 1 1 0 0 23,824 23,824 

R41 4 2 0 2 0 1,030,301 

R42 1 0 1 0 933,843 1,627,729 

R43 25 11 8 6 310,300 4,525,164 

R44 6 3 2 1 969,912 8,262,619 

R41 4 1 1 2 0 335,282 

R42 1 0 1 0 94,500 877,265 

R43 31 6 13 12 0 3,546,580 

R44 3 1 1 1 199,944 3,571,701 

R42 1 0 1 0 194,565 2,300,888 

R43 14 4 4 6 0 2,089,435 

R44 2 2 0 0 726,917 2,040,188 

U24 5 5 0 0 2,341,670 13,392,238 

U54 13 0 13 0 29,752,723 150,703,484 

U01 3 0 3 0 2,845,935 14,351,415 

U01 65 65 0 0 51,161,306 260,061,867

Strategic Partnering to Evaluate

Cancer Signatures

National Cooperative Drug

Discovery Groups (NCDDGs) for

the Treatment of Cancer

Innovation Technologies for the

Molecular Analysis of Cancer II

Applications of Emerging

Technologies for Cancer Research

Innovations in Cancer Sample

Preparation

The Early Detection Research

Network: Clinical Epidemiology

and Validation Centers

Innovative Technologies for

Molecular Analysis of Cancer

SBIR

Applications of Emerging 

Techologies for Cancer 

Research SBIR

Innovations in Cancer Sample

Preparation SBIR/STTR

The Early Detection Research

Network: Biomarker Reference

Laboratory

Transdisciplinary Research on

Energetics and Cancer Centers

Coordination Center for TREC

Centers

Community Networks to Reduce

Cancer Disparities Through

Education, Research, and Training

2

3,4,12,13

2,3,11,14

2,3,11,14

2,3,11,14

2,3,4,14

2,3,11,14

2,3,11,14

2,3,11,14

2,3,4

6,8,9

6,8,9

8

CA04-015

CA05-001

CA06-002

CA05-002

CA06-003

CA05-003

CA06-004

CA05-004

CA05-005

CA06-005

CA05-006

CA06-006

CA05-007

CA06-007

CA05-008

CA05-009

CA05-010

CA05-011

CA05-012

(Continued)
NCI/DEA Annual Report 2005

64

R01 32 0 32 0 $16,674,256 $70,667,111 

R21 35 0 35 0 5,406,736 10,774,311 

U10 22 22 0 0 28,876,413 152,655,321 

U10 8 8 0 0 5,550,242 27,015,297

U24 9 9 0 0 14,641,595 74,518,547

U01 22 0 22 0 5,248,384 26,629,990

U01 40 0 40 0 29,837,584 154,902,754 

P20 32 0 0 32 5,618,593 22,839,540

U54 7 0 0 7 9,253,712 50,046,504

U56 10 0 0 10 3,770,966 19,587,840

U01 50 0 50 0 36,584,519 190,853,740 

U54 28 0 0 28 144,859,239 694,829,410 

F32 4 0 0 4 0 0 

F33 1 0 0 1 0 0 

R01 62 0 0 62 51,613,357 243,416,169 

R43 1 0 0 1 909,012 4,208,170

U01 1 1 0 0 1,999,839 9,999,537 

U01 8 0 8 0 3,282,374 17,355,704 

R43 6 0 0 6 0 702,866 

U19 31 0 31 0 $141,009,726 $706,102,318 

926 293 381 249 $810,964,068 $3,812,578,862 

Reducing Barriers in Symptom

Management and Palliative Care

Community Clinical Oncology

Program

Minority-Based Community

Clinical Oncology Program

Support for Human Specimen

Banking in NCI-Supported Cancer

Clinical Trials

Cancer Intervention and 

Surveillance Modeling Network

Patient Navigator Intervention

Research Program

Planning Grant for Minority

Institution/Cancer Center

Collaboration

Comprehensive Minority

Institution/Cancer Center

Partnership

Cooperative Planning Grant for

Comprehensive Minority Institution/

Cancer Center Partnership

Early Detection Research

Network: Biomarkers

Developmental Laboratories

Centers of Cancer

Nanotechnology Excellence

Multidisciplinary Career

Development in Cancer

Nanotechnology Research

Cancer Nanotechnology Platform

Development

EDRN: Clinical Data Management

Coordinating Center

Breast Cancer Surveillance

Consortium Infrastructure

Circulating Cells in Cancer

Detection

Centers for Medical Countermeasures Against Radiation **

Total

7

13

8,13

2,3,11,13

7,8,10,13,15

7,8,13

8,11,12,13

8,11,12

8,11,12

2,3,4

3,4,12

3,4,11

3,4,11

2,3,12

7,8,10,12,

13

2,3,4

N/A

CA05-013

CA05-014

CA05-015

CA05-017

CA05-018

CA05-019

CA05-020

CA05-021

CA05-022

CA05-023

CA05-024

CA05-025

CA05-026

CA05-501

CA05-502

CA06-001

AI04-045

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA,

FY2005* (Continued)

Applications by NCAB Round Total Costs

Bypass RFA Activity Requested Requested

Title of Initiative Initiative Number Codes Totals Jan May Sept First Year Total Years

** Reviewed by the NCI for the NIAID.
NCI/DEA Annual Report 2005

65

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA,

FY2005*

Applications by NCAB Round Total Costs

Bypass PA Activity Requested Requested

Title of Initiative Initiative Number Codes Totals Jan May Sept First Year Total Years

K07 2 0 2 0 $247,847 $1,266,639 

K08 100 35 38 27 14,161,109 68,515,551 

K07 2 2 0 0 236,686 1,186,302 

K08 1 0 1 0 131,706 658,530 

K23 37 8 17 12 5,527,927 27,199,987 

K24 5 5 0 0 760,009 3,923,670 

K01 7 3 1 3 1,011,973 5,007,456 

K07 1 0 1 0 257,350 1,335,608 

T32 30 12 9 9 8,404,645 50,260,844 

K25 13 3 5 5 1,723,550 8,153,845 

R01 4 0 0 4 3,763,543 13,740,894 

K24 6 0 3 3 1,323,551 6,184,534 

K24 2 2 0 0 277,001 1,418,560 

R25 1 0 1 0 612,096 3,226,809 

K05 1 1 0 0 141,101 707,983 

K01 2 0 1 1 237,351 1,440,146 

K22 3 3 0 0 404,640 1,213,876 

K07 5 1 4 0 666,112 3,369,453

K08 7 1 1 5 1,009,392 5,156,981 

K23 4 0 1 3 551,607 2,831,151 

R03 104 38 26 40 7,958,930 15,436,609 

Mentored Clinical Scientist

Development Award (K08)

Mentored Patient Oriented

Research Career Development

Award

Midcareer Investigator Award in

Patient-Oriented Research (K24)

Mentored Research Scientist

Development Award - K01

Academic Career Award (K07)

NIH National Research Service

Award Institutional Research

Training Grants (T32)

Mentored Quantitative Research

Career Development Award

Clinical Cancer Therapy and

Prevention Research

Midcareer Investigator Award in

Patient-Oriented Research 

Midcareer Investigator Award In

Patient-Oriented Research

Cancer Education Grant Program

Established Investigator Award in

Cancer Prevention, Control,

Behavioral and Population

Research

The Howard Temin Award

NCI Transition Career

Development Award

Cancer Prevention, Control,

Behavioral and Population

Sciences Career Development

Award

Mentored Clinical Scientist Award

for Underrepresented Minorities

Mentored Patient-Oriented

Research for Underrepresented

Minorities

Small Grants Program for Cancer

Epidemiology

N/A

N/A

N/A

N/A

N/A

N/A

4

13

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

11, 14

PA00-003

PA00-004

PA00-005

PA00-019

PA00-070

PA02-109

PA02-127

PA04-046

PA04-107

PA98-053

PAR00-033

PAR00-039

PAR00-066

PAR01-134

PAR01-135

PAR03-002

PAR03-006

PAR03-010

(Continued)

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications. There were 39 withdrawn applications subtracted from the total count.
NCI/DEA Annual Report 2005

66

K01 40 10 14 16 $4,550,361 $25,826,526 

R25 55 16 30 9 16,235,061 77,332,411 

K22 15 5 9 1 2,305,321 6,996,193 

K01 116 42 36 38 14,311,461 82,176,978 

R25 24 7 7 10 9,721,654 57,121,667

K05 7 2 3 2 1,329,401 6,898,044

R21 23 0 23 0 5,527,457 10,591,781 

P50 21 4 12 5 55,623,640 390,126,300 

R13 62 17 27 18 2,564,996 6,784,236 

R03 91 32 28 31 6,938,188 13,506,484 

R01 29 0 16 13 16,609,431 72,972,982 

R21 17 0 9 8 3,401,567 6,217,030 

K22 51 15 20 16 7,218,158 21,667,489

K07 111 44 28 39 14,186,884 70,942,041

P50 6 6 0 0 12,668,739 64,095,537 

K12 12 11 1 0 6,052,896 41,521,526 

R03 205 50 83 72 15,766,690 31,093,049 

NCI Mentored Career

Development Award for

Underrepresented Minorities

Cancer Education Grant Program

NCI Transition Career

Development Award for

Underrepresented Minorities

The Howard Temin Award

Cancer Education and Career

Development Program

Established Investigator Award in

Cancer Prevention, Control,

Behavioral and Population

Sciences

Industry-Academic Partnerships

for Development of Biomedical

Imaging Systems

Specialized Program of Research

Excellence (SPOREs) in Human

Cancer for the Year 2004

Conference Grants

Small Grants Progam for

Behavioral Research in Cancer

Control

Colorectal Cancer Screening in

Primary Care Practice

NCI Transition Career

Development Award

Cancer Prevention, Control,

Behavioral and Population

Sciences Cancer Development

Award

In Vivo Cellular and Molecular

Imaging Centers (ICMICs)

Paul Calabresi Award for Clinical

Oncology

Cancer Prevention Research

Small Grant Program

5,6,7,8,10

N/A

N/A

N/A

N/A

N/A

4

13

N/A

5,6,7,10

10

N/A

N/A

4

N/A

N/A

PAR03-016

PAR03-093

PAR03-101

PAR03-104

PAR03-148

PAR03-149

PAR03-157

PAR03-158

PAR03-176

PAR04-020

PAR04-036

PAR04-040

PAR04-055

PAR04-069

PAR04-096

PAR02-176

PAR04-147

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA,

FY2005* (Continued)

Applications by NCAB Round Total Costs

Bypass PA Activity Requested Requested

Title of Initiative Initiative Number Codes Totals Jan May Sept First Year Total Years

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications. There were 39 withdrawn applications subtracted from the total count.
NCI/DEA Annual Report 2005

67

K22 3 0 0 3 $397,136 $1,214,426 

R25 9 0 0 9 2,718,662 12,633,522 

1,234 375 457 402 $247,535,829 $1,221,953,650

NCI Transition Career

Development Award to Promote

Diversity

Cancer Education (R25E)

Program

Total

N/A

N/A

PAR05-011

PAR05-065

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA,

FY2005* (Continued)

Applications by NCAB Round Total Costs

Bypass PA Activity Requested Requested

Title of Initiative Initiative Number Codes Totals Jan May Sept First Year Total Years

* Source: IMPACII. Includes NCI Primary and Secondary assigned applications. There were 39 withdrawn applications subtracted from the total count.
NCI/DEA Annual Report 2005

68

Table 12. Average Total Cost and Number of Research Project Grant 

Awards, FY2002-FY2005 

Sorted by Division

FY2002 FY2003 FY2004 FY2005 

Average Average Average Average Average

No. Cost No. Cost No. Cost No. Cost No. Cost

R01 Average Cost of Award Data

NCI Overall 3,377 $324,000 3,573 $338,000 3,780 $338,000 3,848 $341,000 13.9% 5.2%

DCB 1,941 291,000 2,028 304,000 2,139 305,000 2,132 306,000 9.8% 5.2%

DCP 126 431,000 151 452,000 169 412,000 203 418,000 61.1% -3.0%

DCTD 916 295,000 973 306,000 1,027 314,000 1,057 319,000 15.4% 8.1%

DCCPS 389 502,000 418 518,000 441 501,000 453 502,000 16.5% 0.0%

OD (CRCHD, OCCAM, 

OCTR, etc.) 5 1,799,000 3 2,886,000 4 N.A. 3 N.A. N.A. N.A.

P01 Average Cost of Award Data

NCI Overall 173 1,836,000 178 1,891,000 177 1,946,000 176 1,924,000 1.7% 4.8%

DCB 63 1,571,000 70 1,651,000 66 1,702,000 67 1,717,000 6.3% 9.3%

DCP 13 1,931,000 12 2,014,000 13 2,065,000 15 2,047,000 15.4% 6.0%

DCTD 80 1,995,000 83 1,988,000 86 2,040,000 84 2,027,000 5.0% 1.6%

DCCPS 16 2,015,000 13 2,321,000 12 2,375,000 9 2,358,000 -43.8% 17.0%

OD (CRCHD, OCCAM, 

OCTR, etc.) 1 1,715,000 N.A. N.A. 1 1,426,000 N.A. N.A.

R03 Average Cost of Award Data

NCI Overall 186 76,000 203 75,000 240 75,000 223 76,000 19.9% 0.0%

DCB 3 90,000 3 85,000 7 76,000 5 70,000 66.7% -22.2%

DCP 81 77,000 74 74,000 137 74,000 85 76,000 4.9% -1.3%

DCTD 3 78,000 1 72,000 5 80,000 5 82,000 66.7% 5.1%

DCCPS 99 75,000 125 74,000 91 76,000 128 76,000 29.3% 1.3%

OD (CRCHD, OCCAM, 

OCTR, etc.) N.A. N.A. N.A. N.A. N.A. N.A.

R21 Average Cost of Award Data

NCI Overall 309 187,000 360 188,000 425 183,000 430 178,000 39.2% -4.8%

DCB 30 138,000 37 149,000 70 157,000 75 150,000 150.0% 8.7%

DCP 18 191,000 24 166,000 76 151,000 42 176,000 133.3% 7.9%

DCTD 236 196,000 231 200,000 241 202,000 240 193,000 1.7% -1.5%

DCCPS 25 148,000 41 157,000 37 177,000 72 153,000 188.0% 3.4%

OD (CRCHD, OCCAM, 

OCTR, etc.) N.A. 27 205,000 1 277,000 1 455,000 N.A. N.A.

(Continued)

Percent Change

02-05
FY2002 FY2003 FY2004 FY2005 

Average Average Average Average Average

No. Cost No. Cost No. Cost No. Cost No Cost

U01/U19 Average Cost of Award Data

NCI Overall 216 $770,000 198 $898,000 174 $942,000 164 $969,000 -24.1% 25.8%

DCB 20 758,000 20 809,000 27 748,000 27 782,000 35.0% 3.2%

DCP 9 1,143,000 10 938,000 9 907,000 10 831,000 11.1% -27.3%

DCTD 136 701,000 121 902,000 103 952,000 85 1,076,000 -37.5% 53.5%

DCCPS 51 880,000 47 903,000 35 1,060,000 42 902,000 17.6% 2.5%

OD (CRCHD, OCCAM, 

OCTR, etc.) N.A. N.A. N.A. N.A. N.A. N.A.

R13 Average Cost of Award Data

NCI Overall 83 26,000 108 23,000 112 19,000 99 23,000 19.3% -11.5%

DCB 44 11,000 48 11,000 56 9,000 55 9,000 25.0% -18.2%

DCP 8 15,000 11 14,000 13 13,000 13 14,000 62.5% -6.7%

DCTD 19 40,000 30 20,000 22 20,000 13 33,000 -31.6% -17.5%

DCCPS 8 43,000 12 53,000 15 26,000 10 63,000 25.0% 46.5%

OD (CRCHD, OCCAM, 

OCTR, etc.) 4 123,000 7 82,000 6 110,000 8 64,000 100.0% -48.0%

U10 Average Cost of Award Data—Includes Cancer Control

NCI Overall 210 1,225,000 151 1,654,000 139 1,785,000 136 1,732,000 -35.2% 41.4%

DCB N.A. N.A. N.A. N.A. N.A. N.A.

DCP 73 1,287,000 73 1,247,000 74 1,258,000 73 1,269,000 0.0% -1.4%

DCTD 137 1,183,000 78 2,026,000 65 2,373,000 63 2,266,000 -54.0% 11.8%

DCCPS N.A. N.A. N.A. N.A. N.A. N.A.

OD (CRCHD, OCCAM, 

OCTR, etc.) N.A. N.A. N.A. N.A. N.A. N.A.

P30 Average Cost of Award Data—Includes Cancer Control

NCI Overall 63 3,215,000 63 3,596,000 63 3,798,000 63 3,945,000 0.0% 22.7%

DCB N.A. N.A. N.A. N.A. N.A. N.A.

DCP 2 729,000 2 728,000 2 960,000 2 818,000 0.0% 12.2%

DCTD N.A. N.A. N.A. N.A. N.A. N.A.

DCCPS 0 N.A. N.A. N.A. N.A. N.A. N.A.

OD (CRCHD, OCCAM, 

OCTR, etc.) 61 3,282,000 61 3,640,000 61 3,834,000 61 3,982,000 0.0% 21.3%

P50 Average Cost of Award Data—Includes Cancer Control

NCI Overall 43 2,706,000 66 2,377,000 83 2,204,000 76 2,197,000 76.7% -18.8%

DCB N.A. N.A. 6 2,189,000 N.A. N.A. N.A.

DCP N.A. N.A. N.A. N.A. N.A. N.A.

DCTD 5 2,203,000 7 2,010,000 7 2,249,000 7 1,984,000 40.0% -9.9%

DCCPS 4 2,603,000 12 2,042,000 12 1,830,000 12 1,868,000 200.0% -28.2%

OD (CRCHD, OCCAM, 

OCTR, etc.) 34 2,792,000 47 2,518,000 58 2,278,000 57 2,292,000 67.6% -17.9%

NCI/DEA Annual Report 2005

69

Table 12. Average Total Cost and Number of Research Project Grant 

Awards, FY2002-FY2005 (Continued) 

Sorted by Division

Percent Change

02-05
NCI/DEA Annual Report 2005

70

Dollars in Thousands % of NCI Total

Award Dollar Average Number Dollar Competing Competing Success 

Mechanism Count Cost Requested Awarded Rate

Research Project Grants (RPG)

R01—Traditional 

Research Grants 3,848 1,312,762 341 54.7% 40.4% 4,038 809 20.0%

P01—Program Project Grants 176 338,660 1,924 2.5% 10.4% 116 39 33.6%

R03—Small Grants 223 16,894 76 3.2% 0.5% 350 89 25.4%

R21—Exploratory/ 

Developmental Grants 430 76,566 178 6.1% 2.4% 1,240 213 17.2%

R33—Phased Innovation 

Grant (Phase 2) 88 36,250 412 1.3% 1.1% 16 4 25.0%

R56—Bridge Award 1 407 407 0.0% 0.0% 1 1 100.0%

R37—MERIT Award 74 40,007 541 1.1% 1.2% 15 15 100.0%

R15—Academic Research 

Enhancement Awards (AREA) 20 4,091 205 0.3% 0.1% 59 20 33.9%

R55—Shannon Awards 2 200 100 0.0% 0.0% 2 2 100.0%

Program Evaluation (tap) 58,721 1.8%

Request for Applications—RFA

(R01, R21, R03, R33 , P01) 121 47,556 393 1.7% 1.5% 387 64 16.5%

RFA—Cooperative Agreements 

(U01, U19) 133 123,847 931 1.9% 3.8% 94 31 33.0%

Cooperative Agreements— 

not RFA 31 35,149 1,134 0.4% 1.1% 7 5 71.4%

Small Business Innovation 

Research (U43, U44, R43, R44) 

—SBIR 231 86,579 375 3.3% 2.7% 944 120 12.7%

Small Business Technology 

Transfer Research (R41, R42)— 

STTR 34 11,196 329 0.5% 0.3% 160 16 10.0%

Subtotal, RPG 5,412 2,188,885 404 77.0% 67.3% 7,429 1,428 19.2%

Centers

CORE 61 247,708 4,061 0.9% 7.6% 15 15 100.0%

P20 Exploratory 7,555 0.2%

SPORE 57 133,025 2,334 0.8% 4.1% 17 4 23.5%

Specialized Centers 

(Cooperative Agreement) 27 39,726 1,471 0.4% 1.2% 25 7 28.0%

Specialized Centers 

(Nanotechnology) 7 26,238 3,748 0.1% 0.8% 28 7 25.0%

Subtotal, Centers 152 454,252 2,989 2.2% 14.0% 85 33 38.8%

(Continued)

Table 13. Summary of NCI Grant Awards by Mechanism, FY2005
NCI/DEA Annual Report 2005

71

Dollars in Thousands % of NCI Total

Award Dollar Average Number Dollar Competing Competing Success 

Mechanism Count Cost Requested Awarded Rate

Other U13—Conference 

Research (Cooperative Agreement) 1 17 17 0.0% 0.0%

(A)

D43, R13—Conference Grants 95 1,883 20 1.4% 0.1% 70 52 74.3%

T15—Training Conference Grants 3 338 113 0.0% 0.0% 2 1 50.0%

R24, U24—Research Resource 

Grant 51 28,178 553 0.7% 0.9% 10 9 90.0%

U10—Clinical Cooperative Group 63 142,847 2,267 0.9% 4.4% 3 2 66.7%

S06—Minority Biomedical 

Research Support 3,367 0.1%

R09, U09—Scientific Evaluation 8,621 0.3%

U56—Exploratory Grants— 

Cooperative Agreement 29 12,487 431 0.4% 0.4% 2 2 100.0%

Subtotal, Other Research (A) 242 197,738 817 3.4% 6.1% 87 66 75.9%

Other R25—Cancer Education 101 34,581 342 1.4% 1.1% 96 17 17.7%

Research

(B)— K08—Mentored Clinical 

Career Scientist 141 17,841 127 2.0% 0.5% 118 25 21.2%

Awards

K07—Preventive Oncology 

Award 110 13,529 123 1.6% 0.4% 104 26 25.0%

K12, K14—Mentored Career 

Award 13 7,436 572 0.2% 0.2% 13 2 15.4%

K01—Temin Award 127 17,734 140 1.8% 0.5% 135 30 22.2%

K22—Clinical Research Track 35 5,344 153 0.5% 0.2% 63 12 19.0%

K23—Mentored Patient-Oriented 

Research Career Development 60 7,533 126 0.9% 0.2% 43 8 18.6%

K24—Mid-Career Investigator in

Patient-Oriented Research Award 16 2,306 144 0.2% 0.1% 14 5 35.7%

K25—Mentored Quantitative 

Research Career Development 

Award 9 1,227 136 0.1% 0.0% 19 5 26.3%

K30—Institutional Curriculum 

Award 1,147 0.0%

K05—Established Investigator in 

Cancer Prevention and Control 20 2,554 128 0.3% 0.1% 8 2 25.0%

Subtotal, Other Research (B) 

—Career Awards 632 76,651 144 7.6% 2.4% 517 115 22.2%

Subtotal, Other Research (A+B) 874 308,970 354 12.4% 9.5% 700 198 28.3%

(Continued)

Table 13. Summary of NCI Grant Awards by Mechanism, FY2005 (Continued)
NCI/DEA Annual Report 2005

72

Dollars in Thousands % of NCI Total

Award Dollar Average Number Dollar Competing Competing Success 

Mechanism Count Cost Requested Awarded Rate

Ruth Kirschstein National Research Service Awards (NRSA)

T32, T34, T35, T36— 

NRSA Institutional Award 172 58,890 342 2.4% 1.8% 90 41 45.6%

F30, F31, F32, F33, F34— 

NRSA Fellowship 195 8,267 42 2.8% 0.3% 329 79 24.0%

NRSA Nanotechnology 

Fellowships 3 142 47 0.0% 0.0% 5 3 60.0%

Subtotal, NRSA 370 67,299 182 5.3% 2.1% 424 123 29.0%

Cancer Control

Cancer Prevention and Control 189 206,990 1,095 2.7% 6.4% 158 47 29.7%

Cancer Control Special 

Populations 33 24,819 752 0.5% 0.8% 105 33 31.4%

Subtotal, Cancer Control 222 231,809 1,044 3.2% 7.1% 263 80 30.4%

Total, All NCI Grants 7,030 3,251,215 462 100.0% 100.0% 8,901 1,862 20.9%

Table 13. Summary of NCI Grant Awards by Mechanism, FY2005 (Continued)
Adoptive Cell Immunotherapy 54,038,845 62,020,806 65,348,655 70,375,002 70,072,700 4,008,464 6.85

Adv. Manufacturing Technology 24,931,210 14,271,896 9,841,911 12,662,969 16,171,766 -2,189,861 -4.36

Aging 115,799,586 139,110,456 165,960,180 160,302,073 171,633,181 13,958,399 10.77

AIDS 60,108,228 60,954,602 119,070,648 130,840,621 131,010,836 17,725,652 26.69

Alternative Medicine, Direct 23,796,940 32,950,143 57,481,994 62,596,463 59,802,451 9,001,378 29.34

Alternative Medicine, Indirect 28,806,239 29,685,596 28,482,503 33,406,568 25,822,838 -745,850 -1.60

Alzheimer's Dementia 712,086 1,030,384 1,621,994 1,558,931 1,536,040 205,989 24.19

Arctic Research 3,040,138 2,824,330 4,052,599 3,477,543 2,227,788 -203,088 -3.43

Arthritis 525,144 1,120,913 1,584,332 1,515,693 1,007,647 120,626 29.24

Asbestos 1,468,410 1,836,892 4,491,877 2,255,176 2,728,981 315,143 35.21

Ataxia Telangiectasia 6,447,560 7,950,411 6,837,168 4,569,973 4,746,714 -425,212 -5.00

Autoimmune Diseases 6,149,176 7,067,297 8,686,585 9,958,212 9,037,735 722,140 10.81

Behavior Research 226,317,414 238,366,446 275,849,766 284,166,605 295,139,435 17,205,505 6.98

Bioengineering 237,827,136 281,461,832 294,659,713 293,329,685 207,349,791 -7,619,336 -1.68

Bioinformatics 65,933,728 100,558,934 104,554,183 124,834,295 147,062,040 20,282,078 23.42

Biological Carcinogenesis, Non-Viral 1,752,242 2,598,885 5,797,028 6,128,334 5,956,723 1,051,120 43.57

Biological Response Modifiers 683,741,092 701,465,562 741,430,361 750,275,261 887,217,706 50,869,154 6.93

Biomaterials Research 14,831,893 23,938,815 33,558,137 39,745,363 37,785,085 5,738,298 28.77

Birth Defects 10,366,083 8,368,607 8,859,294 8,894,762 9,889,474 -119,152 -0.46

Bone Marrow Transplantation 67,242,722 65,937,038 62,342,401 57,457,088 49,480,615 -4,440,527 -7.28

Breast Cancer Detection 82,170,515 88,646,269 90,193,676 97,976,659 101,390,086 4,804,893 5.43

Breast Cancer Early Detection 28,898,616 32,888,952 37,243,747 43,101,816 48,551,540 4,913,231 13.86

Breast Cancer Education 17,542,808 15,776,265 16,917,838 19,386,970 19,854,753 577,986 3.54

Breast Cancer Epidemiology 62,368,195 67,786,774 69,296,280 70,470,523 63,832,544 366,087 0.80

Breast Cancer Genetics 71,506,312 78,890,543 76,659,752 77,442,317 81,815,294 2,577,246 3.54

Breast Cancer Prevention 30,291,170 30,679,526 34,660,141 32,510,070 32,360,672 517,376 1.90

Breast Cancer Rehabilitation 12,704,463 12,294,656 13,111,191 15,549,473 18,220,763 1,379,075 9.80

Breast Cancer Screening 31,798,684 27,483,358 27,174,072 26,554,448 25,913,420 -1,471,316 -4.85

Breast Cancer Treatment 132,584,822 145,793,684 151,796,777 155,143,128 154,285,405 5,425,146 3.93

Breast Cancer, Basic 104,063,834 124,478,880 141,314,873 143,663,931 143,175,326 9,777,873 8.62

Cancer Survivorship 113,381,591 123,650,648 159,528,445 144,326,030 145,043,558 7,915,492 7.26

Carcinogenesis, Environmental 499,193,141 519,803,912 534,983,057 540,898,673 542,772,539 10,894,850 2.13

Cervical Cancer Education 2,875,322 1,988,194 449,332 4,271,351 4,178,353 325,758 185.04

Chemoprevention 118,350,179 137,699,833 171,216,267 187,160,162 187,622,217 17,318,010 12.56

Chemoprevention, Clinical 51,828,752 57,915,038 64,878,256 61,170,813 63,463,878 2,908,782 5.45

Chemotherapy 371,849,362 405,576,212 440,643,645 465,719,189 479,353,115 26,875,938 6.58

Child Health 41,793,487 42,750,912 46,876,216 53,727,243 61,887,153 5,023,417 10.44

Childhood Cancers 115,580,450 134,662,114 145,491,219 155,350,035 159,567,547 10,996,774 8.51

Chronic Myeloproliferative Disorders 18,671,299 20,780,473 27,032,001 30,942,794 36,959,663 4,572,091 18.82

Clinical Trials, Diagnosis 68,399,344 91,207,850 130,311,300 125,946,948 113,103,165 11,175,955 15.67

Clinical Trials, Other 9,407,729 11,642,674 15,562,589 24,130,327 54,757,357 11,337,407 59.85

Clinical Trials, Prevention 67,359,658 65,484,612 79,553,001 71,998,187 68,628,972 317,329 1.13

Clinical Trials, Therapy 351,852,384 383,915,169 411,687,228 419,641,529 401,297,009 12,361,156 3.48

Combined Treatment Modalities 230,278,274 242,999,243 233,777,421 315,475,918 330,666,739 25,097,116 10.37

Diabetes 5,152,356 7,375,423 7,548,368 6,353,949 10,440,254 1,321,975 23.49

Diagnosis 442,517,243 502,737,788 564,021,884 580,801,202 618,317,471 43,950,057 8.81

NCI/DEA Annual Report 2005

73

Table 14. NCI Special Interest Category (SIC) Dollars for FY2001-FY2005 –

Annual Percent Change*

(Continued)

* Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent

of the extramural budget.

Special Interest Categories (SIC) 2001 2002 2003 2004 2005 

Average

Dollar

Change/Yr.

Average

Percent

Change/Yr.

(This table reports funding for research grants and contracts only; training grants and intramural projects are excluded.)
NCI/DEA Annual Report 2005

74

Diagnostic Imaging 211,026,004 237,057,220 277,178,915 294,539,520 317,336,979 26,577,744 10.82

Diethylstilbestrol 1,088,613 2,110,511 1,443,103 1,677,478 2,222,054 283,360 27.74

Dioxin 1,176,288 1,203,176 1,184,362 1,258,661 194,225 -245,516 -19.39

DNA Repair 119,632,425 133,358,200 153,415,262 163,589,431 157,358,768 9,431,586 7.33

Drug Development 371,183,370 404,887,431 447,881,008 516,896,095 559,855,963 47,168,148 10.85

Drug Discovery 29,984,314 39,935,561 46,425,752 54,828,594 66,215,930 9,057,904 22.08

Drug Resistance 84,257,975 91,682,326 106,373,506 115,298,251 120,398,474 9,035,125 9.41

Drugs-Natural Products 120,015,486 135,213,972 136,685,224 138,003,587 132,933,883 3,229,599 2.76

Early Detection 165,943,634 183,145,249 245,520,500 271,300,826 301,025,316 33,770,421 16.47

Endocrinology 143,788,158 161,408,991 186,968,577 178,585,401 183,285,587 9,874,357 6.56

Energy Balance † † 29,829,583 26,440,260 38,184,297 4,177,357 16.53

Epidemiology, Biochemical 253,164,838 251,966,498 245,341,226 219,502,809 206,718,733 -11,611,526 -4.86

Epidemiology, Environmental 216,029,411 223,777,515 218,722,428 215,241,204 218,875,075 711,416 0.36

Epigenetics 21,692,693 18,498,512 51,759,530 65,005,515 94,971,910 18,319,804 59.19

Gene Mapping, Human 227,153,900 234,642,282 247,040,795 217,496,425 182,663,241 -11,122,665 -4.85

Gene Mapping, Non-Human 89,416,780 100,405,277 94,748,524 80,515,173 67,952,386 -5,366,099 -5.99

Gene Transfer, Clinical 15,608,158 19,026,602 20,278,841 20,661,840 17,254,725 411,642 3.47

Genetic Testing Research, Human 209,668,514 222,300,181 225,895,895 191,499,674 196,298,554 -3,342,490 -1.27

Genomics † † 14,134,782 16,217,856 24,245,008 5,055,113 32.12

Health Promotion and Care 177,300,353 181,819,192 214,599,231 211,627,936 238,467,719 15,291,842 7.97

Helicobacter 2,043,806 2,155,965 4,242,773 4,423,309 3,815,249 442,861 23.20

Hematology 375,156,811 416,103,247 445,442,843 447,179,086 450,398,699 18,810,472 4.77

Hematopoietic Stem Cell Research 86,508,848 89,663,101 95,335,267 99,710,757 105,121,325 4,653,119 5.00

Hormone Replacement Therapy 9,312,758 12,170,912 13,502,323 12,859,852 14,254,242 1,235,371 11.93

Hospice 1,631,747 1,554,969 5,429,050 6,272,396 8,671,792 1,760,011 74.56

Iatrogenesis 57,164,355 53,708,534 58,816,401 54,060,109 56,013,837 -287,630 -0.25

Infant Mortality 874,643 415,516 137,648 131,431 216,858 -164,446 -14.72

Information Dissemination 296,003,962 327,420,863 364,362,635 365,997,428 390,365,620 23,590,415 7.25

Magnetic Resonance Imaging 59,418,389 67,609,501 83,051,490 67,077,228 69,701,604 2,570,804 5.33

Mammography 36,078,569 34,681,607 36,033,787 38,427,220 36,724,102 161,383 0.56

Metastasis 205,893,018 253,373,096 296,031,487 309,340,607 310,478,648 26,146,408 11.19

Mind/Body Research 11,496,467 11,405,866 16,186,181 20,374,850 19,535,017 2,009,638 15.72

Molecular Disease 1,050,976,543 1,170,777,839 1,262,060,208 1,339,620,569 1,432,200,446 95,305,976 8.06

Molecular Targeted Therapy 35,856,332 47,514,280 57,225,106 86,681,914 168,524,743 33,167,103 49.71

Nanotechnology 75,632,102 126,332,277 156,533,223 162,067,173 160,886,764 21,313,666 23.44

Neurofibromatosis 4,039,087 5,720,563 5,297,104 4,440,584 5,441,436 350,587 10.15

Nursing Research 7,783,431 9,702,363 11,916,138 12,314,520 12,875,140 1,272,927 13.84

Nutrition 173,040,134 190,887,074 212,521,117 211,442,595 225,476,479 13,109,086 6.94

Nutrition, Fiber 12,213,332 12,665,694 12,613,110 11,497,589 10,944,448 -317,221 -2.59

Nutrition Monitoring 41,047,489 38,850,410 36,098,086 25,273,055 27,724,349 -3,330,785 -8.18

Obesity 24,465,509 28,476,238 31,488,991 29,053,667 47,654,377 5,797,217 20.82

Occupational Cancer 16,353,324 13,853,744 15,206,346 11,920,612 12,431,237 -980,522 -5.71

Oncogenes 500,232,464 551,639,242 620,478,436 634,237,576 650,329,143 37,524,170 6.88

Organ Transplant Research 77,061,181 75,564,744 72,356,860 73,412,458 65,746,345 -2,828,709 -3.79

Osteoporosis 1,287,965 1,372,960 1,168,234 1,141,017 1,657,557 92,398 8.66

Pain 10,031,119 9,302,205 14,411,836 17,002,607 20,644,937 2,653,455 21.77

Palliative Care 14,758,958 16,548,850 21,296,057 22,501,723 24,483,291 2,431,083 13.82

Table 14. NCI Special Interest Category (SIC) Dollars for FY2001-FY2005 –

Annual Percent Change (Continued)

(Continued)

Special Interest Categories (SIC) 2001 2002 2003 2004 2005 

Average

Dollar

Change/Yr.

Average

Percent

Change/Yr.

† Coding not requested or required.

(This table reports funding for research grants and contracts only; training grants and intramural projects are excluded.)
NCI/DEA Annual Report 2005

75

Pap Testing 13,607,240 13,654,479 14,509,718 17,012,637 18,343,787 1,184,137 7.92

Pediatric Research 191,713,838 163,639,187 215,691,002 227,132,843 240,263,190 12,137,338 7.06

Pesticides 4,873,065 4,284,987 4,131,483 3,576,795 2,300,012 -643,263 -16.19

Prevention, Primary 289,129,734 319,636,000 363,759,578 392,570,979 407,329,290 29,549,889 9.01

Proteomics † † 16,447,068 23,290,691 37,141,648 10,347,290 50.54

Radiation, Electromagnetic Fields 202,904 467,375 495,945 427,464 580,932 94,507 39.64

Radiation, Ionizing 40,403,867 42,101,953 40,875,195 39,238,254 43,059,514 663,912 1.76

Radiation, Ionizing Radiotherapy 186,661,321 215,846,842 203,836,509 222,200,058 233,258,022 11,649,175 6.01

Radiation, Non-Ionizing 33,468,407 34,240,777 36,893,495 39,381,363 38,469,271 1,250,216 3.62

Radiation, Non-Ionizing DX or RX 75,539,731 88,065,469 98,809,611 82,190,194 107,407,913 7,967,046 10.66

Radiation, UV 30,963,722 32,083,519 35,021,219 37,662,847 36,599,581 1,408,965 4.37

Radon 2,663,660 3,062,288 2,247,435 311,741 2,064,419 -149,810 116.11

Rare Diseases 30,881,959 38,638,903 41,841,085 42,994,896 41,827,984 2,736,506 8.36

Rehabilitation 23,896,857 23,997,685 25,558,259 28,124,501 33,264,360 2,341,876 8.81

Rural Populations 36,785,996 41,581,846 43,782,335 42,209,191 49,888,988 3,275,748 8.23

Sexually Transmitted Diseases 38,735,494 41,861,170 46,790,495 49,370,699 53,246,020 3,627,632 8.30

Smokeless Tobacco 8,255,406 9,187,608 8,052,530 3,235,635 3,157,981 -1,274,356 -15.82

Smoking and Health 109,359,712 132,181,616 136,772,177 140,691,633 131,902,138 5,635,607 5.24

Smoking Behavior 71,662,082 74,377,943 78,958,064 77,398,392 65,185,509 -1,619,143 -1.95

Smoking, Passive 3,273,435 5,229,306 6,088,321 6,163,806 5,646,628 593,298 17.26

Structural Biology 272,019,072 305,817,182 341,881,210 370,571,496 382,597,297 27,644,556 8.96

Surgery 131,100,384 140,614,550 135,887,501 137,281,620 102,248,250 -7,213,034 -5.15

Taxol 66,028,941 73,334,203 71,638,234 79,061,172 67,584,901 388,990 1.15

Telehealth 115,999,693 142,577,583 136,729,979 137,081,094 122,527,280 1,631,897 2.11

Therapy 935,331,567 1,031,798,021 1,126,832,535 1,217,391,826 1,272,641,374 84,327,452 8.02

Tropical Diseases 6,114,348 9,238,519 11,812,651 10,255,864 11,102,730 1,247,096 18.51

Tumor Markers 372,368,593 424,350,478 489,114,837 451,794,712 434,204,129 15,458,884 4.42

Underserved Populations 91,594,430 102,897,644 130,143,998 138,519,933 177,574,214 21,494,946 18.36

Vaccine Development 10,004,710 11,587,466 14,453,579 21,617,405 27,059,011 4,263,575 28.82

Vaccine Production 543,699 392,138 774,562 1,976,306 1,693,418 287,430 52.62

Vaccine Research 34,472,922 39,766,490 39,445,936 41,596,477 40,521,325 1,512,101 4.35

Vaccine Testing 27,876,903 32,958,589 43,526,814 44,774,687 45,170,380 4,323,369 13.51

Virus Cancer Research 181,555,204 180,659,962 196,287,543 194,880,644 191,052,843 2,374,410 1.37

Virus, Epstein-Barr 16,989,697 21,842,219 23,278,988 23,134,534 24,534,511 1,886,204 10.14

Virus, Genital Herpes 980,918 791,268 666,153 670,672 507,354 -118,391 -14.70

Virus, Hepatitis B 12,282,212 11,227,777 10,387,770 8,795,216 7,739,861 -1,135,588 -10.85

Virus, Hepatitis C 4,209,225 3,747,069 4,715,540 4,263,315 4,890,912 170,422 5.00

Virus, Herpes 44,731,976 49,648,779 51,778,550 53,522,401 52,021,227 1,822,313 3.96

Virus, HHV6 70,059 48,563 40,917 42,500 51,916 -4,536 -5.10

Virus, HHV8 10,517,347 12,455,991 17,787,658 17,648,098 19,069,528 2,138,045 17.13

Virus, HTLV-I 4,689,997 6,502,070 8,443,640 7,369,926 8,734,324 1,011,082 18.57

Virus, HTLV-II 282,943 272,629 15,161 39,299 246,497 -9,112 147.09

Virus, HTLV-Unspecified 323,350 225,104 69,094 72,443 76,253 -61,774 -22.40

Virus, Papilloma 40,928,716 39,498,156 49,870,165 51,897,332 56,846,619 3,979,476 9.09

Virus, Papova 50,657,432 49,274,609 61,875,739 65,462,575 69,718,574 4,765,286 8.79

Virus, SV40 4,923,898 1,813,705 8,645,371 10,130,358 10,464,181 1,385,071 83.49

Vitamin A 20,352,974 26,006,509 22,486,845 22,194,566 23,874,074 880,275 5.13

Vitamin C 5,292,593 6,379,668 6,809,996 5,566,346 5,490,209 49,404 1.91

Vitamins, Other 12,663,827 13,889,605 21,073,817 19,859,860 23,430,615 2,691,697 18.41

Table 14. NCI Special Interest Category (SIC) Dollars for FY2001-FY2005 –

Annual Percent Change (Continued)

Special Interest Categories (SIC) 2001 2002 2003 2004 2005 

Average

Dollar

Change/Yr.

Average

Percent

Change/Yr.

(This table reports funding for research grants and contracts only; training grants and intramural projects are excluded.)
NCI/DEA Annual Report 2005

76

Table 15. NCI Organ Site-Specific Dollars for FY2001-FY2005 – 

Annual Percent Change

Adrenal 1,835,756 2,461,533 3,960,952 2,593,630 2,717,779 220,506 16.32

Anus 3,771,168 2,830,955 4,356,693 6,178,964 6,313,360 635,548 18.24

Bladder 23,690,751 27,301,423 29,375,431 29,192,500 25,392,413 425,416 2.30

Bone Marrow 21,391,584 19,677,230 18,738,105 16,859,731 17,969,897 -855,422 -4.06

Bone, Cartilage 14,391,897 17,247,451 22,398,965 21,436,315 20,296,744 1,476,212 10.02

Brain 65,151,201 83,839,618 95,279,466 105,526,751 101,434,991 9,070,948 12.30

Breast 439,711,614 481,369,725 499,135,321 514,406,565 510,552,531 17,710,229 3.87

Buccal Cavity 4,913,915 5,228,865 5,622,264 6,480,376 5,494,543 145,157 3.50

Central Nervous System 10,830,586 17,612,827 18,946,339 20,699,745 17,192,652 1,590,517 15.63

Cervix 61,534,654 60,044,335 72,057,870 72,682,867 75,787,307 3,563,163 5.68

Childhood Leukemia 40,086,718 47,525,099 47,389,916 48,088,942 45,113,301 1,256,646 3.39

Colon, Rectum 197,850,771 239,871,854 243,188,189 245,543,444 238,230,314 10,094,886 5.15

Connective Tissue 5,535,330 7,857,870 7,572,951 7,094,659 7,558,119 505,697 9.64

Embryonic Tissue, Cells 9,467,501 10,165,631 7,746,541 6,559,473 5,318,429 -1,037,268 -12.67

Esophagus 15,628,257 16,192,090 19,039,683 19,382,040 20,378,823 1,187,642 7.03

Eye 1,596,475 2,504,907 2,432,688 1,513,506 2,465,231 217,189 19.78

Gall Bladder 169,162 222,092 757,328 872,737 899,162 182,500 72.64

Gastrointestinal Tract 14,278,898 13,671,557 15,872,991 19,597,757 21,145,926 1,716,757 10.80

Genital System, Female 2,167,215 2,355,030 1,935,489 5,172,691 4,794,366 656,788 37.70

Genital System, Male 3,337,417 2,718,076 3,167,731 2,262,682 4,243,858 226,610 14.24

Head and Neck 16,726,118 26,533,478 35,716,098 44,167,285 44,641,240 6,978,781 29.49

Heart 5,542,956 6,634,127 6,774,839 4,909,069 4,452,774 -272,546 -3.76

Hodgkin's Lymphoma 8,471,751 11,314,844 15,895,958 16,247,077 16,354,733 1,970,746 19.23

Kaposi Sarcoma 18,734,908 16,570,217 18,753,497 18,688,727 20,071,159 334,063 2.17

Kidney 14,678,860 19,229,812 23,012,397 22,618,493 24,984,890 2,576,508 14.86

Larynx 1,387,440 1,538,946 1,239,045 777,411 491,395 -224,011 -20.65

Leukemia 143,746,914 169,411,195 192,741,377 196,638,676 201,052,444 14,326,383 8.97

Liver 49,834,636 54,405,285 54,925,839 54,341,107 52,888,388 763,438 1.60

Lung 193,525,572 224,762,518 254,003,512 253,490,911 245,457,301 12,982,932 6.44

Lymph Node 750,268 678,029 418,211 1,247,100 4,350,116 899,962 99.77

Lymphatic System 2,664,440 2,068,357 1,772,709 1,130,650 424,632 -559,952 -33.83

Melanoma 63,062,681 75,164,281 83,252,560 86,725,177 94,558,088 7,873,852 10.79

Muscle 8,439,049 9,793,642 10,585,789 9,961,120 9,250,584 202,884 2.78

Myeloma 15,071,246 18,118,361 23,458,037 21,375,570 25,085,863 2,503,654 14.54

Nervous System 3,631,556 3,523,660 2,947,832 2,859,805 2,909,612 -180,486 -5.14

Neuroblastoma 13,374,765 16,908,206 23,109,752 22,723,369 22,004,713 2,157,487 14.57

Non-Hodgkin's Lymphoma 72,201,088 79,556,172 87,701,313 91,103,091 94,545,180 5,586,023 7.02

Nose, Nasal Passages 1,065,629 2,019,221 1,889,287 2,435,202 1,759,357 173,432 21.05

Ovary 72,328,725 87,731,619 94,278,381 93,598,684 91,509,918 4,795,298 6.45

Pancreas 19,233,136 31,603,349 40,665,106 50,924,876 64,697,347 11,366,053 36.32

Parathyroid 302,761 144,535 103,368 206,013 186,052 -29,177 2.22

Penis 659,708 555,233 570,915 1,007,097 1,777,028 279,330 34.96

Pharynx 2,268,913 3,054,679 3,496,979 3,610,213 3,405,521 284,152 11.67

Pituitary 1,759,885 2,330,309 2,223,903 1,958,668 1,904,001 36,029 3.28

Prostate 237,882,832 259,183,447 282,162,848 283,487,876 281,876,087 10,998,314 4.43

Respiratory System 3,428,953 2,231,189 1,752,342 477,322 447,805 -745,287 -33.83

Reticuloendothelial System 29,988,010 25,012,807 22,633,635 19,752,858 16,748,919 -3,309,773 -13.51

Retinoblastoma 1,877,505 2,013,370 2,275,980 2,470,155 3,716,422 459,729 19.82

(Continued)

Site Category 2001 2002 2003 2004 2005 

Average

Dollar

Change/Yr.

Average

Percent

Change/Yr.

(This table reports funding for research grants and contracts only; training grants and intramural projects are excluded.)
NCI/DEA Annual Report 2005

77

Table 15. NCI Organ Site-Specific Dollars for 2001-2005 – 

Annual Percent Change (Continued)

Salivary Glands 282,586 439,828 335,590 305,461 247,997 -8,647 1.04

Skin 53,325,561 57,899,330 60,107,917 63,687,265 63,603,865 2,569,576 4.55

Small Intestine 1,934,219 1,940,181 2,744,882 1,592,051 1,956,314 5,524 5.67

Spleen 346,319 334,096 397,133 561,467 314,378 -7,985 3.18

Stomach 5,977,987 8,653,038 10,410,995 9,841,719 9,259,931 820,486 13.42

Testis 6,160,001 5,435,641 6,182,273 6,584,671 6,138,620 -5,345 0.43

Thymus 1,145,373 1,011,485 830,245 625,911 1,102,792 -10,645 5.49

Thyroid 3,412,520 3,948,141 4,832,175 5,729,563 6,696,420 820,975 18.38

Trachea, Bronchus 1,045,232 779,957 156,675 256,373 272,569 -193,166 -8.84

Urinary System 629,770 703,615 540,930 263,840 360,645 -67,281 -6.48

Uterus 17,739,540 21,863,181 24,399,854 24,678,691 29,654,053 2,978,628 14.04

Vagina 717,998 690,010 542,925 571,670 922,677 51,170 10.37

Vascular 41,016,604 51,851,720 49,015,750 44,089,096 35,543,894 -1,368,178 -2.12

Wilms Tumor 3,768,844 4,499,303 4,773,264 4,243,617 3,394,348 -93,624 -1.41

Site Category 2001 2002 2003 2004 2005 

Average

Dollar

Change/Yr.

Average

Percent

Change/Yr.

(This table reports funding for research grants and contracts only; training grants and intramural projects are excluded.)
NCI/DEA Annual Report 2005

78

Announcement Workload No. of

Number Announcement Title Round Proposals

RFP N44 CM47037-54 

(Topic 190 PhaseII) A New Expression System for G Protein Coupled Receptors 2/05 1

Topic 187 (Phase II) Expert vs. User-Tailored Interactive Media 2/05 1

Topic 189 (Phase II) Real-Time Cancer Communication Data Collection 2/05 2

Topic 183 (Phase II) Microfluidic/Microsphere Flow Cytometer for Detection and Quantification of 

Viral Antibodies 2/05 2

Topic 194 (Phase II) Development and Application of High-Throughput Proteomics Technologies 2/05 2

Topic 192 (Phase II) New Technologies for Monitoring the Tumor Microenvironment 2/05 2

Topic 206 Methods for Innovative Pharmaceutical Manufacturing and Quality Assurance 5/05 3

Topic 207 Synthesis Modules for Radio Pharmaceutical Production 5/05 5

Topic 208 Targetry Systems for Production of Research 5/05 4

Topic 209 Establishment of Benchmark Data Sets for Radiotherapy Quality Assurance 5/05 2

Topic 181 (Phase II) Clinical Trials Data Collection Using Hand-Held Technology 5/05 1

Topic 211 Developing Item Response Theory Software for Outcomes and 

Behavioral Measurement 5/05 5

Topic 212 Integrating Patient-Reported Outcomes in Clinical Oncology Practice 5/05 7

Topic 197 Early Detection Research Network—Bioinformatics Research Program 

(EDRN-BRP) 5/05 5

Topic 196 Antibody Array for Cancer Detection 5/05 5

Topic 203 Development of a Database and Candidate Gene, Protein, and Biochemical 

Pathway Nomination Software for Tobacco-Related Disease and Tobacco 

Addiction Investigations 5/05 2

Topic 204 Plant Genomic Models for Establishing Physiological Relevance of Bioactive 

Components as Cancer Protectants 5/05 6

Topic 198 (Phase II) Chemical Optimization and Structure-Activity Relationships 5/05 1

Topic 198 Chemical Optimization and Structure-Activity Relationships 5/05 1

Topic 213 Portable e-Technology Tools for Real-Time Energy Balance Research 5/05 9

Topic 214 Systems to Enhance Data Collection and Medication Compliance in 

Clinical Trials 5/05 11

Topic 205 Metabolomics for Early Cancer 5/05 3

Topic 210 Using Social Marketing to Disseminate Evidence-Based Energy Balance 

Intervention Approaches to Worksites 5/05 4

N01-CN-55006-72 Preclinical Efficacy and Intermediate Endpoints Assays 5/05 3

(Continued)

Table 16. Requests for Proposals (RFPs) Reviewed by NCI/DEA, FY2005*

* NCI reviewed a total of 471 proposals. The proposals were in response to RFPs (25), the 2005 SBIR contract solicitations— 

Phase II (13), the 2005 SBIR contract solicitations (72), and the Loan Repayment Program (361).
NCI/DEA Annual Report 2005

79

Announcement Workload No. of

Number Announcement Title Round Proposals

RFP N01PC45025-40 SEER Expansion Renewals 5/05 4

Topic 195 Virtual Microscopy for the Early Detection of Cancer 10/05 1

N01-CM-57018-16 Early Therapeutic Development with Phase II Emphasis 10/05 11

N01-CP-55009-39 Laboratory Assessment of Tobacco Use Behavior and Exposure Toxins— 

New Tobacco Products Promoted to Reduce Harm 10/05 2

N01-CP-51010-66 Continuation of Follow-Up of DES-Exposed Cohorts 10/05 5

NOT-OD-04-060 Loan Repayment Program for Clinical Research (L30) 8/05 276

NOT-OD-04-061 Loan Repayment Program for Pediatric Research (L40) 8/05 85

Total 471

Table 16. Requests for Proposals (RFPs) Reviewed by NCI/DEA, FY2005*

(Continued)
NCI/DEA Annual Report 2005

80

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18

members who are appointed by the President and 12 nonvoting ex officio members. The NCAB

advises, assists, consults with, and makes recommendations to the Secretary, DHHS, and to the NCI

Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements,

following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer-reviewed

applications involving requests for more than $50,000 in direct costs, the Board reviewed a total of

7,291 applications in FY2005.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2005, such as:

• NCI Director’s Report

• President’s Cancer Panel Report

• Legislative Update

• New NIH Clinical Center

• Report: Cancer Biomedical Informatics Grid

• Initiative for Discovery of Clinical Biomarkers

• P30/P50 Implementation Plan: SPORES

• Mini-Symposium: Integration of Extramural and Intramural Research Programs

• Interagency Oncology Task Force: Medical and Postdoctoral Fellowship Training Program

• Overview: NCI Intramural Clinical Research Activities 

• Update: Breast and Prostate Cancer Cohort Consortium 

• Update: FDA/NCI Task Force

• Overview: National Advanced Technologies Initiative (NATIc)

• Overview: NCI-Supported Health Care Delivery Research and Resources

• Proteomic Profiling Identifies Prognostic Subsets in Rhabdomyosarcoma

• Progress in the Development of Cell Transfer Immunotherapy for Patients With Cancer

• Update: Human Cancer Genome Project

• Harmonizing Processes and Policies for NCI-Supported Biorepositories
NCI/DEA Annual Report 2005

81

• Evidence Report on Recruitment of Underrepresented Populations to Cancer Clinical Trials

• Epigenetic Concepts in Cancer

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the

NCI Director, the NCI Office of Legislation and Congressional Activities, and the President’s Cancer

Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI

as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the

extramural RFA and RFP concepts acted upon by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed

by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI Web site at: http://

deainfo.nci.nih.gov/advisory/ncabminmenu.htm.

Appendix A: Activities of the NCAB
NCI/DEA Annual Report 2005

82

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI’s extramural research programs, and concept review of

extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard

presentations on the following in FY2005:

• Report of the Director

• NCI/Congressional Relations

• The Case for Early Detection

• Improving Care Delivery Through Translation of Evidence-Based Interventions Into Practice

• Final Report: NCAB Advanced Biomedical Technology Working Group

• BSA at National Meetings Report

• BSA Concepts Review Report

• Cancer Genome Anatomy Project 2

• An Analysis of NCI-Supported Biospecimen Resources

• Final Report: NCAB Clinical Trials Working Group

• Update: CanCORS Initiative

• Status Report: National Biospecimen Network

• Tumor Microenvironment Mini-Symposium

• Update: National Lung Screening Trial (NLST)

• Mini-Symposium: Current State of Cancer Proteomics

• Bioethics and the Future of Biorepositories 

RFA Concepts Approved

Division of Cancer Control and Population Sciences

• The Molecular Epidemiology of Pancreatic Cancer

• Breast/Ovarian Cancer Family Registries (B-CFR)

Division of Cancer Treatment and Diagnosis

• Small Animal Imaging Resource Projects (SAIRPs)

• Blood and Marrow Transplant Clinical Trials Network (BMTCTN)
NCI/DEA Annual Report 2005

83

RFP Concepts Approved

Office of the Director

• NCI Best Case Series: Developmental Support and Prospective Research Projects

• Clinical Proteomic Technologies Initiative

Division of Cancer Treatment and Diagnosis

• Early Therapeutics Development With Phase II Emphasis

Combined RFA/Cooperative Agreements Approved

Division of Cancer Treatment and Diagnosis

• AIDS Malignancies Clinical Trials Consortium 

The full text of recent BSA meeting summaries is available on the NCI Web site at: http://deainfo.

nci.nih.gov/advisory/bsaminmenu.htm.

Appendix B: Activities of the Board of Scientific Advisors
NCI/DEA Annual Report 2005

84

NCI Listens: BSA at National Association Meetings

Society of Behavioral Medicine (SBM)

Boston, MA, April 13-16, 2005

NCI Listens, Thursday, April 14, 2005

Robert Croyle, Ph.D........................................................................................National Cancer Institute

Paulette S. Gray, Ph.D.....................................................................................National Cancer Institute

Jane C. Weeks, M.D. .................................................................................Dana-Farber Cancer Institute

American Association for Cancer Research (AACR)

Anaheim, CA, April 16-20, 2005

NCI Listens, Tuesday, April 19, 2005

Ester H. Chang, Ph.D...................................................................Georgetown University Medical Center

James Doroshow, M.D. ...................................................................................National Cancer Institute

Paulette S. Gray, Ph.D.....................................................................................National Cancer Institute

William N. Hait, Ph.D. ......................................................................The Cancer Institute of New Jersey 

Susan B. Horwitz, Ph.D.....................................................................Albert Einstein College of Medicine

Suresh Mohla, Ph.D. .......................................................................................National Cancer Institute

Carolyn Strete, Ph.D. ......................................................................................National Cancer Institute

Appendix B: Activities of the Board of Scientific Advisors
NCI/DEA Annual Report 2005

85

Appendix C: List of Chartered Committees, FY2005

President’s Cancer Panel

Chair

LaSalle D. Leffall, Jr., M.D. .........................................................Howard University College of Medicine

Members

Lance E. Armstrong ..................................................................................Lance Armstrong Foundation

Margaret L. Kripke, Ph.D. ............................................University of Texas M.D. Anderson Cancer Center

Executive Secretary

Abby B. Sandler, Ph.D. ...................................................................................National Cancer Institute

Past Executive Secretary

Maureen O. Wilson, Ph.D. ..............................................................................National Cancer Institute

National Cancer Advisory Board

Acting Chair

Daniel D. Von Hoff, M.D., F.A.C.P. ............................................Translational Genomics Research Institute

Past Chair

John E. Niederhuber, M.D. ....................................................University of Wisconsin School of Medicine

Members

Samir Abu-Ghazaleh, M.D. ..................................................................................Avera Cancer Institute

James O. Armitage, M.D. ...................................................................................University of Nebraska

Moon S. Chen, Jr., Ph.D., M.P.H. ........................................University of California, Davis Cancer Center

Kenneth H. Cowan, M.D., Ph.D. ...................University of Nebraska, Eppley Institute for Cancer Research

Jean B. deKernion, M.D. .................................University of California at Los Angeles, School of Medicine

Ralph S. Freedman, M.B.B.Ch., Ph.D. ...........................University of Texas M.D. Anderson Cancer Center

James H. French, Jr., M.D. ......................................................................The Center for Plastic Surgery

Kathryn Giusti ............................................................................Multiple Myeloma Research Foundation

David H. Koch..............................................................................................................Koch Industries

Eric S. Lander, Ph.D. ......................................Whitehead Institute, Massachusetts Institute of Technology

Diana M. Lopez, Ph.D. ...............................................................University of Miami School of Medicine 

Arthur W. Nienhuis, M.D. ..............................................................St. Jude Children’s Research Hospital

Marlys Popma ..................................................................................................Independent Consultant

Franklyn Prendergast, M.D., Ph.D. ..................................................Mayo Comprehensive Cancer Center

Carolyn D. Runowicz, M.D. .......................................................University of Connecticut Health Center

Lydia G. Ryan, M.S.N., P.N.P. ..............................................................................AFLAC Cancer Center
NCI/DEA Annual Report 2005

86

Ex Officio Members of the National Cancer Advisory Board

The Honorable Elaine Chao, M.B.A. ................................................................U.S. Department of Labor

Lester M. Crawford, D.V.M., Ph.D. ...................................................U.S. Food and Drug Administration 

Stephen L. Johnson.......................................................................U.S. Environmental Protection Agency

John Howard, M.D., M.P.H., J.D., LL.M. ..................National Institute for Occupational Safety and Health

Michael O. Leavitt...........................................................U.S. Department of Health and Human Services

Rachel Levinson ................................................Office of Science and Technology Policy, The White House

Kenneth Olden, Ph.D. ........................................National Institute of Environmental Health Sciences, NIH

Ari Patrinos, Ph.D. ......................................................................................U.S. Department of Energy

The Honorable Dr. Jonathan Perlin ....................................................U.S. Department of Veterans Affairs

The Honorable Dr. Robert H. Roswell.................................................U.S. Department of Veterans Affairs

David A. Schwartz, M.D. ...................................National Institute of Environmental Health Sciences, NIH

Hal Stratton .........................................................................U.S. Consumer Product Safety Commission

The Honorable Tommy Thompson......................................U.S. Department of Health and Human Services

Andrew C. von Eschenbach, M.D. .....................................................U.S. Food and Drug Administration

The Honorable Dr. William Winkwerder, Jr. ....................................................U.S. Department of Defense

Elias A. Zerhouni, M.D. .............................................................................National Institutes of Health

Alternates to Ex Officio Members of the National Cancer Advisory Board

Michael A. Babich, Ph.D. ......................................................U.S. Consumer Product Safety Commission

Allen Dearry, Ph.D. ............................................National Institute of Environmental Health Sciences, NIH

Raynard Kington, M.D., Ph.D. ...................................................................National Institutes of Health

Peter Kirchner, M.D. ...................................................................................U.S. Department of Energy

Rachel Levinson ..........................................................................Office of Science and Technology Policy

T.G. Patel, M.D., M.A.C.P. ..............................................................U.S. Department of Veterans Affairs

Richard Pazdur, M.D. ......................................................................U.S. Food and Drug Administration

John F. Potter, M.D. ..................................................................................U.S. Department of Defense

R. Julian Preston, Ph.D. ...............................................................U.S. Environmental Protection Agency

Anita L. Schill, Ph.D., M.P.H., M.A., R.N. COHN-S. ......National Institute for Occupational Safety and Health

Donald J. Wright, M.D., M.P.H. ..........................................................U.S. Department of Labor, OSHA

Executive Secretary

Paulette S. Gray, Ph.D. ...................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

87

NCI Advisory Committee to the Director

Chair

Andrew C. von Eschenbach, M.D. ...................................................................National Cancer Institute

Members

Frederick W. Alt, Ph.D. .....................................................................................The Children’s Hospital

LaSalle D. Leffall, Jr., M.D. .........................................................Howard University College of Medicine

John E. Niederhuber, M.D. ....................................................University of Wisconsin School of Medicine

Margaret A. Tempero, M.D. .........................................................University of California, San Francisco

Thea D. Tlsty, Ph.D. ....................................................................University of California, San Francisco

Doug E. Ulman .........................................................................................Lance Armstrong Foundation

Robert C. Young, M.D. ..................................................................................Fox Chase Cancer Center

Ex Officio Members

Paulette S. Gray, Ph.D. ..................................................................................National Cancer Institute

Alan S. Rabson, M.D. ....................................................................................National Cancer Institute

Executive Secretary

Cherie Nichols, M.B.A. ...................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

88

NCI Board of Scientific Advisors

Chair

Robert C. Young, M.D. ..................................................................................Fox Chase Cancer Center

Members

David B. Abrams, Ph.D. ............................................................ The Miriam Hospital, Brown University 

David S. Alberts, M.D. .....................................................The University of Arizona College of Medicine

Hoda A. Anton-Culver, Ph.D. ...................................................................University of California, Irvine

Kirby I. Bland, M.D. .................................................................... University of Alabama at Birmingham

Esther H. Chang, Ph.D. ..............................................................Georgetown University Medical Center

Neil J. Clendeninn, M.D., Ph.D. ..............................................................Drug Development Consultant

Tom M. Curran, Ph.D. ..................................................................St. Jude Children’s Research Hospital

Raymond N. DuBois, M.D., Ph.D. ..................................................Vanderbilt University Medical Center

Shelton H. Earp, III, M.D. ........................................................Lineberger Comprehensive Cancer Center

Kathleen M. Foley, M.D. .......................................................... Memorial Sloan-Kettering Cancer Center

Patricia A. Ganz, M.D. .....................................................UCLA, Jonsson Comprehensive Cancer Center

Joe W. Gray, Ph.D. ................................................................... Lawrence Berkeley National Laboratory

William N. Hait, M.D., Ph.D. ...........................................................The Cancer Institute of New Jersey

Mary J. Hendrix, Ph.D. .................................................................................. Northwestern University 

Susan B. Horwitz, Ph.D. ..................................................................Albert Einstein College of Medicine

Hedvig Hricak, M.D., Ph.D. ......................................................Memorial Sloan-Kettering Cancer Center

Eric Hunter, Ph.D. .............................................................................................University of Alabama

William G. Kaelin, Jr., M.D. ..............................Dana-Farber Cancer Institute and Harvard Medical School

Paula Kim..................................................................................Pancreatic Cancer Action Network, Inc.

Kenneth W. Kinzler, Ph.D. ....................................................................Johns Hopkins Oncology Center

Michael P. Link, M.D. .................................................................Stanford University School of Medicine

Lynn M. Matrisian, Ph.D. .........................................................Vanderbilt University School of Medicine

Christine A. Miaskowski, R.N., Ph.D., F.A.A.N. ..............................University of California, San Francisco

Edith A. Perez, M.D. ...........................................................................................Mayo Medical School

John D. Potter, M.D., Ph.D. ................................................... Fred Hutchinson Cancer Research Center

Mack Roach, III, M.D. .................................................................University of California, San Francisco

Richard L. Schilsky, M.D. ....................................................................................University of Chicago

Ellen V. Sigal, Ph.D. ....................................................................................Friends of Cancer Research

Margaret R. Spitz, M.D., M.P.H. ..................................University of Texas M.D. Anderson Cancer Center

Jane C. Weeks, M.D. .............................................................................. Dana-Farber Cancer Institute

Executive Secretary

Paulette S. Gray, Ph.D. ...................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

89

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Margaret A. Tempero, M.D. ....................................University of California, San Francisco Cancer Center

Members

Leslie Bernstein, Ph.D. ........................................................................University of Southern California

Martin J. Blaser, M.D. ..............................................................New York University School of Medicine

David P. Carbone, M.D., Ph.D. .................................................Vanderbilt University School of Medicine

Esteban Celis, M.D., Ph.D. ..........................................Louisiana State University Health Sciences Center

Leland W. Chung, Ph.D. ................................................................Emory University School of Medicine

Chi V. Dang, M.D., Ph.D. ............................................The Johns Hopkins University School of Medicine

Scott Davis, Ph.D. ..................................................................Fred Hutchinson Cancer Research Center

Elizabeth T. Fontham, Dr.P.H. ........................................Louisiana State University Health Sciences Center

Barbara A. Gilchrest, M.D. ...........................................................Boston University School of Medicine

Stanley R. Hamilton, M.D. ..........................................University of Texas M.D. Anderson Cancer Center

Richard Hoppe, M.D. .................................................................Stanford University School of Medicine

Elizabeth M. Jaffee, M.D. ............................................The Johns Hopkins University School of Medicine

Laurence N. Kolonel, M.D., Ph.D. ..........................................................................University of Hawaii

Bruce R. Korf, M.D., Ph.D. ..........................................................University of Alabama at Birmingham

Theodore S. Lawrence, M.D., Ph.D. ....................................................................University of Michigan

Susan A. Leigh, B.S.N., R.N. ..................................................................................Cancer Survivorship

Maria Elena Martinez, Ph.D. ................................................................................University of Arizona

Susan T. Mayne, Ph.D. ......................................................................Yale University School of Medicine

Daniel M. Medina, Ph.D. .............................................................................Baylor College of Medicine

Monica Morrow, M.D. ..................................................................................Fox Chase Cancer Center

Andrew F. Olshan, Ph.D. ...........................................................................University of North Carolina

Richard J. O’Reilly, M.D. ..........................................................Memorial Sloan-Kettering Cancer Center

Alice P. Pentland, M.D. .....................................University of Rochester School of Medicine and Dentistry

Arthur T. Porter, M.D. ....................................................Wayne State University, Detroit Medical Center

Timothy R. Rebbeck, Ph.D. ................................................University of Pennsylvania School of Medicine

Eric K. Rowinsky, M.D. .....................................University of Texas Health Science Center at San Antonio

Charles L. Sawyers, M.D. ...............................University of California at Los Angeles, School of Medicine

David T. Scadden, M.D. ...................................................................................Harvard Medical School

Steven G. Self, Ph.D. ...............................................................Fred Hutchinson Cancer Research Center

Paul M. Sondel, M.D., Ph.D. ............................................................................University of Wisconsin

Ann D. Thor, M.D. .........................................................University of Oklahoma Health Sciences Center

Michael Thun, M.D. .......................................................................................American Cancer Society

Executive Secretary

Brian E. Wojcik, Ph.D. ...................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

90

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Thea D. Tlsty, Ph.D. .................................................................University of California at San Francisco

Past Chair

Frederick W. Alt, Ph.D. .....................................................................................The Children’s Hospital

Members

Stephen J. Benkovic, Ph.D. .................................................................The Pennsylvania State University

Christine Biron, Ph.D. ...............................................................................................Brown University

Olivera J. Finn, Ph.D. ...........................................................University of Pittsburgh School of Medicine

Sankar Ghosh, Ph.D. .........................................................................Yale University School of Medicine

Michael N. Gould, Ph.D. .....................................................................University of Wisconsin, Madison

James E. Haber, Ph.D. ............................................................................................Brandeis University

Katherine A. Jones, Ph.D. ...........................................................The Salk Institute for Biological Studies

Michael Karin, Ph.D. ........................................................................University of California, San Diego

Richard D. Kolodner, Ph.D. ...............................................................University of California, San Diego

John Kuriyan, Ph.D. ............................................................................University of California, Berkeley

Laimonis A. Laimins, Ph.D. ..............................................................................Northwestern University

Dan R. Littman, M.D., Ph.D. ..........................................................New York University Medical Center

Guillermina Lozano, Ph.D. ...........................................University of Texas M.D. Anderson Cancer Center

Brooke T. Mossman, Ph.D. ....................................................University of Vermont, College of Medicine

Dinshaw J. Patel, Ph.D. ............................................................Memorial Sloan-Kettering Cancer Center

Frank J. Rauscher III, Ph.D. ..............................................................The Wistar Institute Cancer Center

Martine F. Roussel, Ph.D. ...............................................................St. Jude Children’s Research Hospital

Leona D. Samson, Ph.D. ..............................................................Massachusetts Institute of Technology

Robert F. Siliciano, M.D., Ph.D. .....................................The Johns Hopkins University School of Medicine

Harinder Singh, Ph.D. ........................................University of Chicago, Howard Hughes Medical Institute

Ronald I. Swanstrom, Ph.D. ...................................................University of North Carolina at Chapel Hill

Joseph R. Testa, Ph.D. ...................................................................................Fox Chase Cancer Center

Jeffrey M. Trent, Ph.D. ............................................................Translational Genomics Research Institute

Paul O. Ts’o, Ph.D. ...................................................................................................CCC Diagnostics

Cheryl L. Walker, Ph.D. ................................................Univerity of Texas M.D. Anderson Cancer Center

Teresa S. Wang, Ph.D. ............................................................................................Stanford University

Eileen White, Ph.D. ............................................................................Howard Hughes Medical Institute

Jerry L. Workman, Ph.D. .............................................................Stowers Institute for Medical Research

Executive Secretary

Florence E. Farber, Ph.D. ................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

91

NCI Director’s Consumer Liaison Group

Chair

Doug E. Ulman .........................................................................................Lance Armstrong Foundation

Members

Margaret L. Anthony, R.N., M.S. ................................................Yul Brynner Head and Neck Foundation

Vernal Branch........................................................................Y-ME National Breast Cancer Organization

William P. Bro...............................................................................................Kidney Cancer Association

Lourie Campos, M.P.A. ...........................................................................Community Health Partnership

Nancy Davenport-Ennis .............................................................................Patient Advocate Foundation

Bobbi de Cordova-Hanks ........................................................................Women’s Center of Jacksonville

Beverly L. Laird, Ph.D. ..........................................................Susan G. Komen Breast Cancer Foundation

Sylvia M. Ramos, M.D., M.S. ...................................................................People Living Through Cancer

Eric T. Rosenthal, A.B. .............................................................................................Evoca Talk Reports

Mary Jackson Scroggins, M.A. ............................................................Ovarian Cancer National Alliance

Sue Sumpter, R.N., M.S. ......................................................Candlelighters Childhood Cancer Foundation

Marissa Weiss, M.D. .................................................................................Living Beyond Breast Cancer

Celeste Whitewolf, J.D. ...........................................................................Native People’s Circle of Hope

James E. Williams, M.S. ..............................................................Pennsylvania Prostate Cancer Coalition

Executive Secretary

Brooke Hamilton.............................................................................................National Cancer Institute

Past Executive Secretary

Nancy Caliman ...............................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

92

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Chair

James K. Willson, M.D. .................................................University of Texas Southwestern Medical Center

Members

Carlos L. Arteaga, M.D. ......................................................................Vanderbilt-Ingram Cancer Center

Leonard H. Augenlicht, Ph.D. ............................................................Albert Einstein College of Medicine

Stephen B. Baylin, M.D ................................................The Johns Hopkins University School of Medicine

George J. Bosl, M.D. ................................................................Memorial Sloan-Kettering Cancer Center

Grace L. Butler, Ph.D. ...................................................................................Hope Through Grace, Inc.

Marci K. Campbell, M.P.H., Ph.D. ...........................................University of North Carolina at Chapel Hill

William L. Carroll, M.D. .............................................................New York University School of Medicine

Graham A. Colditz, M.D., Ph.D. .......................................Harvard Medical School, Channing Laboratory

Walter J. Curran, Jr., M.D. .........................................................................Thomas Jefferson University 

Timothy J. Eberlein, Jr., M.D. ..................................................Washington University School of Medicine

Michele F. Follen, M.D., Ph.D. ......................................University of Texas M.D. Anderson Cancer Center

Janet A. Houghton, Ph.D. ..............................................................St. Jude Children’s Research Hospital

Francine Renee Huckaby, M.P.H. .................................................... University of Alabama at Birmingham

Robert B. Jenkins, M.D., Ph.D. .............................................................................Mayo Cancer Center

Hsing-Jien Kung, Ph.D. .......................................................University of California, Davis Cancer Center

Michelle M. Le Beau, Ph.D. ..............................................University of Chicago, Cancer Research Center

James R. Marshall, Ph.D. ..........................................................................Roswell Park Cancer Institute

Robin J. Mermelstein, Ph.D. ...................................................................University of Illinois at Chicago

Orhan Nalcioglu, Ph.D. ...........................................................................University of California, Irvine

David M. Ota, M.D. .............................................................................Duke University Medical Center

Jill C. Pelling, Ph.D. .............................................................Northwestern University School of Medicine

Peggy L. Porter, M.D. ..............................................................Fred Hutchinson Cancer Research Center

Joan H. Schiller, M.D. ...........................................University of Wisconsin, Comprehensive Cancer Center

Lynn M. Schuchter, M.D. .........................................University of Pennsylvania, Abramson Cancer Center

Ann G. Schwartz, Ph.D., M.P.H. ....................................................................Karmanos Cancer Institute

Peter G. Shields, M.D. .................................................................Georgetown University Medical Center

Marc A. Shuman, M.D. ................................................................University of California, San Francisco

David W. Speicher, Ph.D. ..............................................................................................Wistar Institute

Jean Y. Wang, Ph.D. .........................................................................University of California, San Diego

George J. Weiner, M.D. .....................................University of Iowa, Holden Comprehensive Cancer Center

Louella S. Wilburn ....................................................................................People Living Through Cancer

David W. Yandell, Sc.D. .......................................................................................University of Vermont

Scientific Review Administrator

David Maslow, Ph.D. .....................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

93

Subcommittee C—Basic and Preclinical

Chair

Denise A. Galloway, Ph.D. .......................................................Fred Hutchinson Cancer Research Center

Members

Hamid Band, M.D., Ph.D. ......................................Evanston Northwestern Healthcare Research Institute

Dafna Bar-Sagi, Ph.D. ........................................................State University of New York at Stony Brook

Richard F. Borch, M.D., Ph.D. ...................................................................................Purdue University

John L. Cleveland, Ph.D. ...............................................................St. Jude Children’s Research Hospital

Robert H. Getzenberg, Ph.D. ......................................................................The Johns Hopkins Hospital

Warren D. Heston, Ph.D. ...............................................................................Lerner Research Institute

Scott W. Hiebert, Ph.D. ............................................................Vanderbilt University School of Medicine

Dave S. Hoon, Ph.D. ................................................................................John Wayne Cancer Institute

Mien-Chie Hung, Ph.D. ...............................................University of Texas M.D. Anderson Cancer Center

Ronald C. Kennedy, Ph.D. ...................................................Texas Tech University Health Sciences Center

Natasha Kyprianou, Ph.D. ...........................................................University of Kentucky Medical Center

Lucia R. Languino, Ph.D. .....................................................University of Massachusetts Medical School

Eva Y. Lee, Ph.D. ....................................................................................University of California, Irvine

Howard B. Lieberman, Ph.D. ...............................Columbia University College of Physicians and Surgeons

Maria G. Pallavicini, Ph.D. ......................................University of California, San Franciscio Cancer Center

Angel G. Pellicer, M.D., Ph.D. .........................................................New York University Medical Center

Salvatore V. Pizzo, M.D., Ph.D. .............................................................Duke University Medical Center

Kevin M. Pumiglia, Ph.D. ..................................................................................Albany Medical College

Vito Quaranta, M.D. ..............................................................................The Scripps Research Institute

Nancy J. Raab-Traub, Ph.D. ...................................................University of North Carolina at Chapel Hill

Eddie Reed, M.D. ............................................................................................West Virgina University

Alan G. Rosmarin, M.D. ................................................................Brown University School of Medicine

Kathleen M. Rundell, Ph.D. ........................................................Northwestern University Cancer Center

Gary S. Stein, Ph.D. ............................................University of Massachusetts Medical School, Worcester

Walter J. Storkus, Ph.D. .......................................................University of Pittsburgh School of Medicine

Kenneth D. Tew, Ph.D. ...................................................................Medical University of South Carolina

Timothy J. Triche, M.D., Ph.D. ...........................................................Children’s Hospital of Los Angeles

Louis M. Weiner, M.D. ..................................................................................Fox Chase Cancer Center

Scientific Review Administrator

Michael Small, Ph.D. .....................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

94

Subcommittee D—Clinical Studies

Chair

Mitchel S. Berger, M.D., F.A.C.S. .................................................University of California, San Franscisco

Past Chair

Robert S. Negrin, M.D. ...............................................................Stanford University School of Medicine

Members

Francis Ali-Osman, D.Sc., Ph.D. .............................................................Duke University Medical Center

Matthew M. Ames, Ph.D. ....................................................................Mayo Clinic College of Medicine

Richard E. Champlin, M.D. ..........................................University of Texas M.D. Anderson Cancer Center

Ennio Antonio Chiocca, M.D., Ph.D. ..............................................Ohio State University Medical Center

Curt I. Civin, M.D. ......................................................The Johns Hopkins University School of Medicine

James L. M. Ferrara, M.D. .................................................................................University of Michigan

Soldano Ferrone, M.D., Ph.D. ...................................................................Roswell Park Cancer Institute

Stanton L. Gerson, M.D. ..........................................Case Western Reserve University School of Medicine

Steven J. Grant, M.D. .......................................................................Virginia Commonwealth University

John G. Gribben, M.D. .............................................................................Dana-Farber Cancer Institute

Louise Barnett Grochow, M.D. ..........................................................................................AstraZeneca

Carl H. June, M.D., Ph.D. .................................................University of Pennsylvania School of Medicine

Jae Ho H. Kim, M.D., Ph.D. ..................................................................................Henry Ford Hospital

Gloria C. Li, Ph.D. ....................................................................Memorial Sloan-Kettering Cancer Center

Fei-Fei Liu, M.D. .................................................................................................University of Toronto

Lawrence G. Lum, D.Sc., M.D. .................................................................Roger Williams Cancer Center

Herbert K. Lyerly, M.D. .........................................................................Duke University Medical Center

William H. McBride, Ph.D. .............................................................Univerisity of California, Los Angeles

Stephen D. Nimer, M.D. ............................................................Memorial Sloan-Kettering Cancer Center

Nancy L. Oleinick, Ph.D. ..........................................Case Western Reserve University School of Medicine

James Lloyd Omel, M.D. .........................................................................................Physician (Retired)

Gina R. Petroni, Ph.D. ....................................................................University of Virginia Health System

Andrew A. Raubitschek, Ph.D. ..................................................... City of Hope National Medical Center

Carol K. Redmond, Ph.D. ..................................University of Pittsburgh Graduate School of Public Health

A. Keith Stewart, M.D. .....................................................................................................Mayo Clinic

Donald L. Trump, M.D. ............................................................................Roswell Park Cancer Institute

Jeanne P. Young, B.A. .......................................................................Childhood Brain Tumor Foundation

Scientific Review Administrator

William Merritt, Ph.D. ....................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

95

Subcommittee E—Cancer Epidemiology, Prevention, and Control

Chair

Doris M. Benbrook, Ph.D. ...............................................University of Oklahoma Health Sciences Center

Members

Marianne Berwick, Ph.D. ..............................................................................University of New Mexico

William J. Blot, Ph.D. ......................................................................International Epidemiology Institute

John R. Finnegan, Jr., Ph.D. ...........................................University of Minnesota School of Public Health

Gary E. Fraser, Ph.D. ...................................................Loma Linda University School of Health Research

Linda B. Johnson...........................................................................American Association of Blood Banks

Kyungmann Kim, Ph.D. ..............................................................University of Wisconsin Medical School

Patrick M. Lynch, M.D. ...............................................University of Texas M.D. Anderson Cancer Center

Jeanne S. Mandelblatt, M.D., M.P.H. ..........................................Lombardi Comprehensive Cancer Center

Barbara C. Pence, Ph.D. .....................................................Texas Tech University Health Sciences Center

Douglas E. Peterson, Ph.D. ........................................................University of Connecticut Health Center

John M. Pezzuto, Ph.D. ...........................................................................................Purdue University

Noma L. Roberson, Ph.D. ..................................................................Roberson Consulting International

Marjorie Romkes, Ph.D. ...................................................................................University of Pittsburgh

Paolo G. Toniolo, M.D., M.P.H. ..................................................New York University School of Medicine

Tor D. Tosteson, Sc.D. .................................................................................Dartmouth Medical School

Michael J. Welch, M.D., Ph.D. ................................................Washington University School of Medicine

Chung S. Yang, Ph.D. ................................................................Rutgers University College of Pharmacy

Scientific Review Administrator

Mary Fletcher, Ph.D.* ....................................................................................National Cancer Institute

Appendix C: List of Chartered Committees

*Retired August 18, 2005.
NCI/DEA Annual Report 2005

96

Subcommittee F—Manpower and Training

Member and Chair

Jeffrey T. Holt, M.D. .........................................................................................University of Colorado

Past Chair

James S. Economou, M.D., Ph.D. ..............................University of California, Los Angeles Medical Center

Members

Amy H. Bouton, Ph.D. .............................................................University of Virginia School of Medicine

Helen M. Chamberlin, Ph.D. ..........................................................................The Ohio State University

Marila Cordeiro-Stone, Ph.D. ......................................................................University of North Carolina

Gerard M. Doherty, M.D. ..................................................................................University of Michigan

Weimin Fan, M.D., M.P.H. ..............................................................Medical University of South Carolina

James W. Freeman, Ph.D. ........................................................University of Texas Health Science Center

Michael M. Graham, M.D., Ph.D. .............................................................................University of Iowa

Ronald E. Kalil, Ph.D. .......................................................................................University of Wisconsin

Diana E. Lake, M.D. .................................................................Memorial Sloan-Kettering Cancer Center

Gregory D. Longmore, M.D. ...................................................Washington University School of Medicine

Steven B. McMahon, Ph.D. ....................................................................................The Wistar Institute

Jaime F. Modiano, V.M.D., Ph.D. .......................................University of Colorado Health Sciences Center

Catherine A. O’Brian, Ph.D. ........................................University of Texas M.D. Anderson Cancer Center

Christopher A. Pennell, Ph.D. ......................................................University of Minnesota Cancer Center

Eric R. Prossnitz, Ph.D. .................................................................................University of New Mexico

Sunil J. Rao, Ph.D. ..............................................................................Case Western Reserve University

Ann Roman, Ph.D. .......................................................................Indiana University School of Medicine

Thais P. Salazar-Mather, Ph.D. ....................................................................................Brown University

George P. Studzinski, M.D., Ph.D. ................................................................New Jersey Medical School

Alice Yu, M.D., Ph.D. .................................................University of California, San Diego Medical Center

Scientific Review Administrator

Lynn M. Amende, Ph.D. .................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

97

Subcommittee G—Education

Co-Chairs

Karen Dow Meneses, F.A.A.N., R.N., Ph.D. .......................University of Central Florida School of Nursing

Scott A. Waldman, M.D., Ph.D. ..................................................................Thomas Jefferson University

Members

Jose M. Esteban, M.D., Ph.D. ...........................................................Providence Hospital Cancer Center

Richard E. Gallagher, Ph.D. ...................................................Wayne State University School of Medicine

Jeffrey J. Guidry, Ph.D. ......................................................................................Texas A&M University

Wanda E. Hardman, Ph.D. .............................................................................Louisiana State University

Joel B. Mason, M.D. ...................................................................................................Tufts University

Kevin T. McDonagh, M.D. ....................................................University of Kentucky College of Medicine

Patricia Dolan Mullen, Dr.P.H. .................................University of Texas Health Science Center at Houston

Ana M. Navarro, Ph.D. .....................................University of California at San Diego, School of Medicine

Sara H. Olson, Ph.D. ................................................................Memorial Sloan-Kettering Cancer Center

Billy U. Philips, Jr., M.P.H., Ph.D. ...................................University of Texas Medical Branch at Galveston

William H. Redd, Ph.D. ..................................Mount Sinai School of Medicine, Ruttenberg Cancer Center

Douglas Ross, M.D., Ph.D. ...................................................University of Maryland School of Medicine

Vernon K. Sondak, M.D. ..........................University of Michigan Comprehensive Cancer/Geriatrics Center

Sandra E. Ward, Ph.D., R.N. ...................................................University of Wisconsin School of Nursing

Katharine A. Whartenby, Ph.D. .................................... The Johns Hopkins University School of Medicine

Scientific Review Administrator

Ilda M. McKenna, Ph.D. ................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

98

Subcommittee H—Clinical Trials

Chair

James A. Stewart, M.D. .......................................................................University of Wisconsin-Madison

Past Chair

Daniel J. Sargent, Ph.D. .............................................................................Mayo Clinic and Foundation

Members

James L. Abbruzzese, M.D. ..........................................University of Texas M.D. Anderson Cancer Center

James R. Anderson, Ph.D. ............................................................University of Nebraska Medical School

Nancy N. Baxter, M.D., Ph.D. .............................................................................St. Michael’s Hospital

Carol L. Brown, M.D. ...............................................................Memorial Sloan-Kettering Cancer Center

John C. Byrd, M.D. .......................................Ohio State University School of Medicine and Public Health

Robert A Chapman, M.D. ........................................................................Josephine Ford Cancer Center

Carolyn C. Compton, M.D., Ph.D. ..............................................................................McGill University

Walter M. Cronin, M.P.H. ........................................University of Pittsburgh, NSABP Biostatistical Center

Darlene J. Demanincor, Ph.D. .................................................................Patient Advocate, Oakland, CA

Lawrence E. Flaherty, M.D. ................................................................................Wayne State University

Laurie E. Gaspar, M.D. .......................................................................................University of Colorado

Mary K. Gospodarowicz, M.D. .....................................................................Princess Margaret Hospital

Stephen L. Graziano, M.D. ........................................................................State University of New York

Stephanie J. Green, Ph.D. ....................................................................................................Pfizer Inc.

Stuart A. Grossman, M.D. ....................................................................Johns Hopkins Oncology Center

Sheilah K. Hurley, M.A. ....................................................................................Independent Consultant

William R. Jewell, M.D. ...................................................................University of Kansas Medical Center

Charles E. Kahn, Jr., M.D. ........................................................................Medical College of Wisconsin

Peggy A. Lambert, M.S. ...................................................................................West Virginia University

Ann Marilyn Leitch, M.D. ........................................................University of Texas Health Science Center

Kevin T. Lewis, M.B.A. ..................................................................................The Colon Cancer Alliance

Deborah B. McGuire, Ph.D., F.A.A.N. .................................................................University of Maryland

Paul A. Meyers, M.D. ...............................................................Memorial Sloan-Kettering Cancer Center

Judith A. Miller, Ph.D. ...............................................................................................Emory University

Lisa A. Newman, M.D. ...........................................University of Michigan Comprehensive Cancer Center

Craig R. Nichols, M.D. .................................................................Oregon Health and Science University

Roman Perez-Soler, M.D. ..............................................................................Montefiore Medical Center

Eric J. Small, M.D. ........................University of California at San Francisco, Comprehensive Cancer Center

James A. Stewart, M.D. ...........................University of Wisconsin, Madison Comprehensive Cancer Center

Everett E. Vokes, M.D. ..................................................................University of Chicago Medical Center

Steven Weitman, M.D., Ph.D. ..................................................................................Ilex Oncology, Inc.

Lari B. Wenzel, Ph.D. ..............................................................................University of California, Irvine

Scientific Review Administrator

Deborah R. Jaffe, Ph.D. .................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

99

Subcommittee I—Career Development

Chair

Mary-Ann Bjornsti, Ph.D. ..............................................................St. Jude Children’s Research Hospital

Members

Deepak Bastia, Ph.D. .....................................................................Medical University of South Carolina

Powel Brown, M.D., Ph.D. ...........................................................................Baylor College of Medicine

Malaya B. Chatterjee, Ph.D. .......................................................University of Cincinnati Medical Center

Edward Copelan, M.D. .....................................................The Ohio State University College of Medicine

Jeffrey A. Drebin, M.D., Ph.D. ...........................................University of Pennsylvania School of Medicine

Michael R. Freeman, Ph.D. ...............................................................................Harvard Medical School

Rafael A. Fridman, Ph.D. .......................................................Wayne State University School of Medicine

Marc F. Hansen, Ph.D. ..............................................................University of Connecticut Health Center

Jeffrey P. Kirscher, Ph.D. ..............................................................................University of South Florida

Jonathan S. Lewin, M.D. ..............................................The Johns Hopkins University School of Medicine

Jeffrey F. Moley, M.D. ............................................................Washington University School of Medicine

John O. Ojeifo, M.D., Ph.D. ..................................................Georgetown University School of Medicine

Reshma Taneja, Ph.D. ...........................................................................Mount Sinai School of Medicine

Theresa L. Whiteside, Ph.D. ......................................................University of Pittsburgh Cancer Institute

Scientific Review Administrator

Robert Bird, Ph.D. .........................................................................................National Cancer Institute

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

100

Subcommittee J—Population and Patient-Oriented Training*

Co-Chairs

Karen Dow Meneses, Ph.D. ........................................................................University of Central Florida

Scott A. Waldman, M.D., Ph.D. ..................................................................Thomas Jefferson University

Members

Elisa V. Bandera, M.D., Ph.D. ....................................University of Medicine and Dentistry of New Jersey

Susan D. Block, M.D. ...............................................................................Dana-Farber Cancer Institute

Jennifer J. Griggs, M.D. ...................................................................................University of Rochester

Wanda Elaine Hardman, Ph.D. .....................................................Marshall University School of Medicine

Joel B. Mason, M.D. ...................................................................................................Tufts University

Kevin T. McDonagh, M.D. ..................................................................................Markey Cancer Center

Ana M. Navarro, Ph.D. ....................................................................University of California, San Diego

Sara H. Olson, Ph.D. ................................................................Memorial Sloan-Kettering Cancer Center

Deborah M. Parra-Medina, Ph.D., M.P.H. ....................................................University of South Carolina

Billy U. Philips, Jr., Ph.D. .................................................University of Texas Medical Branch, Galveston

Douglas Ross, M.D., Ph.D. ....................................................University of Maryland School of Medicine

Suzanne C. Segerstrom, Ph.D. ............................................................................University of Kentucky

Debra C. Thaler-Demers, R.N. .....................................................Stanford University Hospital and Clinics

John H. Ward, M.D. ....................................................................University of Utah School of Medicine

Sandra E. Ward, Ph.D. ...............................................University of Wisconsin-Madison School of Nursing

Scientific Review Administrator

Ilda M. McKenna, Ph.D. .................................................................................National Cancer Institute

* This subcommittee was formed in late FY2005.

Appendix C: List of Chartered Committees
NCI/DEA Annual Report 2005

101

Initial Review Group Subcommittees

Subcommittee A—Cancer Centers

Subcommittee C—Basic and Preclinical

Subcommittee E—Cancer Epidemiology, Prevention, and Control

Continued on page 102.
NCI/DEA Annual Report 2005

102

Initial Review Group Subcommittees (Continued)

Subcommittee G—Education

Subcommittee H—Clinical Trials

Subcommittee I—Career Development
NCI/DEA Annual Report 2005

103

Appendix D: NCI Initial Review Group Consultants, FY2005

1. Consultants Serving as Temporary Members on IRG Subcommittees in

FY2005

A Aaronson, Stuart A., M.D. . . . . . . . . . . . . . . . . . .Mount Sinai Medical Center

Abbruzzese, James L., M.D. . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Ali-Osman, Francis, Ph.D. . . . . . . . . . . . . . . . . . .Duke University

Altman, John D., M.D., Ph.D. . . . . . . . . . . . . . . .Emory University

Anderson, Carolyn J., Ph.D. . . . . . . . . . . . . . . . .Washington University School of Medicine

Anderson, Kathryn H., Ph.D. . . . . . . . . . . . . . . . .Florida International University

Armstrong, Floyd Daniel, Ph.D. . . . . . . . . . . . . . .University of Miami School of Medicine

Armstrong, Scott A., M.D., Ph.D. . . . . . . . . . . . .Children’s Hospital Boston

Auerbach, Robert, Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin

Avrin, David, M.D., Ph.D. . . . . . . . . . . . . . . . . . .Utah State University

B Ballman, Karla, Ph.D. . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Balogh, Lajos Peter, Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Band, Hamid, M.D., Ph.D. . . . . . . . . . . . . . . . . .Evanston Northwestern Healthcare

Bandera, Elisa V., M.D., Ph.D. . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Barr, Frederic G., M.D., Ph.D. . . . . . . . . . . . . . . .University of Pennsylvania

Bar-Sagi, Dafna, M.S. . . . . . . . . . . . . . . . . . . . . .State University of New York

Barsegov, Valeri A., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland College Park Campus

Barsevick, Andrea M., R.N. . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Bastia, Deepak, Ph.D. . . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Baylin, Stephen B., M.D. . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Bear, Harry D., M.D., Ph.D. . . . . . . . . . . . . . . . .Virginia Commonwealth University

Belinsky, Steven A., Ph.D. . . . . . . . . . . . . . . . . . .Lovelace Biomedical & Environmental Research

Benbrook, Doris M., Ph.D. . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Benjamín, Laura E., Ph.D. . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Berek, Jonathan S., M.D. . . . . . . . . . . . . . . . . . .University of California, Los Angeles School of Medicine

Berger, Ann M., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Berger, Mitchel S., M.D. . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Bertics, Paul J., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Berwick, Marianne, Ph.D. . . . . . . . . . . . . . . . . . .University of New Mexico, Albuquerque

Bieberich, Charles J., Ph.D. . . . . . . . . . . . . . . . . .University of Maryland, Baltimore County Campus

Biegon, Anat, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Brookhaven Science Association-Brookhaven Laboratory

Block, Susan D., M.D. . . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Bogler, Oliver, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Bolskar, Robert D., Ph.D. . . . . . . . . . . . . . . . . . .TDA Research, Inc.

Borch, Richard F., M.D., Ph.D. . . . . . . . . . . . . . . .Purdue University, West Lafayette

Bouton, Amy H., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Bouvet, Michael, M.D. . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Bowers, William J., Ph.D. . . . . . . . . . . . . . . . . . .University of Rochester
NCI/DEA Annual Report 2005

104

Boyd, Jeff A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Bramwell, Vivien, Ph.D. . . . . . . . . . . . . . . . . . . . .Tom Baker Cancer Centre

Bright, Robert K., Ph.D. . . . . . . . . . . . . . . . . . . .Texas Tech University Health Sciences Center

Brown, Bob, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Glasgow, Garscube Estate

Brunicardi, F. Charles., M.D. . . . . . . . . . . . . . . . .Baylor College of Medicine

Buki, Lydia P., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Illinois Urbana, Champaign

Burdette, Everette C., Ph.D. . . . . . . . . . . . . . . . .Computerized Medical Systems, Inc.

Burgin, Alex B., Ph.D. . . . . . . . . . . . . . . . . . . . . .Decode Bio-Structures

Burke, Steven D., Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Burns, Linda J., M.D. . . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Bushweller, John H., Ph.D. . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Butler, Susan L. . . . . . . . . . . . . . . . . . . . . . . . . .Ovarian Cancer National Alliance

Byrne, Celia, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Georgetown University

C Capobianco, Anthony J., Ph.D. . . . . . . . . . . . . . .Wistar Institute

Carbone, David P., M.D., Ph.D. . . . . . . . . . . . . . .Vanderbilt University

Cella, David F., Ph.D. . . . . . . . . . . . . . . . . . . . . .Evanston Northwestern Healthcare Research Institutes

Chang, Helena R., M.D., Ph.D. . . . . . . . . . . . . . .University of California, Los Angeles

Chaudhary, Preet M., M.D., Ph.D. . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Chung, Fung-Lung, Ph.D. . . . . . . . . . . . . . . . . . .Georgetown University

Cleveland, John L., Ph.D. . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Clohisy, Denis R., M.D. . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Coetzee, Gerhard A., Ph.D. . . . . . . . . . . . . . . . . .University of Southern California

Colacchio, Thomas, M.D. . . . . . . . . . . . . . . . . . .Dartmouth Hitchcock Medical Center

Coleman, William B., Ph.D. . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Colonna, Marco, M.D. . . . . . . . . . . . . . . . . . . . .Washington University

Cory, Joseph G., Ph.D. . . . . . . . . . . . . . . . . . . . .East Carolina University

Costa, Jose C., M.D. . . . . . . . . . . . . . . . . . . . . .Yale University

Curley, Robert W., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

Curran, Walter J., M.D. . . . . . . . . . . . . . . . . . . .American College of Radiology

D Dalton, William S., M.D., Ph.D. . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Declerck, Yves A., M.D., Ph.D. . . . . . . . . . . . . . .American Association for Cancer Research

Dedon, Peter C., M.D., Ph.D. . . . . . . . . . . . . . . .U.S. PHS Public Advisory Groups

Degregori, James V., Ph.D. . . . . . . . . . . . . . . . . .University of Colorado, Denver/Health Sciences Center at Aurora

Demark-Wahnefried, Wendy, Ph.D. . . . . . . . . . . . .Duke University

Denardo, Sally J., M.D. . . . . . . . . . . . . . . . . . . . .University of California School of Medicine

Desiderio, Stephen V., M.D., Ph.D. . . . . . . . . . . . .Johns Hopkins University

Detterbeck, Frank, M.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Dipersio, John F., M.D., Ph.D. . . . . . . . . . . . . . . .Washington University School of Medicine

Doherty, Gerard M., M.D. . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Drebin, Jeffrey A., M.D., Ph.D. . . . . . . . . . . . . . .Washington University

E Eaton, Kathryn A., D.V.M., Ph.D. . . . . . . . . . . . .University of Michigan at Ann Arbor

Eck, Michael J., M.D., Ph.D. . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Eischen, Christine M., Ph.D. . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Elliott, Dawn M., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Elson, Paul J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

105

Emelianov, Stanislav Y., Ph.D. . . . . . . . . . . . . . . . .University of Texas, Austin

Erickson, Kent L., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

F Fantini, Sergio, Ph.D. . . . . . . . . . . . . . . . . . . . . .Tufts University, Medford

Ferrara, James L. M., M.D. . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Ferrone, Soldano, M.D., Ph.D. . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Figlin, Robert, M.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Fike, John R., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Finn, Olivera J., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Flint, Jonathan, M.D. . . . . . . . . . . . . . . . . . . . . .University of Oxford

Fontanesi, James, M.D. . . . . . . . . . . . . . . . . . . . .University of Mississippi Medical Center

Foreman, Kimberly E., Ph.D. . . . . . . . . . . . . . . . .Loyola University, Chicago

Fotedar, Arun, M.D., Ph.D. . . . . . . . . . . . . . . . . .Sidney Kimmel Cancer Center

Fridman, Rafael A., Ph.D. . . . . . . . . . . . . . . . . . .Wayne State University

Friedman, Eileen A., Ph.D. . . . . . . . . . . . . . . . . . .SUNY Upstate Medical University

Fueyo, Juan, M.D. . . . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Furnari, Frank B., Ph.D. . . . . . . . . . . . . . . . . . . .Ludwig Institute for Cancer Research

G Gamliel, Ziv, M.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Maryland Medical Center

Garrard, William T., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Gendler, Sandra J., Ph.D. . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Gerwick, William H., Ph.D. . . . . . . . . . . . . . . . . .University of California, San Diego

Getzenberg, Robert H., Ph.D. . . . . . . . . . . . . . . .Johns Hopkins University

Giaccia, Amato J., Ph.D. . . . . . . . . . . . . . . . . . . .Stanford University

Girotti, Albert W., Ph.D. . . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

Glaser, Ronald M., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

Gold, David V., Ph.D. . . . . . . . . . . . . . . . . . . . . .Garden State Cancer Center, New Jersey

Goldberg, Zelanna, M.D. . . . . . . . . . . . . . . . . . . .University of California, Davis Cancer Center

Gomer, Charles J., Ph.D. . . . . . . . . . . . . . . . . . . .Children’s Hospital, Los Angeles

Goodrich, David W., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Gospodarowicz, Mary K., M.D. . . . . . . . . . . . . . .Princess Margaret Hospital

Gottesfeld, Joel M., Ph.D. . . . . . . . . . . . . . . . . . .Scripps Research Institute

Grant, Steven, M.D. . . . . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Graziano, Stephen L., M.D. . . . . . . . . . . . . . . . . .SUNY Upstate Medical University

Griggs, Jennifer J., M.D. . . . . . . . . . . . . . . . . . .University of Rochester

Grochow, Louise Barnett, M.D. . . . . . . . . . . . . . .AstraZeneca Research and Development

Groden, Joanna L., Ph.D. . . . . . . . . . . . . . . . . . .University of Cincinnati

Grunberg, Steven M., M.D. . . . . . . . . . . . . . . . . .University of Vermont

H Haines, Dale S., Ph.D. . . . . . . . . . . . . . . . . . . . . .Temple University

Hellstrom, Ingegerd E., M.D., Ph.D. . . . . . . . . . . .Pacific Northwest Research Institute

Henderson, Janet E., Ph.D. . . . . . . . . . . . . . . . . .Center for Bone and Periodontal Research

Henry, Roland G., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Herbst, Roy S., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Hess, Kenneth R., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Heston, Warren D., Ph.D. . . . . . . . . . . . . . . . . . .Case Western Reserve University

Hichwa, Richard D., Ph.D. . . . . . . . . . . . . . . . . . .University of Iowa

Hiebert, Scott W., Ph.D. . . . . . . . . . . . . . . . . . . .Vanderbilt University

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

106

Hill, Richard P., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Toronto

Hoon, Dave S.B., Ph.D. . . . . . . . . . . . . . . . . . . .John Wayne Cancer Institute

Hoopes, P. Jack, D.V.M., Ph.D. . . . . . . . . . . . . . .Dartmouth Medical School

Howe, James R., M.D. . . . . . . . . . . . . . . . . . . . .University of Iowa

Howett, Mary K., Ph.D. . . . . . . . . . . . . . . . . . . .Pennsylvania State University, Hershey Medical Center

Huckaby, Francine Renee, M.P.H. . . . . . . . . . . . . .University of Alabama, Birmingham

I Irwin, Meredith, M.D. . . . . . . . . . . . . . . . . . . . . .University of Toronto

J Jacobsen, Paul B., Ph.D. . . . . . . . . . . . . . . . . . . .University of South Florida

Jaeckle, Kurt A., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Jaffee, Elizabeth M., M.D. . . . . . . . . . . . . . . . . . .Johns Hopkins University

Jaffray, David A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Toronto

Jessup, John M., M.D. . . . . . . . . . . . . . . . . . . . .Georgetown University

Johnson, Bryon D., Ph.D. . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

Johnson, Edward M., Ph.D. . . . . . . . . . . . . . . . . .Eastern Virginia Medical School

Johnson, Linda B., OTH. . . . . . . . . . . . . . . . . . . .National Coalition for Cancer Survivorship

Jones, David A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Utah

Junck, Larry R., M.D. . . . . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

K Kamen, Barton A., M.D., Ph.D. . . . . . . . . . . . . . .Cancer Institute of New Jersey

Kane, Susan E., Ph.D. . . . . . . . . . . . . . . . . . . . . .City of Hope/Beckman Research Institute

Kasahara, Noriyuki, M.D., Ph.D. . . . . . . . . . . . . .University of California, Los Angeles

Kennedy, Ronald C., Ph.D. . . . . . . . . . . . . . . . . . .Texas Tech University

Kerr, William G., Ph.D. . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institutes

Kitchell, Barbara E., D.V.M., Ph.D. . . . . . . . . . . . .Michigan State University

Kreuter, Matthew W., Ph.D. . . . . . . . . . . . . . . . . .St. Louis University

Krown, Susan E., M.D. . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Krupinski, Elizabeth A., Ph.D. . . . . . . . . . . . . . . .University of Arizona

Kruse, Carol A., Ph.D. . . . . . . . . . . . . . . . . . . . .La Jolla Institute for Molecular Medicine

Kulesz-Martin, Molly F., Ph.D. . . . . . . . . . . . . . . .Oregon Health & Science University

Kyprianou, Natasha, Ph.D. . . . . . . . . . . . . . . . . .University of Kentucky

L Landsittel, Douglas P., Ph.D. . . . . . . . . . . . . . . . .Duquesne University

Lang, James C., Ph.D. . . . . . . . . . . . . . . . . . . . .Ohio State University

Languino, Lucia R., Ph.D. . . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Leach, Robin J., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Texas Health Sciences Center, San Antonio

Lee, Eva Y., Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Lee, Sam W., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Leeper, Dennis B., M.D., Ph.D. . . . . . . . . . . . . . .Thomas Jefferson University

Lenkinski, Robert E., Ph.D. . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Levine, Alexandra M., M.D. . . . . . . . . . . . . . . . . .University of California, Los Angeles

Lewin, Jonathan S., M.D. . . . . . . . . . . . . . . . . . .University Hospitals of Cleveland

Lieberman, Howard B., Ph.D. . . . . . . . . . . . . . . . .Columbia University Health Sciences

Lieberman, Paul M., Ph.D. . . . . . . . . . . . . . . . . . .Wistar Institute

Lilge, Lothar, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University Health Network

Link, Brian K., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Iowa

Link, Charles J., M.D. . . . . . . . . . . . . . . . . . . . . .Newlink Genetics, Inc.

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

107

Liu, Yong-Jun, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Lorusso, Patricia M., D.O., M.D. . . . . . . . . . . . . .Wayne State University

Lowe, Scott W., Ph.D. . . . . . . . . . . . . . . . . . . . . .Cold Spring Harbor Laboratory

M Macklin, Ruth, Ph.D. . . . . . . . . . . . . . . . . . . . . .Albert Einstein College of Medicine

Magnotta, Vincent A., Ph.D. . . . . . . . . . . . . . . . .University of Iowa

Magun, Bruce E., Ph.D. . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Malkas, Linda H., Ph.D. . . . . . . . . . . . . . . . . . . .Indiana University School of Medicine

Malloy, Craig R., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center

Mankoff, David A., M.D., Ph.D. . . . . . . . . . . . . .University of Washington

Marciniak, Robert A., M.D., Ph.D. . . . . . . . . . . . .University of Texas Health Sciences Center, San Antonio

Martin, Brian, M.P.A. . . . . . . . . . . . . . . . . . . . . .University of Rochester, Cancer Center

Martin, Jeffrey N., M.D. . . . . . . . . . . . . . . . . . .University of California, San Francisco

Maziak, Donna, M.D. . . . . . . . . . . . . . . . . . . . . .University of Ottawa

McGlave, Philip B., M.D. . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

McGrath, Patrick C., M.D. . . . . . . . . . . . . . . . . .University of Kentucky

Melnick, Ari M., M.D. . . . . . . . . . . . . . . . . . . . .Yeshiva University

Meltzer, Paul S., M.D., Ph.D. . . . . . . . . . . . . . . .National Human Genome Research Institute

Mesa, Ruben A., M.D. . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Meyers, Christina A., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Meyers, Craig M., Ph.D. . . . . . . . . . . . . . . . . . . .Pennsylvania State University Hershey Medical Center

Miller, Andrew H., M.D. . . . . . . . . . . . . . . . . . . .Emory University

Miller, Vincent A., M.D. . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Minden, Mark D., M.D., Ph.D. . . . . . . . . . . . . . .Princess Margaret Hospital

Modiano, Jaime F., Ph.D., D.V.M. . . . . . . . . . . . . .University of Colorado Denver/Health Sciences Center at Aurora

Molnar-Kimber, Katherine L., Ph.D. . . . . . . . . . . . .University of Pennsylvania

Montgomery, Guy, Ph.D. . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Moran, Richard G., Ph.D. . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Morgan, William F., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore Professional School

Morton, Ronald A., M.D. . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of NJ, R.W. Johnson Medical School

Moscow, Jeffrey A., M.D. . . . . . . . . . . . . . . . . . .University of Kentucky

Mossman, Brooke T., Ph.D. . . . . . . . . . . . . . . . . .University of Vermont

Motamedi, Massoud, Ph.D. . . . . . . . . . . . . . . . . .University of Texas Medical Branch, Galveston

Mulder, Kathleen M., Ph.D. . . . . . . . . . . . . . . . . .Pennsylvania State University

Murphy, William Joseph., Ph.D. . . . . . . . . . . . . . .University of Nevada, Reno

N Nasca, Philip C., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Massachusetts, Amherst

Nephew, Kenneth P., Ph.D. . . . . . . . . . . . . . . . . .Indiana University School of Medicine

Nolta, Jan A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Washington University

Norris, James S., Ph.D. . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Noy, Noa, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .Cornell University, Ithaca

Nucifora, Giuseppina, Ph.D. . . . . . . . . . . . . . . . . .University of Chicago

O O’Brian, Catherine A., Ph.D. . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

O’Dorisio, M. Susan., M.D., Ph.D. . . . . . . . . . . . .University of Iowa

Ochs, Michael F., Ph.D. . . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Olson, John A., M.D., Ph.D. . . . . . . . . . . . . . . . .Duke University

Olsson, Carl A., M.D. . . . . . . . . . . . . . . . . . . . . .Columbia University

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

108

Osheroff, Neil, Ph.D. . . . . . . . . . . . . . . . . . . . . .Vanderbilt University

Osley, Mary Ann., Ph.D. . . . . . . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Ostrer, Harry, M.D., Ph.D. . . . . . . . . . . . . . . . . .New York University School of Medicine

Ostrowski, Michael C., Ph.D. . . . . . . . . . . . . . . . .Ohio State University

Ozer, Harvey L., M.D. . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

P Pallavicini, Maria G., Ph.D. . . . . . . . . . . . . . . . . .University of California, San Francisco

Parra-Medina, Deborah M., Ph.D. . . . . . . . . . . . .University of South Carolina at Columbia

Pasternack, Gary R., M.D., Ph.D. . . . . . . . . . . . .Johns Hopkins University

Pellicer, Angel G., M.D., Ph.D. . . . . . . . . . . . . . . .New York University School of Medicine

Pence, Barbara C., Ph.D. . . . . . . . . . . . . . . . . . . .Texas Tech University Health Sciences Center

Penn, Linda Z., Ph.D. . . . . . . . . . . . . . . . . . . . . .Ontario Cancer Institute

Perez-Soler, Roman, M.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Petrelli, Nicholas J., M.D. . . . . . . . . . . . . . . . . . .Christiana Care Health Services, Inc.

Piazza, Gary A., Ph.D. . . . . . . . . . . . . . . . . . . . .Southern Research Institute

Pierce, John P., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Pizzo, Salvatore V., M.D., Ph.D. . . . . . . . . . . . . .Duke University

Plate, Janet M., Ph.D. . . . . . . . . . . . . . . . . . . . .Rush University Medical Center

Pollock, Raphael E., M.D., Ph.D. . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Posner, Marshall R., M.D. . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Price, Ronald R., Ph.D. . . . . . . . . . . . . . . . . . . . .Vanderbilt University

Prossnitz, Eric R., Ph.D. . . . . . . . . . . . . . . . . . . .University of New Mexico, Albuquerque

Pumiglia, Kevin M., Ph.D. . . . . . . . . . . . . . . . . . .Albany Medical College of Union University

Purdy, James A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Davis

Q Quaranta, Vito, M.D. . . . . . . . . . . . . . . . . . . . . .Vanderbilt University

R Raab-Traub, Nancy J., Ph.D. . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Radich, Jerry P., M.D. . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Ramsden, Dale A., Ph.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Raubitschek, Andrew A., M.D. . . . . . . . . . . . . . . .City of Hope/Beckman Research Institute

Reader, Steven, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of South Florida

Reed, Shelby, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Duke University

Reid, Mary E., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Ribas, Antoni, M.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Rigas, Basil A., M.D. . . . . . . . . . . . . . . . . . . . . .State University New York, Stony Brook

Roberts, Charles T., Ph.D. . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Robertson, Erle S., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Robertson, Fredika M., . . . . . . . . . . . . . . . . . . . .Ohio State University

Romkes, Marjorie, Ph.D. . . . . . . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Rosen, Isaac I., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Rosmarin, Alan G., M.D. . . . . . . . . . . . . . . . . . . .Rhode Island Hospital

Roth, Jack, M.D. . . . . . . . . . . . . . . . . . . . . . . . .Introgen Therapeutics, Inc.

Roth, Monica J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of NJ, R.W. Johnson Medical School

Rundell, M. Kathleen, Ph.D. . . . . . . . . . . . . . . . . .Northwestern University

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

109

S Sahler, Olle Jane Z., M.D. . . . . . . . . . . . . . . . . . .University of Rochester

Salisbury, Jeffrey L., Ph.D. . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Samuel, Charles E., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Santa Barbara

Samuels, Robert J., . . . . . . . . . . . . . . . . . . . . . . .National Alliance of Breast Cancer Organization

Sandmaier, Brenda Marie, M.D. . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Scott, Jamie K., M.D., Ph.D. . . . . . . . . . . . . . . . .Simon Fraser University

Scotto, Kathleen W., Ph.D. . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Segerstrom, Suzanne C., Ph.D. . . . . . . . . . . . . . . .University of Kentucky

Seiden, Michael V., M.D., Ph.D. . . . . . . . . . . . . . .Massachusetts General Hospital

Shamsuddin, Abulkalam M., M.D., Ph.D. . . . . . . .University of Maryland School of Medicine

Shaw, Edward G., M.D. . . . . . . . . . . . . . . . . . . . .Wake Forest University

Shen, Xuetong, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Shively, John E., Ph.D. . . . . . . . . . . . . . . . . . . . .City of Hope National Medical Center

Shrikant, Protul A., Ph.D. . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Sinsheimer, Janet S., Ph.D. . . . . . . . . . . . . . . . . .University of California Los Angeles

Smith, Gilbert P., BOTH . . . . . . . . . . . . . . . . . . . .MCMC, LLC, Medical Care Ombudsman Program

Smythe, W. Roy., M.D. . . . . . . . . . . . . . . . . . . . .Texas A&M University Health Science Center

Solomon, Keith R., Ph.D. . . . . . . . . . . . . . . . . . . .Children’s Hospital, Boston

Sondak, Vernon K., M.D. . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institutes

Spangler, John G., M.D. . . . . . . . . . . . . . . . . . . .Wake Forest University Health Sciences

Sparano, Joseph A., M.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Srour, Edward F., Ph.D. . . . . . . . . . . . . . . . . . . . .Indiana University School of Medicine

Stanbridge, Eric J., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Irvine

Stanley, Pamela M., Ph.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Stein, Gary S., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Storkus, Walter J., M.D., Ph.D. . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Strich, Randy S., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Studzinski, George P., M.D., Ph.D. . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Sugden, William M., Ph.D. . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Suva, Larry J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Arkansas Medical Sciences, Little Rock

Swanson, Scott J., M.D. . . . . . . . . . . . . . . . . . . .Mount Sinai Medical Center

T Taneja, Reshma, Ph.D. . . . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Tangen, Catherine M., Dr.P.H. . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Taylor, Jeremy MG., Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Tebbi, Cameron K., M.D. . . . . . . . . . . . . . . . . . . .Tampa Children’s Hospital

Terry, Michael A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Rochester

Tew, Kenneth D., Ph.D. . . . . . . . . . . . . . . . . . . . .Novelos Therapeutics, Inc.

Thaler-Demers, Debra K., R.N. . . . . . . . . . . . . . . .National Coalition/Cancer Survivorship

Tindall, Donald J., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Tonks, Nicholas K., Ph.D. . . . . . . . . . . . . . . . . . .Cold Spring Harbor Laboratory

Torchilin, Vladimir P., Ph.D. . . . . . . . . . . . . . . . . .Northeastern University

Torti, Frank M., M.D. . . . . . . . . . . . . . . . . . . . .Wake Forest University Health Sciences Center

Trapnell, Bruce C., M.D. . . . . . . . . . . . . . . . . . . .Pulmonary Alveolar Proteinosis Foundation

Traub, Linton M., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Triche, Timothy J., M.D., Ph.D. . . . . . . . . . . . . . .Novelix Pharmaceuticals, Inc.

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

110

Triozzi, Pierre L., M.D. . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Troxel, Andrea B., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Truitt, Robert L., Ph.D. . . . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

V Van Ness, Brian G., Ph.D. . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Vannier, Michael W., M.D. . . . . . . . . . . . . . . . . . .University of Chicago

Verhey, Lynn James, Ph.D. . . . . . . . . . . . . . . . . . .University of California, San Francisco

Vile, Richard G., Ph.D. . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Volpert, Olga V., Ph.D. . . . . . . . . . . . . . . . . . . . .Northwestern University

Von Mehren, Margaret, M.D. . . . . . . . . . . . . . . . .Fox Chase Cancer Center

W Wadler, Scott H., M.D. . . . . . . . . . . . . . . . . . . . .Montefiore Medical Center, Bronx, NY

Wang, Jean Y., Ph.D. . . . . . . . . . . . . . . . . . . . . .Kosan Biosciences, Inc.

Ward, John H., M.D. . . . . . . . . . . . . . . . . . . . . .University of Utah

Weiner, Louis M., M.D. . . . . . . . . . . . . . . . . . . . .Immunicon Corporation

Weiner, Ronald E., Ph.D. . . . . . . . . . . . . . . . . . . .University of Connecticut Health Center

Weiss, Geoffrey R., M.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Welch, Michael J., M.D., Ph.D. . . . . . . . . . . . . . .Washington University

Westendorf, Jennifer J., Ph.D. . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Wilburn, Louella S. . . . . . . . . . . . . . . . . . . . . . . .People Living With Cancer

Wingard, John R., M.D. . . . . . . . . . . . . . . . . . . .University of Florida

Workman, Jerry L., Ph.D. . . . . . . . . . . . . . . . . . .Stowers Institute for Medical Research

Wu, Jie, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institutes

X Xiao, Hua, M.D., Ph.D. . . . . . . . . . . . . . . . . . . . .Michigan State University

Xu, Yan, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Cleveland State University

Y Yandell, David W., Ph.D. . . . . . . . . . . . . . . . . . . .University of Vermont

Yang, Chung S., Ph.D. . . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Yee, Douglas, M.D. . . . . . . . . . . . . . . . . . . . . . . .University of Minnesota

Yoo, George H., M.D. . . . . . . . . . . . . . . . . . . . . .Wayne State University

Yu, Dihua, M.D., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Z Zimbrick, John D., Ph.D. . . . . . . . . . . . . . . . . . . .Colorado State University, Fort Collins

Total Number of D-1 Reviewers: 334

Appendix D-1: Consultants Serving as Temporary Members on IRG Subcommittees in FY2005
NCI/DEA Annual Report 2005

111

2. Consultants Serving as Ad Hoc Committee Members on IRG Site Visit

Teams in FY2005

A Abraham, Robert T., Ph.D. . . . . . . . . . . . . . . . . . .Cyntellect, Inc.

Altman, Norman Harry, V.M.D. . . . . . . . . . . . . . .University of Miami School of Medicine

Andrews, Robert G., M.D. . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Antonia, Scott J., M.D. . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Ashikaga, Taka, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Vermont and State Agricultural College

Au, Jessie L.-S., M.D., Ph.D. . . . . . . . . . . . . . . . .Ohio State University

B Baker, Henry J., D.V.M. . . . . . . . . . . . . . . . . . . .Auburn University at Auburn

Baker, Vicki V., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Michigan Medical Center

Bastia, Deepak, Ph.D. . . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Belk, Bonnie F., M.P.A. . . . . . . . . . . . . . . . . . . . .Private Practice

Benson, Mitchell C., M.D. . . . . . . . . . . . . . . . . . .Columbia University Health Sciences

Bepler, Gerold, M.D., Ph.D. . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Boggan, James E., M.D. . . . . . . . . . . . . . . . . . . .University of California at Davis

Bond, Jeffrey P., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Vermont and State Agricultural College

Bondy, Melissa L., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Borch, Richard F., M.D., Ph.D. . . . . . . . . . . . . . . .Purdue University, West Lafayette

Bourdon, Mario A., Ph.D. . . . . . . . . . . . . . . . . . .La Jolla Institute for Molecular Medicine

Bowen, Deborah J., Ph.D. . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Bronson, Roderick T., D.V.M. . . . . . . . . . . . . . . . .Tulane University of Louisiana

Bryant, Joseph L., D.V.M. . . . . . . . . . . . . . . . . . .University of Maryland Biotechnology Institute

Bryant, Peter J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Butel, Janet S., Ph.D. . . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

C Caligiuri, Michael A., M.D., Ph.D. . . . . . . . . . . . .Ohio State University

Capen, Charles C., D.V.M., Ph.D. . . . . . . . . . . . .Ohio State University

Carducci, Michael A., M.D., Ph.D. . . . . . . . . . . . .Johns Hopkins University

Casagrande, John Thomas, Dr.P.H. . . . . . . . . . . . .University of Southern California

Catalano, Paul J., Sc.D. . . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Caterina, Michael J., M.D., Ph.D. . . . . . . . . . . . .Johns Hopkins University

Champion, Victoria L., Ph.D., R.N. . . . . . . . . . . . .Indiana University School of Nursing

Cho, Kathleen R., M.D. . . . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Christman, Judith K., Ph.D. . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Clohisy, Denis R., M.D. . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Cody, Vivian, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Hauptman-Woodward Medical Research Institute

Cohen, Edward P., M.D. . . . . . . . . . . . . . . . . . . .University of Illinois at Chicago

Cory, Joseph G., Ph.D. . . . . . . . . . . . . . . . . . . . .East Carolina University

Creek, Kim E., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of South Carolina at Aiken

Cullen, Kevin J., M.D. . . . . . . . . . . . . . . . . . . . . .University of Maryland School of Medicine

Curley, Robert W., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

D Damania, Blossom A., Ph.D. . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Darling, Michael W. . . . . . . . . . . . . . . . . . . . . . .Indiana University Cancer Center

Davis, Jerry K., D.V.M., Ph.D. . . . . . . . . . . . . . . .Purdue University
NCI/DEA Annual Report 2005

112

Dent, Paul, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Devere White, Ralph W., M.D. . . . . . . . . . . . . . . .University of California, Davis

Dhir, Rajiv, M.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Djeu, Julie Y., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of South Florida

Dove, William F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Drabkin, Harry A., M.D. . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

E Egelman, Edward H., Ph.D. . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

F Figlin, Robert, M.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Fontham, Elizabeth T., Ph.D. . . . . . . . . . . . . . . . .Louisiana State University Health Sciences Center

Fox, Bernard A., Ph.D. . . . . . . . . . . . . . . . . . . . .Providence Portland Medical Center

Freireich, Emil J., D.Sc., M.D. . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Frueh, Klaus J., Ph.D. . . . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

G Garewal, Harinder S., M.D., Ph.D. . . . . . . . . . . . .University of Arizona

Garrard, William T., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas Southwest Medical Center, Dallas

Gehan, Edmund A., Ph.D. . . . . . . . . . . . . . . . . . .Georgetown University Medical Center

Gentleman, Robert C., Ph.D. . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Geoghegan, Cynthia, B.A. . . . . . . . . . . . . . . . . . .Georgetown University Medical Center

Gerlach, Robert, Ph.D. . . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Gerson, Stanton L., M.D., Ph.D. . . . . . . . . . . . . .Virxsys Corporation

Gerwick, William H., Ph.D. . . . . . . . . . . . . . . . . .University of California, San Diego

Getzenberg, Robert H., Ph.D. . . . . . . . . . . . . . . .Johns Hopkins University

Gimotty, Phyllis A., Ph.D. . . . . . . . . . . . . . . . . . .University of Pennsylvania

Girotti, Albert W., Ph.D. . . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

Goldring, Mary B., Ph.D. . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Gottesfeld, Joel M., Ph.D. . . . . . . . . . . . . . . . . . .Scripps Research Institute

Green, Sylvan B., M.D., Ph.D. . . . . . . . . . . . . . . .Case Western Reserve University

Guy, Barbara B., Ph.D. . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

H Hackney, David B., M.D. . . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Hanash, Samir M., M.D., Ph.D. . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Harrison, Anita L., M.A. . . . . . . . . . . . . . . . . . . .Eastern Virginia Medical School

Havill-Ryan, Diana, OTH. . . . . . . . . . . . . . . . . . . .University of Chicago, Pritzker School of Medicine

Heerema, Nyla A., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

Heitjan, Daniel F., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Held, William A., Ph.D. . . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Henderson, Janet E., Ph.D. . . . . . . . . . . . . . . . . .Center for Bone and Periodontal Research

Hilsenbeck, Susan G., Ph.D. . . . . . . . . . . . . . . . . .Baylor College of Medicine

Howett, Mary K., Ph.D. . . . . . . . . . . . . . . . . . . .Pennsylvania State University Hershey Medical Center

Huang, Jung S., Ph.D. . . . . . . . . . . . . . . . . . . . .St. Louis University

Humphries, Keith, M.D., Ph.D. . . . . . . . . . . . . . .British Columbia Cancer Agency

Hurley, Sheilah K., M.A. . . . . . . . . . . . . . . . . . . .Fronter Science

Hussein, Mohamad, M.D. . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Appendix D-2: Consultants Serving as Ad Hoc Committee Members on IRG Site Visit Teams
NCI/DEA Annual Report 2005

113

I Iritani, Brian M., D.V.M., Ph.D. . . . . . . . . . . . . . .University of Washington

J Jenkins, Robert B., M.D., Ph.D. . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Johnson, Candace S., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Jones, David A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Utah

June, Carl H., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Jung, Jae U., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Harvard University Medical School

K Kan-Mitchell, June K., Ph.D. . . . . . . . . . . . . . . . .Wayne State University

Kaufman, Russel E., M.D. . . . . . . . . . . . . . . . . . .Wistar Institute

Kepner, James L., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Kim, Kyungmann, Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Kiviat, Nancy B., M.D. . . . . . . . . . . . . . . . . . . . .University of Washington

Knowles, Barbara B., Ph.D. . . . . . . . . . . . . . . . . .The Jackson Laboratory

Knutson, Keith L., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Kong, Tony Ah-Ng, Ph.D. . . . . . . . . . . . . . . . . . .Rutgers University College of Pharmacy

Kruse, Carol A., Ph.D. . . . . . . . . . . . . . . . . . . . .La Jolla Institute for Molecular Medicine

Kuo, Macus T., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

L Ladisch, Stephan, M.D. . . . . . . . . . . . . . . . . . . . .Children’s National Medical Center

Lattime, Edmund C., Ph.D. . . . . . . . . . . . . . . . . . .Robert Wood Johnson School of Medicine and Dentistry of New Jersey

Lazo, John S., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh at Pittsburgh

Le, Chap T., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Lewis, Jason S., Ph.D. . . . . . . . . . . . . . . . . . . . . .Washington University

Lichtor, Terence R., M.D., Ph.D. . . . . . . . . . . . . . .Rush University Medical Center

Lieberman, Michael, M.D., Ph.D. . . . . . . . . . . . . .Baylor College of Medicine

Liu, P.Y., Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Lomax, Randy, M.A. . . . . . . . . . . . . . . . . . . . . . .Melanoma Research Foundation

London, Jack W., Ph.D. . . . . . . . . . . . . . . . . . . . .Thomas Jefferson University

Lowry, Diana . . . . . . . . . . . . . . . . . . . . . . . . . . .Southwest Oncology Group

M Macoska, Jill A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Malkas, Linda H., Ph.D. . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University at Indianapolis

Mantyh, Patrick W., Ph.D. . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Marshall, James R., Ph.D. . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Maurer, Barry J., M.D., Ph.D. . . . . . . . . . . . . . . .Children’s Hospital, Los Angeles

McGarry, Michael P., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Mesri, Enrique A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Miami School of Medicine

Minden, Mark D., M.D., Ph.D. . . . . . . . . . . . . . .Princess Margaret Hospital

Mori, Motomi, Ph.D. . . . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Morse, Michael A., M.D. . . . . . . . . . . . . . . . . . . .Duke University

Moscow, Jeffrey A., M.D. . . . . . . . . . . . . . . . . . .University of Kentucky

Mukhtar, Hasan, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Murphy, William Joseph, Ph.D. . . . . . . . . . . . . . . .University of Nevada, Reno

Appendix D-2: Consultants Serving as Ad Hoc Committee Members on IRG Site Visit Teams
NCI/DEA Annual Report 2005

114

N Nelson, Peter S., M.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Neugut, Alfred I., M.D., Ph.D. . . . . . . . . . . . . . . .Columbia University

Nowak, Norma J., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

O Oberyszyn, Tatiana M., Ph.D. . . . . . . . . . . . . . . .Ohio State University

Ochs, Michael F., Ph.D. . . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

O’Neill, Brian P., M.D., Ph.D. . . . . . . . . . . . . . . .Brown University

Ostrer, Harry, M.D., Ph.D. . . . . . . . . . . . . . . . . .New York University School of Medicine

Ou, Jing-Hsiung J., Ph.D. . . . . . . . . . . . . . . . . . .University of Southern California

Ozer, Harvey L., M.D. . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Ozols, Robert F., M.D., Ph.D. . . . . . . . . . . . . . . .Fox Chase Cancer Center

P Paskett, Electra D., Ph.D. . . . . . . . . . . . . . . . . . .Ohio State University

Patchell, Roy A., M.D., Ph.D. . . . . . . . . . . . . . . .University of Kentucky

Perez-Soler, Roman, M.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Peters, Jeffrey M., Ph.D. . . . . . . . . . . . . . . . . . . .Pennsylvania State University, University Park

Pieper, Russ O., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Pierce, John P., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Plate, Janet M., Ph.D. . . . . . . . . . . . . . . . . . . . .Rush University Medical Center

Pledger, W.J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Powell, Robert S., M.A. . . . . . . . . . . . . . . . . . . . .University of Miami School of Medicine

Q Quaranta, Vito, M.D. . . . . . . . . . . . . . . . . . . . . .Vanderbilt University

R Rabson, Arnold B., M.D. . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Rademaker, Alfred W., Ph.D. . . . . . . . . . . . . . . . .Northwestern University

Raghavan, Derek, M.D., Ph.D. . . . . . . . . . . . . . .Cleveland Clinic Foundation

Raubitschek, Andrew A., M.D. . . . . . . . . . . . . . . .City of Hope/Beckman Research Institute

Rauscher, Frank J., Ph.D. . . . . . . . . . . . . . . . . . .Wistar Institute

Remick, Scot C., M.D. . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Riethman, Harold C., Ph.D. . . . . . . . . . . . . . . . . .Wistar Institute

Rosenblatt, Joseph D., M.D. . . . . . . . . . . . . . . . .University of Rochester Cancer Center

Rosenfeld, Steven S., M.D., Ph.D. . . . . . . . . . . . .Columbia University Health Sciences

Rosenman, Julian G., M.D., Ph.D. . . . . . . . . . . . .University of North Carolina

Rosmarin, Alan G., M.D. . . . . . . . . . . . . . . . . . . .Rhode Island Hospital

Roth, Michael D., M.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

S Sandri-Goldin, Rozanne M., Ph.D. . . . . . . . . . . . .University of California, Irvine

Sayre, James W., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Schottenfeld, David, M.D. . . . . . . . . . . . . . . . . . .University of Michigan Comprehensive Cancer Center

Schwartz, Ann G., Ph.D. . . . . . . . . . . . . . . . . . . .Wayne State University

Sellers, Thomas A., Ph.D. . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Seto, Edward, Ph.D. . . . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Shull, James D., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Shyr, Yu, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Vanderbilt University Medical School

Simons, Jonathan W., M.D. . . . . . . . . . . . . . . . . .Emory University

Slamon, Dennis J., M.D., Ph.D. . . . . . . . . . . . . . .University of California, Los Angeles

Appendix D-2: Consultants Serving as Ad Hoc Committee Members on IRG Site Visit Teams
NCI/DEA Annual Report 2005

115

Smith, David I., Ph.D. . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Spriggs, David R., M.D. . . . . . . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Stack, Mary S., Ph.D. . . . . . . . . . . . . . . . . . . . . .Northwestern University

Stahl, Douglas, Ph.D. . . . . . . . . . . . . . . . . . . . . .City of Hope/Beckman Research Institute

Stanbridge, Eric J., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Irvine

Stanley, Pamela M., Ph.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Stauffacher, Cynthia V., Ph.D. . . . . . . . . . . . . . . .Indiana University-Purdue University at Indianapolis

Stein, Gary S., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Storer, Barry E., Ph.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Stout, C. David, Ph.D. . . . . . . . . . . . . . . . . . . . .Scripps Research Institute

Sugden, William M., Ph.D. . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Suva, Larry J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Arkansas Medical Sciences Center, Little Rock

Szyf, Moshe, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .McGill University

T Terry, Michael A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Rochester

Tew, Kenneth D., Ph.D. . . . . . . . . . . . . . . . . . . . .Novelos Therapeutics, Inc.

Tindall, Donald J., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Townsend, Alan J., Ph.D. . . . . . . . . . . . . . . . . . . .Wake Forest University Health Sciences Center

U Ullrich, Stephen E., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

V Vail, David M., D.V.M. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Vallera, Daniel A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Minnesota

Vannier, Michael W., M.D. . . . . . . . . . . . . . . . . . .University of Chicago

Varella-Garcia, Marileila, Ph.D. . . . . . . . . . . . . . . .University of Colorado, Denver

Verma, Ajit K., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin

Verma, Inder M., Ph.D. . . . . . . . . . . . . . . . . . . . .Salk Institute for Biological Studies

W Walter, Mark R., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Alabama at Birmingham

Wasik, Mariusz A., M.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Waxman, Samuel, M.D. . . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Weber, Michael J., Ph.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Wei, Wei-Zen, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Wayne State University

Weick, Martin P., M.S. . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Weiss, Geoffrey R., M.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Wheeler, David A., Ph.D. . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Wicha, Max S., M.D. . . . . . . . . . . . . . . . . . . . . .University of Michigan at Ann Arbor

Wilson-Sanders, Susan E., D.V.M. . . . . . . . . . . . . .University of Arizona

Wolfe, John H., Ph.D., D.V.M. . . . . . . . . . . . . . . .University of Pennsylvania

Woodgett, James R., Ph.D. . . . . . . . . . . . . . . . . .Ontario Cancer Institute

Wrensch, Margaret R., Ph.D. . . . . . . . . . . . . . . . .University of California, San Francisco

Y Yi, Qing, M.D., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Z Zhang, Michael Q., Ph.D. . . . . . . . . . . . . . . . . . .Cold Spring Harbor Laboratory

Total Number of D-2 Reviewers: 203

Appendix D-2: Consultants Serving as Ad Hoc Committee Members on IRG Site Visit Teams
NCI/DEA Annual Report 2005

116

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2005

A Aaronson, Stuart A., M.D. . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Abboud, Camille N., M.D., Ph.D. . . . . . . . . . . . . .University of Rochester

Abdel-Nabi, Hani H., M.D., Ph.D. . . . . . . . . . . . .State University of New York, Buffalo

Abraham, Edward H., M.D. . . . . . . . . . . . . . . . . .Adenylate Diagnostics, LLC

Abraham, George N., M.D., Ph.D. . . . . . . . . . . . .University of Rochester

Abrams, Judith, M.D., Ph.D. . . . . . . . . . . . . . . . .Wayne State University

Ackerman, Eric J., Ph.D. . . . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratories

Ackerman, Terry A., Ph.D. . . . . . . . . . . . . . . . . . .University of North Carolina

Adams, Mary L., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas, Austin

Adams-Campbell, Lucile L., Ph.D. . . . . . . . . . . . . .Howard University

Adjei, Alex A., M.D., Ph.D. . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Affonso, Dyanne D., Ph.D. . . . . . . . . . . . . . . . . .University of Hawaii, Hilo

Agarwal, Rajesh, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Agnew, Brian J., Ph.D. . . . . . . . . . . . . . . . . . . . .Molecular Probes, Inc.

Agrawal, Babita, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Alberta

Agrawal, Krishna C., Ph.D. . . . . . . . . . . . . . . . . .Tulane University of Louisiana

Aguiar, Ricardo C., M.D., Ph.D. . . . . . . . . . . . . . .University of Texas Health Science Center, San Antonio

Ahles, Tim A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Dartmouth College

Ahmed, Farid E., Ph.D. . . . . . . . . . . . . . . . . . . . .East Carolina University

Ahmed, Nayaz, Ph.D. . . . . . . . . . . . . . . . . . . . . .LKT Laboratories, Inc.

Ahn, Jeonghoon, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Southern California

Ahnen, Dennis J., M.D. . . . . . . . . . . . . . . . . . . . .Ludwig Institute for Cancer Research

Akporiaye, Emmanuel T., Ph.D. . . . . . . . . . . . . . . .University of Arizona

Albala, Joanna S., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

Albino, Anthony P., Ph.D. . . . . . . . . . . . . . . . . . .Institute for Cancer Prevention

Ali-Osman, Francis, Ph.D. . . . . . . . . . . . . . . . . . .Duke University

Alvarez, Ronald D., M.D. . . . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Ambinder, Richard F., M.D., Ph.D. . . . . . . . . . . . .Johns Hopkins University

Ambrosone, Christine B., Ph.D. . . . . . . . . . . . . . .American Association for Cancer Research

Andersen, Bogi, M.D. . . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Andersen, M. Robyn, Ph.D. . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Anderson, Carolyn J., Ph.D. . . . . . . . . . . . . . . . .Washington University School of Medicine

Anderson, Garth R., Ph.D. . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Anderson, Kenneth C., M.D. . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Anderson, Peter M., M.D., Ph.D. . . . . . . . . . . . . .Mayo Medical School Foundation

Androphy, Elliot J., M.D. . . . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Andruss, Bernard, Ph.D. . . . . . . . . . . . . . . . . . . .Ambion, Inc.

Andrykowski, Michael A., R.N., Ph.D. . . . . . . . . .University of Kentucky

Angeletti, Ruth Hogue, Ph.D. . . . . . . . . . . . . . . . .Yeshiva University

Antonia, Scott J., M.D. . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Antoun, Mikhail D., Ph.D. . . . . . . . . . . . . . . . . . .University of Puerto Rico

Aplenc, Richard, M.D. . . . . . . . . . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Arai, Andrew E., M.D. . . . . . . . . . . . . . . . . . . . .National Heart, Lung, and Blood Institute

Arap, Wadih, M.D., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center
NCI/DEA Annual Report 2005

117

Arber, Daniel A., M.D. . . . . . . . . . . . . . . . . . . . .Stanford University Hospital

Arenaz, Pablo, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas, El Paso

Argyropoulos, George, Ph.D. . . . . . . . . . . . . . . . .Louisiana State University

Arlinghaus, Ralph B., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Armstrong, Deborah K., M.D. . . . . . . . . . . . . . . .Johns Hopkins University

Armstrong, Floyd Daniel, Ph.D. . . . . . . . . . . . . . .University of Miami

Arora, Neeraj K., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Arrick, Bradley A., M.D., Ph.D. . . . . . . . . . . . . . .Dartmouth College

Ashendel, Curtis L., Ph.D. . . . . . . . . . . . . . . . . . .Purdue University, West Lafayette

Ashikaga, Taka, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Vermont and State Agricultural College

Atkins, Michael B., M.D. . . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Atkinson, E Neely, Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Auborn, Karen J., Ph.D. . . . . . . . . . . . . . . . . . . .Feinstein Institute for Medical Research

Auerbach, Robert, Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin

Austin, Robert H., Ph.D. . . . . . . . . . . . . . . . . . . .Princeton University

Azzam, Edouard I., Ph.D. . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

B Babaian, Richard J., M.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Babich, John W., Ph.D. . . . . . . . . . . . . . . . . . . . .Molecular Insight Pharmaceuticals, Inc.

Babu, John S., D.V.M.., Ph.D. . . . . . . . . . . . . . . .Bioflexis, LLC

Bachmann, Andre S., Ph.D. . . . . . . . . . . . . . . . . .University of Hawaii, Manoa

Backman, Vadim, Ph.D. . . . . . . . . . . . . . . . . . . . .Northwestern University

Bae, You Han, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Utah

Baezconde-Garbanati, Lourdes, Ph.D. . . . . . . . . . .University of Southern California

Baillargeon, Jacques G., Ph.D. . . . . . . . . . . . . . . .University of Texas Health Science Center, San Antonio

Baker, David C., M.D., Ph.D. . . . . . . . . . . . . . . .University of Tennessee

Baker, Nathan A., Ph.D. . . . . . . . . . . . . . . . . . . .Washington University

Baker, Vicki V., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Michigan Medical Center

Balaban, Barbara J. . . . . . . . . . . . . . . . . . . . . . . .West Islip Cancer Coalition

Balch, R. Curtis, Ph.D. . . . . . . . . . . . . . . . . . . . .Indiana University

Balducci, Lodovico, M.D. . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Ball, Louise M., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of North Carolina

Ballman, Karla, Ph.D. . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Balogh, Lajos Peter, Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Balon, Thomas W., Ph.D. . . . . . . . . . . . . . . . . . . .City of Hope, Beckman Research Institute

Balter, James M., M.D., Ph.D. . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Band, Hamid, M.D., Ph.D. . . . . . . . . . . . . . . . . .Evanston Northwestern Healthcare

Banks, William A., M.D., Ph.D. . . . . . . . . . . . . . .St. Louis University

Banks, William L., Ph.D. . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Bao, Gang, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Georgia Institute of Technology

Baquet, Claudia R., M.D., Ph.D. . . . . . . . . . . . . .University of Maryland

Barany, Francis, M.D., Ph.D. . . . . . . . . . . . . . . . .Weill Medical College of Cornell University

Barg, Frances K., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Barile, Frank A., Ph.D. . . . . . . . . . . . . . . . . . . . .St. John’s University

Baron, Andre T., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Kentucky

Batra, Surinder Kumar, Ph.D. . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Batt, Carl A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Illuminaria, LLC

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

118

Bauer, Brent A., M.D. . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Baum, Stanley, M.D. . . . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Baumbach, Lisa L., Ph.D. . . . . . . . . . . . . . . . . . .University of Miami

Baxter-Lowe, Lee Ann A., Ph.D. . . . . . . . . . . . . . .Palmetto Richland Memorial Hospital

Bearman, Gregory H., Ph.D. . . . . . . . . . . . . . . . .National Aeronautics and Space Administration

Becich, Michael J., M.D., Ph.D. . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Beck, J. Robert, M.D. . . . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Beck, William T., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Illinois, Chicago

Becker, Christopher H., Ph.D. . . . . . . . . . . . . . . .Surromed, Inc.

Behm, Frederick G., M.D. . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Beitz, Alvin J. Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Bellamy, Scarlett, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Benaron, David A., M.D. . . . . . . . . . . . . . . . . . . .Spectros Corporation

Benbrook, Doris M., Ph.D. . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Bennett, Jill A., Ph.D. . . . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Bennett, William P., M.D. . . . . . . . . . . . . . . . . . .City of Hope National Medical Center

Bentley, William E., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland

Berens, Michael E., Ph.D. . . . . . . . . . . . . . . . . . .Translational Genomics Research Institute

Berezney, Ronald, Ph.D. . . . . . . . . . . . . . . . . . . .State University of New York, Buffalo

Berger, Mitchel S., M.D., . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Berger, Nathan A., D.V.M., M.D. . . . . . . . . . . . . .Case Western Reserve University

Berger, Sondra H., Ph.D. . . . . . . . . . . . . . . . . . . .University of South Carolina

Bergman, Ira, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Bernacki, Ralph J., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Bernstein, Jonine Lisa, Ph.D. . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Berridge, Marc S., Ph.D. . . . . . . . . . . . . . . . . . . .3D Imaging, LLC

Berry, Donna L., R.N., Ph.D. . . . . . . . . . . . . . . . .Oncology Nursing Society

Bertino, Joseph R., M.D. . . . . . . . . . . . . . . . . . . .The Cancer Institute of New Jersey

Bertone-Johnson, Elizabeth R., Ph.D. . . . . . . . . . . .University of Massachusetts, Amherst

Besson, Guy M., Ph.D. . . . . . . . . . . . . . . . . . . . .ForeVision Technologies Corporation

Bestor, Timothy H., Ph.D. . . . . . . . . . . . . . . . . . .Columbia University Health Sciences

Bhagwat, Ashok S., Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Bickell, Nina A., M.D. . . . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Biegon, Anat, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Brookhaven Science Association-Brookhaven Laboratory

Bies, Robert R., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh

Bigbee, William L., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pittsburgh

Billingsley, Melvin L., Ph.D. . . . . . . . . . . . . . . . . .Pennsylvania State University Hershey Medical Center

Bjorner, Jakob B., M.D., Ph.D. . . . . . . . . . . . . . .Quality Metric, Inc.

Black, Margaret E., Ph.D. . . . . . . . . . . . . . . . . . .Washington State University

Blackburn, George L., M.D., Ph.D. . . . . . . . . . . . .Beth Israel-Deaconess Medical Center

Blanchard, Rebecca L., Ph.D. . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Block, Susan D., M.D. . . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Bloom, Joan R., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of California, Berkeley

Boardman, Lisa A., M.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Bogen, Steven A., M.D., Ph.D. . . . . . . . . . . . . . .Medical Discovery Partners, LLC.

Boggan, James E., M.D. . . . . . . . . . . . . . . . . . . .University of California at Davis

Bogler, Oliver, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Bolinger, Lizann, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Iowa

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

119

Bonavida, Benjamin, Ph.D. . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Boothman, David A., Ph.D. . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Bornhop, Darryl J., Ph.D. . . . . . . . . . . . . . . . . . .Vanderbilt University

Bos, Timothy J., Ph.D. . . . . . . . . . . . . . . . . . . . .Eastern Virginia Medical School

Boss, Gerry R., M.D. . . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Bourne, David, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Oklahoma

Bouvet, Michael, M.D. . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Bowen, Deborah J., Ph.D. . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Bowers, William J., Ph.D. . . . . . . . . . . . . . . . . . .University of Rochester

Boyajian, Richard Nishan . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Boyd, Jeff A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Brachmann, Rainer K., M.D. . . . . . . . . . . . . . . . .University of California, Irvine

Bradley, Cathy J., Ph.D. . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Brahmbhatt, Dhaval J. . . . . . . . . . . . . . . . . . . . .PHYchip Corporation

Bram, Richard J., M.D., Ph.D. . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Brandt, Cynthia A., M.D. . . . . . . . . . . . . . . . . . .Yale University

Brannon-Peppas, Lisa, Ph.D. . . . . . . . . . . . . . . . .University of Texas, Austin

Brat, Daniel J., M.D., Ph.D. . . . . . . . . . . . . . . . .Emory University

Brenan, Colin J.H., Ph.D. . . . . . . . . . . . . . . . . . .BioTrove, Inc.

Brenna, James T., Ph.D. . . . . . . . . . . . . . . . . . . .Cornell University, Ithaca

Brenner, Malcolm K., M.D., Ph.D. . . . . . . . . . . . .Baylor College of Medicine

Brett, John A., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Brewer, Molly A., D.V.M.., M.D. . . . . . . . . . . . . .University of Arizona

Bright, Robert K., Ph.D. . . . . . . . . . . . . . . . . . . .Texas Tech University Health Sciences Center

Brink, Susan G., Ph.D. . . . . . . . . . . . . . . . . . . . .Healthmark Multimedia, LLC

Broaddus, Russell R., M.D., Ph.D. . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Brock, Graham J., Ph.D. . . . . . . . . . . . . . . . . . . .Ordway Research Institute, Inc.

Brodeur, Garrett M., M.D. . . . . . . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Brodie, Angela M., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland

Brooks, Antone L., Ph.D. . . . . . . . . . . . . . . . . . .Battelle, Pacific NW Labs

Brooks, Mai Nguyen, M.D. . . . . . . . . . . . . . . . . .University of California, Los Angeles

Brousseau, Louis C., Ph.D. . . . . . . . . . . . . . . . . .Quantum Logic Devices

Brown, C. Perry, Ph.D. . . . . . . . . . . . . . . . . . . . .Florida A&M University

Brown, Jean, R.N., Ph.D. . . . . . . . . . . . . . . . . . .State University of New York, Buffalo

Brown, Jeremy, M.D. . . . . . . . . . . . . . . . . . . . . .George Washington University

Brown, Kathlynn C., Ph.D. . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Brown, Powel, M.D., Ph.D. . . . . . . . . . . . . . . . . .Baylor College of Medicine

Broxmeyer, Hal E., M.D., Ph.D. . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Bruce, James Edward, Ph.D. . . . . . . . . . . . . . . . .Washington State University

Bruck, Hugh A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Maryland College Park Campus

Bruera, Eduardo, M.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Bruner, Deborah W., Ph.D., R.N. . . . . . . . . . . . . .Fox Chase Cancer Center

Buatti, John M., M.D. . . . . . . . . . . . . . . . . . . . .University of Iowa

Buchanan, George R., M.D. . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Buchsbaum, Donald J., Ph.D. . . . . . . . . . . . . . . .University of Alabama, Birmingham

Bukowski, Ronald M., M.D. . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Bulik, Robert J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas Medical Branch, Galveston

Bull, Joan M., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, Houston

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

120

Bumgarner, Roger E., Ph.D. . . . . . . . . . . . . . . . . .University of Washington

Burdette, Everette C., Ph.D. . . . . . . . . . . . . . . . .Computerized Medical Systems, Inc.

Burgess, Kevin, Ph.D. . . . . . . . . . . . . . . . . . . . . .Texas A&M University System

Burghardt, Thomas P., Ph.D. . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Burke, Harry B., M.D., Ph.D. . . . . . . . . . . . . . . .George Washington University

Burns, David Michael, M.D. . . . . . . . . . . . . . . . .University of California, San Diego

Burns, Fredric J., Ph.D. . . . . . . . . . . . . . . . . . . . .New York University Medical Center

Burns, Linda J., M.D. . . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Burt, Randall W., M.D. . . . . . . . . . . . . . . . . . . . .University of Utah

Butler, Grace L., Ph.D. . . . . . . . . . . . . . . . . . . . .Hope Through Grace, Inc.

Butler, Robert W., Ph.D. . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Butt, Tauseef R., Ph.D. . . . . . . . . . . . . . . . . . . . .Lifesensors, Inc.

Byrd, John C., M.D. . . . . . . . . . . . . . . . . . . . . . .Ohio State University

Byrns, Patricia J., M.D. . . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

C Caan, Bette J., Ph.D. . . . . . . . . . . . . . . . . . . . . .Kaiser Foundation Research Institute

Cairns, Paul, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Cairo, Mitchell S., M.D. . . . . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Caldwell, Charles W., M.D., Ph.D. . . . . . . . . . . . .Ellis Fischel Cancer Center

Caligiuri, Michael A., M.D., Ph.D. . . . . . . . . . . . .Ohio State University

Call, Katherine M., Ph.D. . . . . . . . . . . . . . . . . . .Sanofi-Aventis

Campbell, Catherine, Ph.D. . . . . . . . . . . . . . . . . .SRA International, Inc.

Cao, Weiguo, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Clemson University

Caplan, Arthur L., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Capuano, Saverio V., D.V.M. . . . . . . . . . . . . . . . .Magee-Women’s Hospital of University of Pittsburgh

Carbone, David P., M.D., Ph.D. . . . . . . . . . . . . . .Vanderbilt University

Carbone, Michele, M.D., Ph.D. . . . . . . . . . . . . . .Loyola University of Chicago

Carey, Lisa A., M.D., Ph.D. . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Carey, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . .RPC Associates, Inc.

Carroll, William L., M.D. . . . . . . . . . . . . . . . . . . .New York University School of Medicine

Carter, Christopher A., Ph.D. . . . . . . . . . . . . . . . .Southern Research Institute

Castleberry, Robert P., M.D. . . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Catalano, Susan M., Ph.D. . . . . . . . . . . . . . . . . .Acumen Pharmaceuticals, Inc.

Chalmers, Jeffrey J., Ph.D. . . . . . . . . . . . . . . . . .Ohio State University

Champlin, Richard E., M.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Chao, K.S. Clifford, M.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Chapman, Paul B., M.D. . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Chen, Chu, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Chen, George T.Y., Ph.D. . . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Chen, James K., Ph.D. . . . . . . . . . . . . . . . . . . . .Stanford University

Chen, Wen-Tien, Ph.D. . . . . . . . . . . . . . . . . . . . .Vitatex, Inc.

Chen, Wen Y., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Greenville Hospital System

Chen, Xi, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .University of California, Davis

Chen, Xinbin, D.V.M., Ph.D. . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Chenevert, Thomas L., Ph.D. . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Chen-Kiang, Selina Y., Ph.D. . . . . . . . . . . . . . . . .Weill Medical College of Cornell University

Chervenak, Robert P., Ph.D. . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, Shreveport

Cheung, Vivian G., M.D. . . . . . . . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

121

Chia, David I., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Chien, Chia-Ling, Ph.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Chlebowski, Rowan T., M.D., Ph.D. . . . . . . . . . . .Los Angeles Biomedical Research Institute at Harbor

Chow, Gary . . . . . . . . . . . . . . . . . . . . . . . . . . .American Cancer Society, California

Christensen, Neil D., Ph.D. . . . . . . . . . . . . . . . . .Pennsylvania State University Hershey Medical Center

Christian, Bradley, Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Christiani, David C., M.D., Ph.D. . . . . . . . . . . . . .Harvard University, School of Public Health

Christie, Debra W., Ph.D. . . . . . . . . . . . . . . . . . .University of Mississippi Medical Center

Chu, Fong-Fong, Ph.D. . . . . . . . . . . . . . . . . . . . .City of Hope National Medical Center

Claffey, Kevin P., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Connecticut School of Medicine and Dentistry

Clarke, Robert R., Ph.D. . . . . . . . . . . . . . . . . . . .Georgetown University

Clawson, Gary A., M.D., Ph.D. . . . . . . . . . . . . . .Pennsylvania State University

Clayman, Gary L., D.D.S., M.D., Ph.D. . . . . . . . .University of Texas M.D. Anderson Cancer Center

Cleary, Margot P., Ph.D. . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Cleaver, Vicki L. . . . . . . . . . . . . . . . . . . . . . . . . .Oklahoma University Health Sciences Center

Cline, Rebecca J., Ph.D. . . . . . . . . . . . . . . . . . . .Karmanos Cancer Institute

Close, David R., M.D. . . . . . . . . . . . . . . . . . . . . .Joe Arrington Cancer Center

Cobb, Nathaniel, M.D. . . . . . . . . . . . . . . . . . . . .Indian Health Service

Cobos, Everardo, M.D. . . . . . . . . . . . . . . . . . . . .Texas Tech University

Cody, Michael J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Southern California

Coffman, James A., Ph.D. . . . . . . . . . . . . . . . . . .Mount Desert Island Biological Laboratory

Cohen, Leonard A., Ph.D. . . . . . . . . . . . . . . . . . .American Health Foundation

Colcher, David Morris, Ph.D. . . . . . . . . . . . . . . . .Beckman Research Institute of the City of Hope

Colditz, Graham A., M.D. . . . . . . . . . . . . . . . . .Harvard University, School of Public Health

Collins, Scott D., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Maine

Colonna, Marco, M.D. . . . . . . . . . . . . . . . . . . . .Washington University

Cominelli, Fabio, M.D., Ph.D. . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Conaway, Mark R., Ph.D. . . . . . . . . . . . . . . . . . .University of Virginia Health Science Center

Conley, Virginia M., Ph.D. . . . . . . . . . . . . . . . . . .University of South Florida

Conney, Allan H., Ph.D. . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Connolly, Denise C., Ph.D. . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Conti, Peter S., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Southern California

Coop, Andrew, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Maryland Baltimore School of Medicine

Copelan, Edward A., M.D. . . . . . . . . . . . . . . . . . .Ohio State University

Corey, David R., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Coronado, Gloria D., Ph.D. . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Correa, Catherine N., M.P.H. . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

Correia, John A., Ph.D. . . . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Cox, Adrienne D., Ph.D. . . . . . . . . . . . . . . . . . . .Federation of American Societies for Experimental Biology

Craig, Bruce A., Ph.D. . . . . . . . . . . . . . . . . . . . .Purdue University, West Lafayette

Craighead, Harold G., Ph.D. . . . . . . . . . . . . . . . .Cornell University, Ithaca

Crain, Pamela F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Utah

Craiu, Abie, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Science Research Laboratory, Inc.

Crawford, Stephanie Y., Ph.D. . . . . . . . . . . . . . . .University of Illinois, Chicago

Creek, Kim E., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of South Carolina, Aiken

Crichton, Dan J., Ph.D. . . . . . . . . . . . . . . . . . . . .NASA, Jet Propulsion Laboratory

Cronin, Maureen T., Ph.D. . . . . . . . . . . . . . . . . . .Genomic Health, Inc.

Crosby, Margaree S., Ed.D. . . . . . . . . . . . . . . . . .Clemson University

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

122

Crowell, Pamela L., Ph.D. . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Croy, Robert G., Ph.D. . . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Cruciani, Ricardo, M.D., Ph.D. . . . . . . . . . . . . . .Beth Israel Medical Center, New York

Cruz Correa, Marcia R., M.D., Ph.D. . . . . . . . . . .University of Puerto Rico Medical Sciences

Cullis, Christorpher A., Ph.D. . . . . . . . . . . . . . . . .Case Western Reserve University

D Daling, Janet R., Ph.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Dalton, Jo Ann, R.N. . . . . . . . . . . . . . . . . . . . . .Emory University

Dalton, William S., M.D., Ph.D. . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Danielson, Catherine, OTH . . . . . . . . . . . . . . . . .Colorado River Head and Neck Cancer Support Group

Danks, Mary K., Ph.D. . . . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Dannals, Robert F., Ph.D. . . . . . . . . . . . . . . . . . .Johns Hopkins University

Das Gupta, Tapas K., M.D., Ph.D. . . . . . . . . . . . .University of Illinois, Chicago

Daskalakis, Constantine, Ph.D. . . . . . . . . . . . . . .Thomas Jefferson University

Datta, Milton W., M.D. . . . . . . . . . . . . . . . . . . . .Emory University

Dave, Digant P., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas, Arlington

Davidson, Nancy E., M.D., Ph.D. . . . . . . . . . . . . .Johns Hopkins University

Davie, James R., M.D., Ph.D. . . . . . . . . . . . . . . .University of Manitoba

Davis, Mellar P., M.D. . . . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Davis-King, Donna T., Ph.D. . . . . . . . . . . . . . . . .Charles Drew University

Davisson, Vincent J., Ph.D. . . . . . . . . . . . . . . . . .Indigo Biosystems, Inc.

Day, Billy W., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Deapen, Dennis M., Ph.D. . . . . . . . . . . . . . . . . . .University of Southern California

Deen, Dennis F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California

De La Monte, Suzanne M., M.D. . . . . . . . . . . . .Rhode Island Hospital

Deluca, Paul M., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Denberg, Thomas D., M.D., Ph.D. . . . . . . . . . . . .University of Colorado, Denver

Denis, Gerald V., Ph.D. . . . . . . . . . . . . . . . . . . . .Boston University School of Medicine

Dennis, John U., D.V.M. . . . . . . . . . . . . . . . . . . .Duke University

Descour, Michael R., Ph.D. . . . . . . . . . . . . . . . . .University of Arizona

Deshong, Philip, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Maryland College Park Campus

Devere White, Ralph W., M.D. . . . . . . . . . . . . . . .University of California, Davis 

Devine, Scott E., Ph.D. . . . . . . . . . . . . . . . . . . . .Emory University

Dewerd, Larry A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Dhir, Rajiv, M.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Diamond, Alan M., Ph.D. . . . . . . . . . . . . . . . . . .University of Illinois, Chicago

Dicker, Adam Paul, M.D., Ph.D. . . . . . . . . . . . . . .Thomas Jefferson University

Dickson, Robert B., Ph.D. . . . . . . . . . . . . . . . . . .Georgetown University

Diefenbach, Andreas, M.D., Ph.D. . . . . . . . . . . . .New York University School of Medicine

Dietrich, Allen, M.D. . . . . . . . . . . . . . . . . . . . . . .New Hampshire Minority Health Coalition

Dignan, Mark B., Ph.D. . . . . . . . . . . . . . . . . . . .University of Kentucky

Dinney, Colin P., M.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Disaia, Philip J., M.D. . . . . . . . . . . . . . . . . . . . . .Gynecology Oncology Group

Distefano, Mark D., Ph.D. . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Djuric, Zora, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Michigan

Does, Mark D., Ph.D. . . . . . . . . . . . . . . . . . . . . .Vanderbilt University

Doherty, Gerard M., M.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Doktycz, Mitchel J., Ph.D. . . . . . . . . . . . . . . . . .UT-Battelle, LLC-Oak Ridge National Laboratory

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

123

Dolnick, Bruce J., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Donnenberg, Albert D., Ph.D. . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Doranz, Benjamin, Ph.D. . . . . . . . . . . . . . . . . . . .Integral Molecular

Dougherty, Thomas J., Ph.D. . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Doyle, Terrence William, Ph.D. . . . . . . . . . . . . . . .Vion Pharmaceuticals, Inc.

Drabkin, Harry A., M.D. . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Drake, Richard R., Ph.D. . . . . . . . . . . . . . . . . . . .Eastern Virginia Medical School

Drees, Beth E., Ph.D. . . . . . . . . . . . . . . . . . . . . .Echelon Biosciences, Inc.

Dressman, Holly K., Ph.D. . . . . . . . . . . . . . . . . . .Duke University

Drisko, Jeanne A., M.D. . . . . . . . . . . . . . . . . . . .University of Kansas Medical Center

Dube, Catherine E., Ph.D. . . . . . . . . . . . . . . . . . .Brown University

Dubeau, Louis, M.D., Ph.D. . . . . . . . . . . . . . . . .University of Southern California

Dynan, William S., Ph.D. . . . . . . . . . . . . . . . . . . .Medical College of Georgia

E Eastman, Alan R., Ph.D. . . . . . . . . . . . . . . . . . . .Dartmouth College

Eaton, Charles B., M.D. . . . . . . . . . . . . . . . . . . .Memorial Hospital of Rhode Island

Eaton, David L., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Washington

Eckhart, Walter, Ph.D. . . . . . . . . . . . . . . . . . . . . .Salk Institute for Biological Studies

Edwards, Lloyd J., Ph.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Egelman, Edward H., Ph.D. . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Eisenberger, Mario A., M.D. . . . . . . . . . . . . . . . . .Johns Hopkins University

El-Deiry, Wafik S., M.D., Ph.D. . . . . . . . . . . . . . .University of Pennsylvania

Eliason, James F., Ph.D. . . . . . . . . . . . . . . . . . . . .Wayne State University

Ellenhorn, Joshua D.I., M.D. . . . . . . . . . . . . . . . .City of Hope, Beckman Research Institute

Ellerton, John A., M.D. . . . . . . . . . . . . . . . . . . . .Southern Nevada Cancer Research Foundation

Elliott, Thomas E., M.D., Ph.D., R.N. . . . . . . . . . .Duluth Clinic

Ellis, Matthew J., M.D., Ph.D. . . . . . . . . . . . . . . .Washington University

Elson, Paul J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Engelman, Kimberly K., Ph.D. . . . . . . . . . . . . . . .University of Kansas Medical Center

Eppard, Wayland, B.A. . . . . . . . . . . . . . . . . . . . .North Central Cancer Treatment Group

Erdmann, Christine, Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Erdreich-Epstein, M.D., Ph.D. . . . . . . . . . . . . . . .Children’s Hospital, Los Angeles

Erickson, Kent L., Ph.D. . . . . . . . . . . . . . . . . . . .University of California

Erlichman, Charles, M.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Esenaliev, Rinat O., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Espinoza, Paula A., Ph.D. . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Esterowitz, Leon, Ph.D. . . . . . . . . . . . . . . . . . . . .National Science Foundation

Etzioni, Ruth B., Ph.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Evelhoch, Jeffrey L., Ph.D. . . . . . . . . . . . . . . . . . .Pharmacia Corporation

F Fabry, Mary E., Ph.D. . . . . . . . . . . . . . . . . . . . . .Yeshiva University

Fan, Z Hugh, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Florida

Farone, William A., Ph.D. . . . . . . . . . . . . . . . . . .Applied Power Concepts, Inc.

Fatouros, Panos P., Ph.D. . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Fayad, Zahi A., Ph.D. . . . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Feldman, Benjamin, Ph.D. . . . . . . . . . . . . . . . . . .Medical Research Council

Feldman, Henry A., Ph.D. . . . . . . . . . . . . . . . . . .New England Research Institutes, Inc.

Felsburg, Peter J., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

124

Feng, Ziding, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Fenoglio-Preiser, Cecilia M., M.D. . . . . . . . . . . . . .University of Cincinnati

Fenselau, Catherine C., Ph.D. . . . . . . . . . . . . . . . .University of Maryland College Park Campus

Ferrer, Robert L., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, San Antonio

Ferris, Greg . . . . . . . . . . . . . . . . . . . . . . . . . . . .Lance Armstrong Foundation

Ferrone, Soldano, M.D., Ph.D. . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Finkelstein, Dianne M., Ph.D. . . . . . . . . . . . . . . . .Massachusetts General Hospital

Finkelstein, Jacob N., Ph.D. . . . . . . . . . . . . . . . . .University of Rochester

Finn, Ronald D., Ph.D. . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Fisher, Paul G., M.D. . . . . . . . . . . . . . . . . . . . . . .Stanford University

Fishman, David, M.D. . . . . . . . . . . . . . . . . . . . . .Gordon Research Conferences

Fitzgerald, Thomas J., M.D. . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Fitzpatrick, Frank A., Ph.D. . . . . . . . . . . . . . . . . .University of Utah

Fleischman, Aaron J., Ph.D. . . . . . . . . . . . . . . . . .Case Western Reserve University

Flocke, Susan A., Ph.D. . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Foley, Kathleen M., M.D. . . . . . . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Fong, Timothy C., Ph.D. . . . . . . . . . . . . . . . . . . .Becton, Dickinson Immunocyrometry System

Fonseca, Rafael, M.D. . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Foos, David Howard, M.S. . . . . . . . . . . . . . . . . . .Kodak Research Laboratories

Fortina, Paolo M., M.D., Ph.D. . . . . . . . . . . . . . .Thomas Jefferson University

Fotedar, Arun, M.D., Ph.D. . . . . . . . . . . . . . . . . .Sidney Kimmel Cancer Center

Fountain, Augustus W., Ph.D. . . . . . . . . . . . . . . .United States Military Academy

Frackelton, Raymond A., Ph.D. . . . . . . . . . . . . . .Roger Williams Hospital

Francis, David M., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

Franck, Richard W., Ph.D. . . . . . . . . . . . . . . . . . .Hunter College

Frankel, Arthur, M.D., Ph.D. . . . . . . . . . . . . . . . .Scott and White Memorial Hospital

Frank-Kamenetskii, Maxim D., Ph.D. . . . . . . . . . . .Boston University Charles River Campus

Franklin, Wilbur A., M.D. . . . . . . . . . . . . . . . . . .University of Colorado Health Sciences Center

Franks, Melissa M., Ph.D. . . . . . . . . . . . . . . . . . .Wayne State University

Freitas, Michael A., Ph.D. . . . . . . . . . . . . . . . . . .Ohio State University

Frenkel, Krystyna, Ph.D. . . . . . . . . . . . . . . . . . . .New York University Medical Center

Fresco, Jacques R., Ph.D. . . . . . . . . . . . . . . . . . .Princeton University

Frey, Eric C., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Freyer, James P., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Alamos National Laboratory

Freytag, Svend O., Ph.D. . . . . . . . . . . . . . . . . . . .Henry Ford Health System

Friedman, Henry S., M.D. . . . . . . . . . . . . . . . . . .Duke University

Friedrich, Christopher, Ph.D. . . . . . . . . . . . . . . . .University of Mississippi Medical Center

Frost, Marlene H., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Fuchs, Ephraim J., M.D. . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Fueyo, Juan, Ph.D., M.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Furge, Kyle A., Ph.D. . . . . . . . . . . . . . . . . . . . . .Van Andel Research Institute

Futscher, Bernard W., Ph.D. . . . . . . . . . . . . . . . . .University of Arizona

G Gaasterland, Terry, Ph.D. . . . . . . . . . . . . . . . . . . .University of California, San Diego

Gabrielson, Edward W., M.D. . . . . . . . . . . . . . . . .Johns Hopkins University

Gabrilove, Janice L., M.D. . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Gajewski, Thomas F., M.D., Ph.D. . . . . . . . . . . . .University of Chicago

Galbraith, David W., Ph.D. . . . . . . . . . . . . . . . . .University of Arizona

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

125

Ganapathi, Ram N., Ph.D. . . . . . . . . . . . . . . . . . .Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Ganjei, J. Kelly, B.S. . . . . . . . . . . . . . . . . . . . . . .Tissue Gene, Inc.

Gann, Peter H., M.D. . . . . . . . . . . . . . . . . . . . . .Northwestern University

Garner, Elizabeth, M.D., Ph.D. . . . . . . . . . . . . . . .Brigham and Women’s Hospital

Gascoyne, Peter R., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Gassman, Jennifer J., Ph.D. . . . . . . . . . . . . . . . . .Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Gasson, Judith C., M.D., Ph.D. . . . . . . . . . . . . . .University of California, Los Angeles

Gaston, Sandra M., Ph.D. . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Gatley, Samuel John, Ph.D. . . . . . . . . . . . . . . . . .Brookhaven Science Association, Brookhaven Laboratory

Gau, Vincent J., Ph.D. . . . . . . . . . . . . . . . . . . . .Gene Fluidics, Inc.

Gazdar, Adi F., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Geller, Berta M., E.D.D. . . . . . . . . . . . . . . . . . . .University of Vermont and State Agricultural College

Gelovani, Juri G., M.D., Ph.D. . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Geng, Lei, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .University of Iowa

George, John S., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Alamos National Laboratory

Gerald, William L., M.D., Ph.D. . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Gerlach, Robert, Ph.D. . . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Gershenwald, Jeffrey E., M.D. . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Gershman, Susan T., Ph.D. . . . . . . . . . . . . . . . . .Massachusetts Department of Public Health

Gettig, Elizabeth A., M.S. . . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Gewirtz, Alan M., M.D., Ph.D. . . . . . . . . . . . . . .University of Pennsylvania

Ghandehari, Hamid, Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland

Ghosh, Kaushik, Ph.D. . . . . . . . . . . . . . . . . . . . .George Washington University

Giaccia, Amato J., Ph.D. . . . . . . . . . . . . . . . . . . .Stanford University

Gibbs, Richard A., Ph.D. . . . . . . . . . . . . . . . . . . .Purdue University, West Lafayette

Gibson, Raymond E., Ph.D. . . . . . . . . . . . . . . . . .Merck Research Laboratories

Giesler, R. Brian, Ph.D. . . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Gilchrist, Gerald S., M.D. . . . . . . . . . . . . . . . . . .Mayo Medical School Foundation

Gillespie, G. Yancey, Ph.D. . . . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Gillison, Maura L., M.D., Ph.D. . . . . . . . . . . . . . .Johns Hopkins University

Gimotty, Phyllis A., Ph.D. . . . . . . . . . . . . . . . . . .University of Pennsylvania

Gimzewski, James K., Ph.D. . . . . . . . . . . . . . . . . .University of California, Los Angeles

Giralt, Sergio A., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Given, Barbara A., Ph.D., R.N. . . . . . . . . . . . . . .Michigan State University

Gjerset, Ruth A., Ph.D. . . . . . . . . . . . . . . . . . . . .Sidney Kimmel Cancer Center

Glass, Andrew G., M.D. . . . . . . . . . . . . . . . . . . .Kaiser Foundation Research Institute

Glynn, Thomas J., Ph.D. . . . . . . . . . . . . . . . . . . .Cancer Science and Trends

Godwin, Andrew K., Ph.D. . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Goff, R. Blake, Ph.D. . . . . . . . . . . . . . . . . . . . . .Vical, Inc.

Gogal, Robert M., D.V.M. . . . . . . . . . . . . . . . . . .Virginia College of Osteopathic Medicine

Goggins, Michael G., M.D. . . . . . . . . . . . . . . . . .Johns Hopkins University

Gold, David V., Ph.D. . . . . . . . . . . . . . . . . . . . . .Center for Molecular Medicine and Immunology

Gold, Leslie I., Ph.D. . . . . . . . . . . . . . . . . . . . . . .New York University Medical Center

Goldberg, Bennett B., Ph.D. . . . . . . . . . . . . . . . .Boston University Charles River Campus

Goldberg, Judith D., Ph.D. . . . . . . . . . . . . . . . . .New York University School of Medicine

Goldenring, James R., M.D., Ph.D. . . . . . . . . . . . .Vanderbilt University

Goldfarb, Adam N., M.D. . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Goldin, Barry R., Ph.D. . . . . . . . . . . . . . . . . . . . .Tufts University, Boston

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

126

Goldrick, Marianna M., Ph.D. . . . . . . . . . . . . . . .Ambion, Inc.

Gollin, Susanne M., Ph.D. . . . . . . . . . . . . . . . . . .University of Pittsburgh

Gollnick, Sandra O., Ph.D. . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Gololobov, Mikhail, Ph.D. . . . . . . . . . . . . . . . . . .Polium Technologies, Inc.

Golovlev, Val V., Ph.D. . . . . . . . . . . . . . . . . . . . .Science-Tec, Inc.

Gomer, Charles J., Ph.D. . . . . . . . . . . . . . . . . . . .Children’s Hospital, Los Angeles

Gomez, Leo S., Ph.D. . . . . . . . . . . . . . . . . . . . . .Orion International Technologies, Inc.

Gonzalez Burchard, Esteban G., M.D. . . . . . . . . . .University of California, San Francisco

Gooding, Linda R., Ph.D. . . . . . . . . . . . . . . . . . . .Emory University

Goodlett, David Robinson, Ph.D. . . . . . . . . . . . . .University of Washington

Goodrich, David W., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Gooley, Ted A., Ph.D. . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Gore, Steven D., M.D., Ph.D. . . . . . . . . . . . . . . .Johns Hopkins University

Goyal, Tanya M., Ph.D. . . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Grainger, David W., Ph.D. . . . . . . . . . . . . . . . . . .Colorado State University, Fort Collins

Grando, Sergei A., M.D., Ph.D. . . . . . . . . . . . . . .University of California, Davis

Grant, Marcia L., Ph.D., R.N. . . . . . . . . . . . . . . .City of Hope, Beckman Research Institute

Grant, Steven, M.D. . . . . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Graves, Barbara J., Ph.D. . . . . . . . . . . . . . . . . . .University of Utah

Greco, William R., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Green, Daniel M., M.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Green, Mark A., Ph.D. . . . . . . . . . . . . . . . . . . . .Purdue University, West Lafayette

Gregorio, David I., Ph.D. . . . . . . . . . . . . . . . . . . .University of Connecticut School of Medicine and Dentistry

Greipp, Philip R., M.D. . . . . . . . . . . . . . . . . . . . .Mayo Clinic, Jacksonville

Grem, Jean, M.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Grimson, Eric, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Grizzle, William E., M.D., Ph.D. . . . . . . . . . . . . . .University of Alabama, Birmingham

Grufferman, Seymour, M.D. . . . . . . . . . . . . . . . .University of Pittsburgh

Grunberg, Steven M., M.D. . . . . . . . . . . . . . . . . .University of Vermont

Grundfest, Warren S., M.D. . . . . . . . . . . . . . . . . .University of California, Los Angeles

Grupp, Stephan A., M.D., Ph.D. . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Guidry, Jeffery J., Ph.D. . . . . . . . . . . . . . . . . . . .Texas A&M University

Gunatilaka, Leslie, Ph.D. . . . . . . . . . . . . . . . . . . .University of Arizona

Guo, Baochuan, Ph.D. . . . . . . . . . . . . . . . . . . . .GLC Biotechnology, Inc.

Gustafson, David H., Ph.D. . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Guthold, Martin, Ph.D. . . . . . . . . . . . . . . . . . . . .Wake Forest University

Gutierrez, Peter L., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland Cancer Center

H Haab, Brian B., Ph.D. . . . . . . . . . . . . . . . . . . . . .Van Andel Research Institute

Haddad, Bassem R., M.D. . . . . . . . . . . . . . . . . . .Georgetown University

Halazonetis, Thanos D., D.D.S., Ph.D. . . . . . . . . .Wistar Institute

Hall, Jeff M., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Genoptix, Inc.

Hamilton, Thomas C., Ph.D. . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Hammond, Elizabeth H., M.D. . . . . . . . . . . . . . . .LDS Hospital

Hammons, George J., Ph.D. . . . . . . . . . . . . . . . . .Philander Smith College

Hampton, James, M.D. . . . . . . . . . . . . . . . . . . . .University of Oklahoma

Handgretinger, Rupert, M.D., Ph.D. . . . . . . . . . . .St. Jude Children’s Research Hospital

Hank, Jacquelyn A., Ph.D. . . . . . . . . . . . . . . . . . .University of Wisconsin Centers

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

127

Hansen, Marc F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Connecticut School of Medicine

Hansen, Ted H., Ph.D. . . . . . . . . . . . . . . . . . . . . .Washington University

Hargreaves, Margaret K., Ph.D. . . . . . . . . . . . . . .Meharry Medical College

Harris, Randall E., M.D., Ph.D. . . . . . . . . . . . . . .Ohio State University

Harrison, Gail G., Ph.D. . . . . . . . . . . . . . . . . . . .University of California at Los Angeles, School of Public Health

Hartline, Jo Ann, M.P.H. . . . . . . . . . . . . . . . . . . .Select Statistical Center

Hartov, Alexander, Ph.D. . . . . . . . . . . . . . . . . . . .Hanover Medical Imaging Project, LLC

Hasan, Tayyaba, Ph.D. . . . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Hawley, Sarah T., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Heid, Kermit K., M.S. . . . . . . . . . . . . . . . . . . . . .Consultant

Heiney, Sue P., R.N., Ph.D. . . . . . . . . . . . . . . . . .Palmetto Richland Memorial Hospital

Heinrich, Michael C., M.D. . . . . . . . . . . . . . . . . .Oregon Health and Science University

Heisterkamp, Nora C., Ph.D. . . . . . . . . . . . . . . . .Children’s Hospital, Los Angeles

Heitjan, Daniel F., Ph.D. . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Hemminger, Bradley M., Ph.D. . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Hemstreet, George P., M.D., Ph.D. . . . . . . . . . . . .Academic Research Enterprises, LLC

Henry-Tillman, Ronda S., M.D. . . . . . . . . . . . . . . .University of Arkansas Medical Sciences, Little Rock

Herman, James G., M.D. . . . . . . . . . . . . . . . . . . .Johns Hopkins University Medical School

Hernandez, Brenda Y., Ph.D. . . . . . . . . . . . . . . . .University of Hawaii, Manoa

Herscovics, Annette A., Ph.D. . . . . . . . . . . . . . . .McGill University

Heslop, Helen E., M.D. . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Heston, Warren D., Ph.D. . . . . . . . . . . . . . . . . . .Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Hettich, Robert L., Ph.D. . . . . . . . . . . . . . . . . . . .Oak Ridge National Laboratory

Hichwa, Richard D., Ph.D. . . . . . . . . . . . . . . . . . .University of Iowa

Hickey, Matthew S., Ph.D. . . . . . . . . . . . . . . . . . .Colorado State University, Fort Collins

Hiebert, Scott W., Ph.D. . . . . . . . . . . . . . . . . . . .Vanderbilt University

Hilakivi-Clarke, Leena A., Ph.D. . . . . . . . . . . . . . .Georgetown University

Hill, David E., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Hilliard, Julia K., Ph.D. . . . . . . . . . . . . . . . . . . . .SW Foundation for Biomedical Research

Hinds, Philip W., Ph.D. . . . . . . . . . . . . . . . . . . . .New England Medical Center Hospitals

Hittelman, Walter N., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Hlatky, Lynn R., Ph.D. . . . . . . . . . . . . . . . . . . . . .St. Elizabeth’s Medical Center of Boston

Hnatowich, Donald J., Ph.D. . . . . . . . . . . . . . . . .Feinstein Institute for Medical Research

Ho, Gloria Yf, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Yeshiva University

Hockenbery, David M., M.D. . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Hockensmith, Joel W., Ph.D. . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Hoffman, Richard M., M.D., Ph.D. . . . . . . . . . . . .University of New Mexico, Albuquerque

Hoh, Jan H., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .John Hopkins University School of Medicine

Hohl, Raymond J., M.D., Ph.D. . . . . . . . . . . . . . .University of Iowa

Holcombe, Randall F., M.D. . . . . . . . . . . . . . . . . .University of California, Irvine

Holiday, David B., Ph.D. . . . . . . . . . . . . . . . . . . .Research Triangle Institute

Holl, Mark, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Washington

Holland, Jimmie C. B., M.D. . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Holland, Lisa A., Ph.D. . . . . . . . . . . . . . . . . . . . .West Virginia University

Hollingsworth, Michael A., Ph.D. . . . . . . . . . . . . .University of Nebraska Medical Center

Holmgren, Robert A., Ph.D. . . . . . . . . . . . . . . . . .Northwestern University

Holt, Jeffrey, M.D. . . . . . . . . . . . . . . . . . . . . . . .Tissue Genetics, LLC

Hood, Elizabeth, Ph.D. . . . . . . . . . . . . . . . . . . . .Arkansas State University

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

128

Hoon, Dave S.B., Ph.D. . . . . . . . . . . . . . . . . . . .John Wayne Cancer Institute

Hoopes, P Jack, D.V.M., Ph.D. . . . . . . . . . . . . . .Dartmouth Medical School

Hopf, Harriet W., M.D. . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Hord, Norman G., Ph.D. . . . . . . . . . . . . . . . . . . .Michigan State University

Hortobagyi, Gabriel N., M.D. . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Horton, John, M.D. . . . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Hosking, James D., Ph.D. . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Hoskins, William J., M.D. . . . . . . . . . . . . . . . . . .Memorial Health University Medical Center

Houghton, Alan N., M.D. . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Houldin, Arlene D., Ph.D., R.N. . . . . . . . . . . . . . .University of Pennsylvania

Houlette, Judy Kasey, M.A. . . . . . . . . . . . . . . . . .Friend for Life Cancer Support Network

Howe, Louise R., Ph.D. . . . . . . . . . . . . . . . . . . . .Weill Medical College of Cornell University

Howell, Gillian M., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute

Hrushesky, William J., M.D. . . . . . . . . . . . . . . . . .Dorn Research Institute

Hsu, Edward W., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Utah

Hu, Longqin, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Hu, Yinling, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Huang, Chuanshu, M.D., Ph.D. . . . . . . . . . . . . . .New York University School of Medicine

Huang, Peng, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Huang, Ruo-Pan, M.D., Ph.D. . . . . . . . . . . . . . . .RayBiotech, Inc.

Huang, Tim H., Ph.D. . . . . . . . . . . . . . . . . . . . . .Ohio State University

Hubbell, F. Allan, M.D. . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Humphrey, Peter A., M.D., Ph.D. . . . . . . . . . . . . .Washington University

Humphrey, Rachel, M.D. . . . . . . . . . . . . . . . . . . .Bristol Myers Squibb

Hunt, Jay D., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

Hurley, Karen E., Ph.D. . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Hurst, Robert E., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Hutchins, Gary D., Ph.D. . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Huth, James F., M.D. . . . . . . . . . . . . . . . . . . . . .University of Texas Southwestern Medical Center

Hyslop, Terry M., Ph.D. . . . . . . . . . . . . . . . . . . .Thomas Jefferson University

I Iden, Charles R., Ph.D. . . . . . . . . . . . . . . . . . . . .State University of New York, Stony Brook

Iglehart, James D., M.D. . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Im, Eun-Ok, Ph.D., R.N. . . . . . . . . . . . . . . . . . . .University of Texas, Austin

Inadomi, John M., M.D. . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Ip, Edward H., Ph.D. . . . . . . . . . . . . . . . . . . . . .Wake Forest University

Israel, Barbara A., Ph.D. . . . . . . . . . . . . . . . . . . .Platypus Technologies, LLC

Issa, Jean-Pierre J., M.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Ittmann, Michael M., M.D., Ph.D. . . . . . . . . . . . .New York University

Izumi, Tadahide, Ph.D. . . . . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

J Jackson, Sharon A., Ph.D. . . . . . . . . . . . . . . . . . .Wake Forest University Health Sciences

Jacobberger, James W., Ph.D. . . . . . . . . . . . . . . .Case Western Reserve University

Jacobs, Michael A., Ph.D. . . . . . . . . . . . . . . . . . .Johns Hopkins University

Jacobs, Russell E., Ph.D. . . . . . . . . . . . . . . . . . . .California Institute of Technology

Jacobson, Elaine L., Ph.D. . . . . . . . . . . . . . . . . . .University of Arizona

Jacobson, Stephen C., Ph.D. . . . . . . . . . . . . . . . .Indiana University, Bloomington

Jain, Rakesh K., Ph.D. . . . . . . . . . . . . . . . . . . . . .American Association for Cancer Research

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

129

James, Charles D., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Janjan, Nora A., M.D. . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Jatoi, Aminah, M.D. . . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Jeffery, Elizabeth H., Ph.D. . . . . . . . . . . . . . . . . .University of Illinois, Urbana-Champaign

Jenkins, Robert B., M.D., Ph.D. . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Jensen, Roy A., M.D. . . . . . . . . . . . . . . . . . . . . .University of Kansas Medical Center

Jeraj, Robert, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Jewell, William R., M.D. . . . . . . . . . . . . . . . . . . .University of Kansas Medical Center

Jiang, Stephen P., B.A. . . . . . . . . . . . . . . . . . . . .American Cancer Society

Johnson, Bruce E., M.D. . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Johnson, Linda B., B.S. . . . . . . . . . . . . . . . . . . . .National Coalition for Cancer Survivorship

Johnson, Valen E., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, Houston

Jones, Dean P., Ph.D. . . . . . . . . . . . . . . . . . . . . .Emory University-Winship Cancer Center

Jones, Jeffrey P., Ph.D. . . . . . . . . . . . . . . . . . . . .Washington State University

Jones, Richard J., M.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Jouridine, Linda A., Ph.D. . . . . . . . . . . . . . . . . . .University of Kentucky

Ju, Jingfang, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of South Alabama

Juliano, Rudolph L., Ph.D. . . . . . . . . . . . . . . . . . .Keystone Symposia

June, Carl H., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

K Kafadar, Karen, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Kalinski, Pawel, M.D., Ph.D. . . . . . . . . . . . . . . . .University of Pittsburgh

Kaluzny, Arnold D., Ph.D. . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Kanade, Takeo, Ph.D. . . . . . . . . . . . . . . . . . . . . .Carnegie-Mellon University

Kang, Kyung A., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Louisville

Kangarlu, Alayar, Ph.D. . . . . . . . . . . . . . . . . . . . .New York State Psychiatric Institute

Kantoff, Philip W., M.D. . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Kaplan, Alan M., Ph.D. . . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Kapoor, Mini, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Karagas, Margaret R., Ph.D. . . . . . . . . . . . . . . . .Dartmouth College

Karam, Lisa, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .National Institute of Standards and Technology

Karellas, Andrew, Ph.D. . . . . . . . . . . . . . . . . . . . .Emory University

Karrison, Theodore, M.D., Ph.D. . . . . . . . . . . . . .University of Chicago

Kashani-Sabet, Mohammed, M.D. . . . . . . . . . . . . .University of California, San Francisco

Kasid, Usha N., Ph.D. . . . . . . . . . . . . . . . . . . . . .Georgetown University

Kaste, Sue C., D.O. . . . . . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Katti, Kattesh V., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Missouri, Columbia

Kaufman, Howard L., M.D. . . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Kaul, Karen L., M.D., Ph.D. . . . . . . . . . . . . . . . .Evanston Northwestern Healthcare

Keating, Christine D., Ph.D. . . . . . . . . . . . . . . . .Pennsylvania State University, University Park

Keefe, Francis J., Ph.D. . . . . . . . . . . . . . . . . . . . .Duke University Medical Center

Keegan, Achsah D., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Kehrer, James P., Ph.D. . . . . . . . . . . . . . . . . . . . .Washington State University

Kelder, Steven H., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center

Kelliher, Michelle A., Ph.D. . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Kelly, Thomas F., Ph.D. . . . . . . . . . . . . . . . . . . . .Imago Scientific Instruments Corporation

Kern, Scott E., M.D. . . . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Khan, Mohamed K., M.D., Ph.D. . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

130

Khan, Seema A., M.D. . . . . . . . . . . . . . . . . . . . .Northwestern University

Khatri, Vijay P., M.D., M.D. . . . . . . . . . . . . . . . . .University of California, Davis

Khokha, Rama, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Toronto

Khuri, Fadlo R., M.D. . . . . . . . . . . . . . . . . . . . . .Emory University

Killackey, Maureen A., M.D., Ph.D. . . . . . . . . . . .Bassett Cancer Center

Killen, Joel D., M.D., Ph.D. . . . . . . . . . . . . . . . . .Stanford University

Kim, Edmund E., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Kim, Helen, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Kim, Raymond, Ph.D. . . . . . . . . . . . . . . . . . . . . .Geneprism, Inc.

Kimler, Bruce F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Kansas Medical Center

Kinsel, Gary R., Ph.D. . . . . . . . . . . . . . . . . . . . . .Southern Illinois University, Carbondale

Kinter, Michael T., Ph.D. . . . . . . . . . . . . . . . . . . .Cleveland Clinic Foundation

Kipps, Thomas J., M.D., Ph.D. . . . . . . . . . . . . . . .University of California, San Diego

Kirk, Bernadette L., Ph.D. . . . . . . . . . . . . . . . . . .UT-Battelle, LLC-Oak Ridge National Laboratory

Kirschner, Marvin A., M.D. . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Kiselev, Maxim Y., Ph.D. . . . . . . . . . . . . . . . . . . .Tomotrace, Inc.

Kittur, Dilip S., M.D., Ph.D. . . . . . . . . . . . . . . . . .State University of New York, Downstate Medical Center

Kiviat, Nancy B., M.D. . . . . . . . . . . . . . . . . . . . .University of Washington

Klassen, Ann C., Ph.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Klein, Eric, M.D. . . . . . . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Klingemann, Hans G., M.D., Ph.D. . . . . . . . . . . . .New England Medical Center Hospitals

Klonoff, Elizabeth A., Ph.D. . . . . . . . . . . . . . . . . .San Diego State University

Knight, Linda C., Ph.D. . . . . . . . . . . . . . . . . . . . .Temple University

Knowles, Daniel M., M.D. . . . . . . . . . . . . . . . . . .New York Hospital-Cornell University Medical Center

Knutson, Keith L., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Kochevar, Gerald J., M.D. . . . . . . . . . . . . . . . . . .Texas A&M University Health Science Center

Kong, Tony Ah-Ng, Ph.D. . . . . . . . . . . . . . . . . . .Rutgers University College of Pharmacy

Konigsberg, William H., Ph.D. . . . . . . . . . . . . . . .Yale University

Kontos, Christopher D., M.D. . . . . . . . . . . . . . . .Duke University

Koos, Robert D., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Kopelman, Raoul, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Korneluk, Robert G., Ph.D. . . . . . . . . . . . . . . . . .Children’s Research Institute

Korzekwa, Kenneth R., Ph.D. . . . . . . . . . . . . . . . .Merck Research Laboratories

Kosinski, Andrzej S., Ph.D. . . . . . . . . . . . . . . . . .Duke University

Koumenis, Constantinos, Ph.D. . . . . . . . . . . . . . .Wake Forest University Health Sciences Center

Krebs, Joseph F., Ph.D. . . . . . . . . . . . . . . . . . . . .Ambion, Inc.

Kreiger, Robert I., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, Riverside

Kremsky, Jonathan N., Ph.D. . . . . . . . . . . . . . . . .Prime Organics, Inc.

Kricka, Larry J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Krischer, Jeffrey P., Ph.D. . . . . . . . . . . . . . . . . . .University of South Florida

Krishnamurthy, Savitri, M.D. . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Kristal, Bruce S., Ph.D. . . . . . . . . . . . . . . . . . . . .Winifred Masterson Burke Medical Research Institute

Krohn, Kenneth A., Ph.D. . . . . . . . . . . . . . . . . . .University of Washington

Kron, Stephen J., M.D., Ph.D. . . . . . . . . . . . . . . .University of Chicago

Kufta, Conrad V., M.D. . . . . . . . . . . . . . . . . . . . .Consultant

Kulldorff, Martin, Ph.D. . . . . . . . . . . . . . . . . . . . .Harvard University Medical School

Kuller, Lewis H., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Pittsburgh

Kumar, Nagi B., Ph.D. . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

131

Kunicki, Thomas J., Ph.D. . . . . . . . . . . . . . . . . . .Scripps Research Institute

Kuntz, Karen M., Ph.D. . . . . . . . . . . . . . . . . . . . .Harvard University School of Public Health

Kurzrock, Razelle, M.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Kuzel, Timothy M., M.D. . . . . . . . . . . . . . . . . . . .Northwestern University

L Ladisch, Stephan, M.D. . . . . . . . . . . . . . . . . . . . .Children’s Research Institute

Lai, Shenghan, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Miami School of Medicine

Lal, Ratneshwar, Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Santa Barbara

Lambert, Paul F., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Lance, M. Peter, M.D. . . . . . . . . . . . . . . . . . . . . .University of Arizona

Land, Stephanie R., Ph.D. . . . . . . . . . . . . . . . . . .University of Pittsburgh

Landers, James P., Ph.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Landsittel, Douglas P., Ph.D. . . . . . . . . . . . . . . . .Duquesne University

Lange, Beverly J., M.D. . . . . . . . . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Langer, Mark, M.D. . . . . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Lantz, Paula M., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Largaespada, David A., Ph.D. . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Larson, Ronald G., Ph.D. . . . . . . . . . . . . . . . . . . .University of Michigan

Larson, Steven M., M.D., Ph.D. . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Lasalle, Janine M., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

Lau, Derick H., M.D., Ph.D. . . . . . . . . . . . . . . . .University of California, Davis

Law, Meng, M.D. . . . . . . . . . . . . . . . . . . . . . . . .New York University School of Medicine

Leary, James F., Ph.D. . . . . . . . . . . . . . . . . . . . . .Purdue University

Lechago, Juan, M.D., Ph.D. . . . . . . . . . . . . . . . .Baylor College of Medicine

Lechner, Suzanne C., Ph.D. . . . . . . . . . . . . . . . . .University of Miami

Lee, Chung, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Northwestern University

Lee, Jack, D.D.S., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Lee, Jeffrey R., M.D. . . . . . . . . . . . . . . . . . . . . . .Medical College of Georgia

Lee, Robert J., Ph.D. . . . . . . . . . . . . . . . . . . . . .Ohio State University

Lee, Stephen C., Ph.D. . . . . . . . . . . . . . . . . . . . .Ohio State University

Lee, Ving J., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .ADESIS, Inc.

Lehmann, Harold P., M.D., Ph.D. . . . . . . . . . . . . .Johns Hopkins University

Leite, John F., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Invitrogen Corporation

Lemon, Stephenie C., Ph.D. . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Lenz, Heinz Josef, M.D. . . . . . . . . . . . . . . . . . . .University of Southern California

Leo, Gerald . . . . . . . . . . . . . . . . . . . . . . . . . . . .Kimmel Cancer Center

Leonowich, John A., Ph.D. . . . . . . . . . . . . . . . . .Department of Energy

Lerner, Seth, M.D. . . . . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Lesser, Martin L., Ph.D. . . . . . . . . . . . . . . . . . . .New York University

Levenson, Richard M., M.D. . . . . . . . . . . . . . . . .Cambridge Research and Instrumentation

Levin, Bernard, M.D. . . . . . . . . . . . . . . . . . . . . .University of Texas, M.D. Anderson Cancer Center

Levin, David L., M.D., Ph.D. . . . . . . . . . . . . . . . .University of California, San Diego

Levin, Theodore R., M.D. . . . . . . . . . . . . . . . . . .Kaiser Foundation Research Institute

Levinson, Arnold H., Ph.D. . . . . . . . . . . . . . . . . .University of Colorado, Denver

Levy, Barcey Thurston, M.D., Ph.D. . . . . . . . . . . .University of Iowa

Lewis, Norman G., Ph.D. . . . . . . . . . . . . . . . . . . .Washington State University

Li, Jian, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Planning Systems, Inc.

Li, Jun, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . . .U.S. Ames Research Center

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

132

Li, King C., M.D. . . . . . . . . . . . . . . . . . . . . . . . .Stanford University

Li, Sara, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .The University of Kansas Medical Center

Li, Yanchun, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Chicago

Liang, Zhi-Pei, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Illinois, Urbana-Champaign

Liau, Linda M., M.D., Ph.D. . . . . . . . . . . . . . . . .University of California, Los Angeles

Liber, Howard L., Ph.D. . . . . . . . . . . . . . . . . . . . .Colorado State University, Fort Collins

Lieberman, David A., M.D. . . . . . . . . . . . . . . . . .Oregon Health and Science University

Lieberman, Howard B., Ph.D. . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Lieh-Lai, Mary W., M.D. . . . . . . . . . . . . . . . . . . .Wayne State University

Liff, Jonathan M., Ph.D. . . . . . . . . . . . . . . . . . . .Emory University

Lightdale, Charles J., M.D. . . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Lim, Megan S., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Utah

Limbach, Patrick A., Ph.D. . . . . . . . . . . . . . . . . . .University of Cincinnati

Lin, Haiqun, M.D., Ph.D. . . . . . . . . . . . . . . . . . .Yale University

Line, Bruce R., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Maryland System

Link, Brian K., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Iowa

Liu, P.Y., Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Liu, Rui H., M.D., Ph.D. . . . . . . . . . . . . . . . . . . .Cornell University, Ithaca

Lizardi, Paul M., Ph.D. . . . . . . . . . . . . . . . . . . . .Yale University School of Medicine

Lobert, Sharon A., Ph.D., R.N. . . . . . . . . . . . . . . .University of Mississippi Medical Center

Loechler, Edward L., Ph.D. . . . . . . . . . . . . . . . . . .Boston University Charles River Campus

Loeppky, Richard N., Ph.D. . . . . . . . . . . . . . . . . .University of Missouri, Columbia

Lokeshwar, Vinata B., Ph.D. . . . . . . . . . . . . . . . .University of Miami

Lomax, Randy, M.A. . . . . . . . . . . . . . . . . . . . . . .Melanoma Research Foundation

Lopez-Berestein, Gabriel G., M.D. . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Lorensen, William E., M.S. . . . . . . . . . . . . . . . . . .General Electric

Lorusso, Patricia M., M.D. . . . . . . . . . . . . . . . . .Wayne State University

Lothstein, Leonard,, Ph.D. . . . . . . . . . . . . . . . . . .University of Tennessee Health Science Center

Lotze, Michael T., M.D., Ph.D. . . . . . . . . . . . . . . .University of Pittsburgh Medical Center

Louie, Stan Gee, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Southern California

Lovett, Michael, Ph.D. . . . . . . . . . . . . . . . . . . . .Washington University

Lowe, John B., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Iowa

Lu, H. Peter, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratories

Luborsky, Judith L., Ph.D. . . . . . . . . . . . . . . . . . .TSI Mason Laboratories

Lucito, Robert D., Ph.D. . . . . . . . . . . . . . . . . . . .Cold Spring Harbor Laboratory

Lukasik, Victoria M., D.V.M. . . . . . . . . . . . . . . . .University of Arizona

Lunney, June R., Ph.D., R.N. . . . . . . . . . . . . . . . .West Virginia University

Lyerly, Herbert Kim, M.D. . . . . . . . . . . . . . . . . . .Duke University

Lynch, Charles F., M.D., Ph.D. . . . . . . . . . . . . . . .University of Iowa

Lyons-Weiler, James F., Ph.D. . . . . . . . . . . . . . . . .University of Pittsburgh

M Ma, Grace X., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Temple University

MacDonald, Ruth S., Ph.D. . . . . . . . . . . . . . . . . .Iowa State University

MacIntyre, Elizabeth, M.D. . . . . . . . . . . . . . . . . .Hospital Necker

Mackey, Michael A., Ph.D. . . . . . . . . . . . . . . . . .University of Iowa

Macleod, Carol L., Ph.D. . . . . . . . . . . . . . . . . . . .National Cancer Institute

Maddox, Anne-Marie Marie, M.D. . . . . . . . . . . . .University of Arkansas for Medical Science

Magoffin, Denis A., Ph.D. . . . . . . . . . . . . . . . . . .Cedars-Sinai Medical Center

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

133

Maitra, Anirban, M.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Makoul, Gregory T., Ph.D. . . . . . . . . . . . . . . . . . .Northwestern University

Makrigiorgos, G.M., Ph.D. . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Malkas, Linda H., Ph.D. . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Malkhosyan, Sergei R., Ph.D. . . . . . . . . . . . . . . . .Burnham Institute

Mallapragada, Surya K., Ph.D. . . . . . . . . . . . . . . .Iowa State University

Manchester, Marianne, Ph.D. . . . . . . . . . . . . . . . .Scripps Research Institute

Mandelson, Margaret T., Ph.D. . . . . . . . . . . . . . .Center for Health Studies

Manfredi, James J., Ph.D. . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Mankoff, David A., M.D., Ph.D. . . . . . . . . . . . . .University of Washington

Manne, Sharon L., Ph.D. . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Manni, Andrea, M.D. . . . . . . . . . . . . . . . . . . . . .Pennsylvania State University Hershey Medical Center

Marcus, Stevan, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Mariadason, John M., Ph.D. . . . . . . . . . . . . . . . .Montefiore Medical Center, Bronx, NY

Markman, Maurie, M.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Marrogi, Aizen J., M.D. . . . . . . . . . . . . . . . . . . .GRL, Inc.

Marshall, James R., Ph.D. . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Martin, Melissa Carol, M.S. . . . . . . . . . . . . . . . . .Therapy Physics, Inc.

Marziali, Andre, Ph.D. . . . . . . . . . . . . . . . . . . . .University of British Columbia

Mathis, J. Michael, Ph.D. . . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, Shreveport

Mathur, Subbi P., Ph.D. . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Mattern, Michael R., Ph.D. . . . . . . . . . . . . . . . . .Progenra, Inc.

Matthay, Katherine K., M.D. . . . . . . . . . . . . . . . .University of California, San Francisco

Matthews, Alicia K., Ph.D., R.N. . . . . . . . . . . . . .University of Illinois, Chicago

Matthews, Charles E., Ph.D. . . . . . . . . . . . . . . . .Vanderbilt University

May, Judith . . . . . . . . . . . . . . . . . . . . . . . . . . . .Y-ME National Breast Cancer Organization

McCaffrey, David J., Ph.D. . . . . . . . . . . . . . . . . .University of Mississippi

McCarty, Kenneth S., M.D., Ph.D. . . . . . . . . . . . .University of Pittsburgh Health System

McCaul, Kevin D., Ph.D. . . . . . . . . . . . . . . . . . . .North Dakota State University

McChesney, James D., Ph.D. . . . . . . . . . . . . . . . .Tapestry Pharmaceuticals, Inc.

McClain, Larry D., Ph.D. . . . . . . . . . . . . . . . . . .Diagnostic Biomarkers, Inc.

McClatchey, Will, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Hawaii, Manoa

McConkey, David J., Ph.D. . . . . . . . . . . . . . . . . .University of Texas Health Science Center, Houston

McCormick, David L., Ph.D. . . . . . . . . . . . . . . . .IIT Research Institute

McCoy, G. David, Ph.D. . . . . . . . . . . . . . . . . . . .Case Western Reserve University

McDonald, Paige A., Ph.D. . . . . . . . . . . . . . . . . .Howard University

McGregor, William G., M.D. . . . . . . . . . . . . . . . .University of Louisville

McGuire, John J., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

McIntosh, Martin W., Ph.D. . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

McIntyre, James O., Ph.D. . . . . . . . . . . . . . . . . .Vanderbilt University

McKay, Paul P. . . . . . . . . . . . . . . . . . . . . . . . . . .Consultant

McLennan, Ian J., Ph.D. . . . . . . . . . . . . . . . . . . .Ecosynthetix, Inc.

McMasters, Kelly M., M.D., Ph.D. . . . . . . . . . . . .Loan Repayment Applications

McNeel, Douglas G., M.D., Ph.D. . . . . . . . . . . . .University of Wisconsin, Madison

McNeil, Ann E., R.N. . . . . . . . . . . . . . . . . . . . . .University of Miami

McNiece, Ian K., Ph.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

McNorney, Colleen A., Ph.D. . . . . . . . . . . . . . . . .Merck & Co., Inc.

McWeeney, Shannon K., Ph.D. . . . . . . . . . . . . . . .Oregon Health and Science University

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

134

Mead, Keith T., Ph.D. . . . . . . . . . . . . . . . . . . . . .Mississippi State University

Meade, Cathy D., Ph.D., R.N. . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Mehta, Rajendra G., Ph.D. . . . . . . . . . . . . . . . . .Illinois Institute of Technology

Meier, Diane E., M.D. . . . . . . . . . . . . . . . . . . . . .Mount Sinai School of Medicine of New York University

Melancon, Donald James, Ph.D. . . . . . . . . . . . . . .Lemoyne-Owen College

Melese, Teri, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Melnikow, Joy A., M.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

Mendonca, Paulo Ricardo, Ph.D. . . . . . . . . . . . . .General Electric Global Research

Mercola, Dan, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of California, Irvine

Metaxas, Dimitris N., Ph.D. . . . . . . . . . . . . . . . . .University of Pennsylvania

Mettlin, Curtis J., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Metzker, Michael L., Ph.D. . . . . . . . . . . . . . . . . .Merck Research Laboratories

Meyn, Raymond E., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Mezrich, Reuben S., M.D., Ph.D. . . . . . . . . . . . . .University of Maryland Baltimore School of Medicine

Michalek, Arthur M., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Mifflin, Theodore E., Ph.D. . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Miglioretti, Diana L., Ph.D. . . . . . . . . . . . . . . . . .Center for Health Studies

Mikkelsen, Ross B., Ph.D. . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Miller, John H., Ph.D. . . . . . . . . . . . . . . . . . . . . .Washington State University

Mills, Sherry L., M.P.H. . . . . . . . . . . . . . . . . . . . .ABT Associates, Inc.

Milner, Thomas E., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas, Austin

Minko, Tamara, Ph.D. . . . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Minna, John D., M.D. . . . . . . . . . . . . . . . . . . . . .American Association for Cancer Research

Mirvish, Sidney S., Ph.D. . . . . . . . . . . . . . . . . . . .University of Nebraska Medical Centers

Mirzadeh, Saed, Ph.D. . . . . . . . . . . . . . . . . . . . .Oak Ridge National Laboratory

Mitchell, Edith P., M.D., Ph.D. . . . . . . . . . . . . . . .Thomas Jefferson University

Mitra, Sankar, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Texas Medical Branch

Moen, Phillip T., Ph.D. . . . . . . . . . . . . . . . . . . . .One Cell Systems, Inc.

Mohapatra, Shyam S., M.D., Ph.D. . . . . . . . . . . .University of South Florida

Moinpour, Carol M., Ph.D. . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Molloy, Janelle A., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Monahan, Patrick, Ph.D. . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Mooney, Kathleen H., Ph.D., R.N. . . . . . . . . . . . .Oncology Nursing Society

Moon-Howard, Joyce J., Ph.D. . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Moore, Anna, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Moorman, Patricia G., Ph.D. . . . . . . . . . . . . . . . .Duke University

Moran, Richard G., Ph.D. . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Moraru, Ion I., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Connecticut School of Medicine and Dentistry

Morgan, Jennifer F., MOTH . . . . . . . . . . . . . . . . .Medical University of South Carolina

Morgan, William F., Ph.D. . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Morisky, Donald E., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Morris, Michael D., Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan

Morrow, Gary R., Ph.D. . . . . . . . . . . . . . . . . . . .University of Rochester

Morse, Michael A., M.D. . . . . . . . . . . . . . . . . . . .Duke University

Morton, Ronald A., M.D. . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of NJ-R.W. Johnson Medical School

Morton, William R., D.V.M., Ph.D. . . . . . . . . . . .University of Washington

Moscicki, Anna-Barbara, M.D. . . . . . . . . . . . . . . .University of California, San Francisco

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

135

Moses, William W., Ph.D. . . . . . . . . . . . . . . . . . .Berkley National Laboratory for Life Science

Moskaluk, Christopher A., M.D., Ph.D. . . . . . . . .University of Virginia, Charlottesville

Mourant, Judith R., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Los Alamos National Laboratory

Moyer, James D., Ph.D. . . . . . . . . . . . . . . . . . . .Pfizer, Inc.

Moysich, Kirsten B., Ph.D. . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Muddiman, David C., Ph.D. . . . . . . . . . . . . . . . . .North Carolina State University, Raleigh

Mueller, Beth A., Ph.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Mullin, James M., Ph.D. . . . . . . . . . . . . . . . . . . .Lankenau Institute for Medical Research

Mulvihill, John J., M.D., . . . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Munshi, Nikhil C., M.D. . . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Murphy, William Joseph, Ph.D. . . . . . . . . . . . . . . .University of Nevada, Reno

Murray, David, Ph.D. . . . . . . . . . . . . . . . . . . . . .Alberta Cancer Board

Myers, James R., Ph.D. . . . . . . . . . . . . . . . . . . . .Oregon State University

Mysliwiec, Pauline A., M.D. . . . . . . . . . . . . . . . .University of California, Davis

N Nadkarni, Prakash M., M.D. . . . . . . . . . . . . . . . .Yale University

Nagase, Hiroki, M.D., Ph.D. . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Nair, Madhavan P., Ph.D. . . . . . . . . . . . . . . . . . .State University of New York, Buffalo

Nease, Donald E., M.D. . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Nedelkov, Dobrin, Ph.D. . . . . . . . . . . . . . . . . . . .Intrinsic Bioprobes, Inc.

Nelson, David L., Ph.D. . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Nelson, Randall W., Ph.D. . . . . . . . . . . . . . . . . . .Intrinsic Bioprobes, Inc.

Nelson, Sarah J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Nelson, William G., M.D., Ph.D. . . . . . . . . . . . . .American Urological Association

Nephew, Kenneth P., Ph.D. . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Nering, Michael L., Ph.D. . . . . . . . . . . . . . . . . . .Measured Progress

Neuberg, Donna S., Ph.D. . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Newcomb, Elizabeth W., Ph.D. . . . . . . . . . . . . . . .New York University Medical Center

Nicholson, Henry Stacy, M.D. . . . . . . . . . . . . . . .Oregon Health and Science University

Nickles, Robert J., Ph.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Nicosia, Santo V., M.D. . . . . . . . . . . . . . . . . . . . .University of South Florida

Nielsen, Ulrik B., Ph.D. . . . . . . . . . . . . . . . . . . . .Merrimack Pharmaceuticals, Inc.

Nimer, Stephen D., M.D. . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Nitiss, John L., Ph.D. . . . . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Nixon, Patricia A., Ph.D. . . . . . . . . . . . . . . . . . . .Wake Forest University

Noe, Dennis A., M.D. . . . . . . . . . . . . . . . . . . . . .Pfizer Inc.

Noelle, Randolph J., Ph.D. . . . . . . . . . . . . . . . . . .Dartmouth College

Noonan, Frances P., Ph.D. . . . . . . . . . . . . . . . . . .George Washington University

Noring, Lois E., R.N. . . . . . . . . . . . . . . . . . . . . . .American Cancer Society

Norman, Sandra A., Ph.D. . . . . . . . . . . . . . . . . . .University of Pennsylvania

Normolle, Daniel P., Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan

Norris, James S., Ph.D. . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Norton, Larry, M.D. . . . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Nowell, Susan A., Ph.D. . . . . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Noy, Noa, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .Cornell University, Ithaca

Nucifora, Giuseppina, Ph.D. . . . . . . . . . . . . . . . . .University of Chicago

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

136

O O’Connell, Mary A., Ph.D. . . . . . . . . . . . . . . . . .New Mexico State University

O’Connell, Peter, Ph.D. . . . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

O’Malley, Michael S., Ph.D. . . . . . . . . . . . . . . . . .University of North Carolina, Lineberger Cancer Center

O’Neal, D. Patrick, Ph.D. . . . . . . . . . . . . . . . . . .Nanospectra Biosciences, Inc.

O’Reilly, Richard J., M.D. . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

O’Riordan, David L., Ph.D. . . . . . . . . . . . . . . . . .University of Hawaii, Manoa

Ojeifo, John O., M.D., Ph.D. . . . . . . . . . . . . . . . .Georgetown University

Ojima, Iwao, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .State University of New York, Stony Brook

Okuyemi, Kolawole S., M.D. . . . . . . . . . . . . . . . .University of Kansas Medical Center

Oliver, Janet M., Ph.D. . . . . . . . . . . . . . . . . . . . .University of New Mexico

Olivi, Alessandro, M.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Olopade, Olufunmilayo I., M.D. . . . . . . . . . . . . . .University of Chicago Medical Center

Omel, James Lloyd, M.D. . . . . . . . . . . . . . . . . . .Consultant

Omenn, Gilbert S., M.D., Ph.D. . . . . . . . . . . . . . .University of Michigan

Ong, Tiong S., M.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Orlando, Maria, Ph.D. . . . . . . . . . . . . . . . . . . . .Rand Corporation

Ostrer, Harry, M.D., Ph.D. . . . . . . . . . . . . . . . . .New York University School of Medicine

P Pace, Lorraine, M.S. . . . . . . . . . . . . . . . . . . . . . .Breast Cancer Help, Inc.

Page, David L., M.D. . . . . . . . . . . . . . . . . . . . . .Vanderbilt University

Pallavicini, Maria G., Ph.D. . . . . . . . . . . . . . . . . .University of California, San Francisco

Pandey, Akhilesh, M.D., Ph.D. . . . . . . . . . . . . . . .Johns Hopkins University

Papanikolaou, Nikos, Ph.D. . . . . . . . . . . . . . . . . .University of Arkansas Medical Sciences Center, Little Rock

Pardo, Francisco S., M.D., Ph.D. . . . . . . . . . . . . .University of California, San Diego

Park, Kinam, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Purdue University

Parker, Patricia A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Parker, William B., M.D., Ph.D. . . . . . . . . . . . . . .PNP Therapeutics, Inc.

Pasa-Tolic, Ljiljana, Ph.D. . . . . . . . . . . . . . . . . . . .Pacific Northwest National Laboratory

Paskett, Electra D., Ph.D. . . . . . . . . . . . . . . . . . .Ohio State University

Pasqualini, Renata R., Ph.D. . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Pate, Russell R., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of South Carolina at Columbia

Patriotis, Christos F., Ph.D. . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Patterson, Gregory M., Ph.D. . . . . . . . . . . . . . . .Southwest Foundation for Biomedical Research

Patz, Edward F., M.D. . . . . . . . . . . . . . . . . . . . . .Duke University

Paulson, K. Eric, Ph.D. . . . . . . . . . . . . . . . . . . . .New England Medical Center Hospitals

Pearman, Timothy, Ph.D. . . . . . . . . . . . . . . . . . . .Tulane University of Louisiana

Peehl, Donna M., Ph.D. . . . . . . . . . . . . . . . . . . .Stanford University

Pellicer, Angel G., M.D., Ph.D. . . . . . . . . . . . . . . .New York University School of Medicine

Pelling, Jill C., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Northwestern University

Pence, Barbara C., Ph.D. . . . . . . . . . . . . . . . . . . .Texas Tech University Health Sciences Center

Pence, William H., Ph.D. . . . . . . . . . . . . . . . . . . .Orca Photonic Systems, Inc.

Peng, Junmin, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Emory University

Penichet, Manuel L., M.D., Ph.D. . . . . . . . . . . . . .University of California, Los Angeles

Pennell, Christopher A., Ph.D. . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Perez, Carlos A., M.D. . . . . . . . . . . . . . . . . . . . .Washington University

Perez-Soler, Roman, M.D. . . . . . . . . . . . . . . . . . .Yeshiva University

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

137

Pergolizzi, Robert G., Ph.D. . . . . . . . . . . . . . . . . .Weill Medical College of Cornell University

Perkins, Edward L., Ph.D. . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Persons, Derek A., M.D., Ph.D. . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Peterson, Karen E., Ph.D. . . . . . . . . . . . . . . . . . .Harvard University, School of Public Health

Peterson, Leif E., Ph.D. . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Petroni, Gina R., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Virginia Health System

Piazza, Gary A., Ph.D. . . . . . . . . . . . . . . . . . . . .Southern Research Institute

Piccirillo, Jay F., M.D. . . . . . . . . . . . . . . . . . . . . .Washington University

Pieper, Rembert, Ph.D. . . . . . . . . . . . . . . . . . . . .The Institute for Genomic Research

Pierce, J. Michael, Ph.D. . . . . . . . . . . . . . . . . . . .University of Georgia

Pili, Roberto, M.D. . . . . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Pinto, Harlan A., M.D., Ph.D. . . . . . . . . . . . . . . .Stanford University Medical Center

Pishko, Michael V., Ph.D. . . . . . . . . . . . . . . . . . .Pennsylvania State University, University Park

Plate, Janet M., Ph.D. . . . . . . . . . . . . . . . . . . . .Rush University Medical Center

Platsoucas, Chris D., Ph.D. . . . . . . . . . . . . . . . . .Temple University

Pleasure, David E., M.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

Pledger, W.J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Plevritis, Sylvia K., Ph.D. . . . . . . . . . . . . . . . . . . .Stanford University

Pogue, Brian William, Ph.D. . . . . . . . . . . . . . . . . .Dartmouth College

Pohl, Nicola L., Ph.D. . . . . . . . . . . . . . . . . . . . . .Fluorous Technologies, Inc.

Pollack, Jonathan R., M.D., Ph.D. . . . . . . . . . . . .Stanford University

Pollock, Brad H., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, San Antonio

Pollock, John C., Ph.D. . . . . . . . . . . . . . . . . . . . .College of New Jersey

Pomper, Martin G., M.D., Ph.D. . . . . . . . . . . . . .Johns Hopkins University

Poole, Leslie B., Ph.D. . . . . . . . . . . . . . . . . . . . . .Wake Forest University Health Sciences Center

Popple, Richard A., Ph.D. . . . . . . . . . . . . . . . . . .University of Alabama

Porter, David L., M.D. . . . . . . . . . . . . . . . . . . . . .University of Pennsylvania

Porter, Laura S., Ph.D. . . . . . . . . . . . . . . . . . . . .Duke University

Posner, Marshall R., M.D. . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Powell, Charles A., M.D. . . . . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Powell, Marianne Broome, Ph.D. . . . . . . . . . . . . .Stanford University

Price, Ronald R., Ph.D. . . . . . . . . . . . . . . . . . . . .Vanderbilt University

Prigerson, Holly G., Ph.D. . . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Pumiglia, Kevin M., Ph.D. . . . . . . . . . . . . . . . . . .Albany Medical College of Union University

Q Qualman, Stephen J., M.D. . . . . . . . . . . . . . . . . .Children’s Research Institute

Quan, Zoe S., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Qingchu Thinking, LLC

Quesenberry, Peter J., M.D. . . . . . . . . . . . . . . . . .Roger Williams Hospital

R Rabkin, Samuel D., Ph.D. . . . . . . . . . . . . . . . . . .Massachusetts General Hospital

Radich, Jerry P., M.D. . . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Rahman, Irfan, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Rochester

Rai, Shesh N., Ph.D. . . . . . . . . . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Rajski, Scott R., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Rakowski, William, Ph.D. . . . . . . . . . . . . . . . . . . .Miriam Hospital

Raleigh, James A., Ph.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

138

Rao, Anita . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Consultant

Raubitschek, Andrew A., M.D. . . . . . . . . . . . . . . .City of Hope, Beckman Research Institute

Raychaudhuri, Pradip, Ph.D. . . . . . . . . . . . . . . . .University of Illinois, Chicago

Read, G. Sullivan, Ph.D. . . . . . . . . . . . . . . . . . . .University of Missouri

Reader, Steven, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of South Florida

Redenbaugh, Keith, Ph.D. . . . . . . . . . . . . . . . . . .Seminis Vegetable Seed, Inc.

Redmond, Carol K., Ph.D. . . . . . . . . . . . . . . . . . .University of Pittsburgh

Redondo, Jose P., Ph.D. . . . . . . . . . . . . . . . . . . . .Inflexxion, Inc.

Reed, Eddie, M.D. . . . . . . . . . . . . . . . . . . . . . . .West Virginia University

Reed, Michael W., Ph.D. . . . . . . . . . . . . . . . . . . .Bioconjugate Consulting

Reis, Isildinha Marques, Ph.D. . . . . . . . . . . . . . . .University of Miami

Reiser, Jakob, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

Repasky, Elizabeth A., Ph.D. . . . . . . . . . . . . . . . .Roswell Park Cancer Institute Corporation

Resing, Katheryn A., Ph.D. . . . . . . . . . . . . . . . . .University of Colorado at Boulder

Reuben, James M., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Reya, Tannishtha, Ph.D. . . . . . . . . . . . . . . . . . . .Duke University

Reynolds, Charles Patrick, M.D., Ph.D. . . . . . . . . .University of Southern California

Rice, Kevin G., M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Iowa

Richards, Nigel Gordon John, Ph.D. . . . . . . . . . . .University of Florida

Rich-Edwards, Janet W., Ph.D. . . . . . . . . . . . . . . .Brigham and Women’s Hospital

Richman, Carol M., M.D. . . . . . . . . . . . . . . . . . .University of California, Davis

Richmond, Robert C., Ph.D. . . . . . . . . . . . . . . . . .Analytical Spectral Devices, Inc.

Riggins, Gregory J., M.D., Ph.D. . . . . . . . . . . . . .Johns Hopkins University

Ringquist, Steven M., Ph.D. . . . . . . . . . . . . . . . . .University of Pittsburgh

Rios, Elena V., M.D. . . . . . . . . . . . . . . . . . . . . . .National Hispanic Medical Association

Risendal, Betsy C., Ph.D. . . . . . . . . . . . . . . . . . . .University of Colorado, Denver

Ritenbaugh, Cheryl K., Ph.D. . . . . . . . . . . . . . . . .National College of Naturopathic Medicine

Rivard, Mark J., Ph.D. . . . . . . . . . . . . . . . . . . . .New England Medical Center Hospitals

Roback, John D., M.D., Ph.D. . . . . . . . . . . . . . . .Emory University

Roberge, Michel, Ph.D. . . . . . . . . . . . . . . . . . . . .University of British Columbia

Roberts, Charles T., Ph.D. . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Robinson, Daniel R., Ph.D. . . . . . . . . . . . . . . . . .University of California, Davis

Roden, Richard, Ph.D. . . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Rodgers, William H., M.D., Ph.D. . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Rodi, Diane J., Ph.D. . . . . . . . . . . . . . . . . . . . . .Argonne National Laboratory

Rodland, Karin D., Ph.D. . . . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratories

Rodriguez-Bigas, Miguel, M.D. . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Rogatko, Andre, Ph.D. . . . . . . . . . . . . . . . . . . . .Emory University

Rogers, Adrianne E., M.D. . . . . . . . . . . . . . . . . . .Boston University Medical Campus

Rogers, Buck E., Ph.D. . . . . . . . . . . . . . . . . . . . .Washington University

Rohr, Jurgen, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Kentucky

Romano, Louis J., Ph.D. . . . . . . . . . . . . . . . . . . .Wayne State University

Romkes, Marjorie, Ph.D. . . . . . . . . . . . . . . . . . . .University of Pittsburgh

Ronai, Ze’ev A., Ph.D. . . . . . . . . . . . . . . . . . . . .Burnham Institute

Root, Richard T., M.S. . . . . . . . . . . . . . . . . . . . . .Bion Diagnostic Sciences

Rose, Julia H., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Rosen, Coleman W., M.S. . . . . . . . . . . . . . . . . . .Radameirca II, LLC

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

139

Rosenfeld, Kenneth, M.D. . . . . . . . . . . . . . . . . . .Brentwood Biomedical Research Institute

Ross, Jeffrey S., M.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Roth, Kevin A., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Roth, Michael D., M.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Rothschild, Michael L., Ph.D. . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Roubideaux, Yvette, M.D. . . . . . . . . . . . . . . . . . .University of Arizona

Roy, Saroj K., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Polyorg, Inc.

Royce, Melanie E., M.D., Ph.D. . . . . . . . . . . . . . .University of New Mexico, Albuquerque

Rozen, Steven G., Ph.D. . . . . . . . . . . . . . . . . . . .Whitehead Institute for Biomedical Research

Rubin, Eric H., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Rubnitz, Jeffrey E., M.D., Ph.D. . . . . . . . . . . . . . .St. Jude Children’s Research Hospital

Ruffin, Mack T., M.D., . . . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Ruggiero, Christy E., Ph.D. . . . . . . . . . . . . . . . . .University of California, Los Alamos National Laboratory

Rundell, M. Kathleen, Ph.D. . . . . . . . . . . . . . . . . .Northwestern University

Rusling, James F., Ph.D. . . . . . . . . . . . . . . . . . . .University of Connecticut Storrs

Russell, Stephen J., M.D., Ph.D. . . . . . . . . . . . . . .Mayo Clinic, Rochester

Russo, Jose, M.D. . . . . . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Rutledge, John C., M.D. . . . . . . . . . . . . . . . . . . .University of California, Davis

Rybak, Mary E., M.D. . . . . . . . . . . . . . . . . . . . . .Johnson & Johnson

Rybicki, Benjamin A., Ph.D. . . . . . . . . . . . . . . . . .Henry Ford Health System

S Saelens, Brian E., Ph.D. . . . . . . . . . . . . . . . . . . . .Children’s Hospital Medical Center, Cincinnati

Said, Jonathan W., M.D., Ph.D. . . . . . . . . . . . . . .University of California, Los Angeles

Samuel, John, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Alberta

Sanders, Jean E., M.D. . . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

Sarikaya, Mehmet, Ph.D. . . . . . . . . . . . . . . . . . . .University of Washington

Sarkaria, Jann N., M.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Sarna, Linda P., Ph.D., R.N. . . . . . . . . . . . . . . . .University of California, Los Angeles

Satia, Jessie A., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Sausville, Edward A., M.D., Ph.D. . . . . . . . . . . . .University of Maryland Hospital

Sawicki, Janet A., Ph.D. . . . . . . . . . . . . . . . . . . .Lankenau Institute for Medical Research

Saxe, Gordon A., M.D., Ph.D. . . . . . . . . . . . . . . .University of California, San Diego

Sayre, James W., Ph.D. . . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Schad, Peter A., Ph.D. . . . . . . . . . . . . . . . . . . . .Pathosense Inc.

Scheid, Dewey C., M.D. . . . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Scheinberg, David A., M.D., Ph.D. . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Schell, Michael J., Ph.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Schellhase, Kenneth G., M.D. . . . . . . . . . . . . . . .Medical College of Wisconsin

Schiller, Joan H., M.D. . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Schleiss, Mark R., M.D. . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Schmidt, Ann Marie, M.D., Ph.D. . . . . . . . . . . . . .Columbia University College Physicians and Surgeons

Schnitzer, Jan E., M.D. . . . . . . . . . . . . . . . . . . . .Sidney Kimmel Cancer Center

Schnoll, Robert A., Ph.D. . . . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Schraeder, Cheryl D., Ph.D., R.N. . . . . . . . . . . . . .Carle Foundation Hospital, Urbana

Schrag, Deborah, M.D. . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Schroeder, Jane, D.V.M., Ph.D. . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Schuller, Hildegard M., D.V.M., Ph.D. . . . . . . . . . .Tennessee College of Veterinary Medicine

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

140

Schumacher, Karen L., Ph.D., R.N. . . . . . . . . . . . .University of Pennsylvania

Schwartz, Ann G., Ph.D. . . . . . . . . . . . . . . . . . . .Wayne State University

Schwartz, David C., Ph.D. . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Schwartz, Gary G., M.D., Ph.D. . . . . . . . . . . . . .Wake Forest University Health Sciences Center

Schwartz, Jeffrey L., Ph.D. . . . . . . . . . . . . . . . . .University of Washington

Schwartz, Joel L., D.M.D., M.D. . . . . . . . . . . . . .University of Illinois, Chicago

Schwartz, Stephen Marc, Ph.D. . . . . . . . . . . . . . .University of Washington

Schwartz, Stuart, Ph.D. . . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Scott, Charles B., Ph.D. . . . . . . . . . . . . . . . . . . .Children’s Hospital of Philadelphia

Semenov, Serguei Y., M.D., Ph.D. . . . . . . . . . . . . .MWI, LLC

Semmes, Oliver John, Ph.D. . . . . . . . . . . . . . . . . .Eastern Virginia Medical School

Serody, Jonathan S., M.D., Ph.D. . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Sevick-Muraca, Eva M., Ph.D. . . . . . . . . . . . . . . .Baylor College of Medicine

Seymour, Lesley K., M.D., Ph.D. . . . . . . . . . . . . .National Cancer Institute Canada CTG, Queens University

Shaaban, Aimen F., M.D. . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Shah, Keerti V., M.D., Ph.D. . . . . . . . . . . . . . . . .Johns Hopkins School of Public Health

Shannon, Jackilen, Ph.D. . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Sharon, Jacqueline, Ph.D. . . . . . . . . . . . . . . . . . .Boston University Medical Campus

Shaw, Edward G., M.D. . . . . . . . . . . . . . . . . . . . .Wake Forest University

Shea, Thomas B., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Massachusetts, Lowell

Sheikh, M. Saeed, M.D., Ph.D. . . . . . . . . . . . . . .Upstate Medical University

Shekhar, Raj, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Shelby, Jane, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Wyoming Research Innovations, Inc.

Sherman, Simon, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Sherry, A. Dean, Ph.D. . . . . . . . . . . . . . . . . . . . .University of Texas Dallas

Shibata, Darryl K., M.D. . . . . . . . . . . . . . . . . . . .University of Southern California

Shields, Anthony F., M.D., Ph.D. . . . . . . . . . . . . .Wayne State University

Shriver, Mark D., Ph.D. . . . . . . . . . . . . . . . . . . . .Pennsylvania State University, University Park

Shroyer, Kenneth Reed, M.D., Ph.D. . . . . . . . . . . .University of Colorado, Denver

Shuman, Marc A., M.D. . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Shyr, Yu, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Vanderbilt University Medical School

Sidransky, David, M.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Silletti, Steven A., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, San Diego

Silver, Robert B., Ph.D. . . . . . . . . . . . . . . . . . . . .Marine Biological Laboratory

Simione, Frank Peter, M.S. . . . . . . . . . . . . . . . . . .American Type Culture Collection

Simmen, Rosalia C., Ph.D. . . . . . . . . . . . . . . . . . .Arkansas Children’s Hospital Research Institute

Simon, Cassandra E., Ph.D. . . . . . . . . . . . . . . . . .University of Alabama, Tuscaloosa

Simon, Scott Irwin, Ph.D. . . . . . . . . . . . . . . . . . .University of California, Davis

Simoneau, Anne R., M.D. . . . . . . . . . . . . . . . . . .University of California, Irvine

Sims, Millicent . . . . . . . . . . . . . . . . . . . . . . . . . .African American Cancer Support Group

Singer, Mendel E., Ph.D. . . . . . . . . . . . . . . . . . . .Case Western Reserve University

Singh, Karan P., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of North Texas Health Science Center

Singh, Sheo, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Merck & Co., Inc.

Sison, Cristina P., Ph.D. . . . . . . . . . . . . . . . . . . . .Feinstein Institute for Medical Research

Siuzdak, Gary E., Ph.D. . . . . . . . . . . . . . . . . . . . .Scripps Research Institute

Sixbey, John W., M.D. . . . . . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, Shreveport

Skipper, Paul L., Ph.D. . . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

141

Sklar, Charles A., M.D. . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Slaga, Thomas J., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas Health Sciences Center, San Antonio

Slater, Michael D., Ph.D. . . . . . . . . . . . . . . . . . . .Ohio State University

Sligh, James E., M.D., Ph.D. . . . . . . . . . . . . . . . .Vanderbilt University

Sloan, Jeff A., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Smith, Brian Richard, M.D. . . . . . . . . . . . . . . . . .Yale University

Snetselaar, Linda G., Ph.D. . . . . . . . . . . . . . . . . .University of Iowa

So, Peter T., Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Soliman, Amr, M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Sondak, Vernon K., M.D. . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Song, Chang W., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Minnesota Medical School

Sorensen, Glorian C., Ph.D. . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Sorenson, George D., M.D. . . . . . . . . . . . . . . . . .Dartmouth College

Sowa, Marianne Barbara, Ph.D. . . . . . . . . . . . . . .Pacific Northwest National Laboratory

Speicher, David W., Ph.D. . . . . . . . . . . . . . . . . . .Wistar Institute

Speyer, James, M.D. . . . . . . . . . . . . . . . . . . . . . .New York University Medical Center

Spink, David C., Ph.D. . . . . . . . . . . . . . . . . . . . .New York State Department of Health

Spriggs, David R., M.D. . . . . . . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Squire, Jeremy A., Ph.D. . . . . . . . . . . . . . . . . . . .Ontario Cancer Institute

Staab, Edward V., M.D. . . . . . . . . . . . . . . . . . . . .Wake Forest University

Stadler, Walter M., M.D. . . . . . . . . . . . . . . . . . . .University of Chicago

Stamp, Velma Grant, B.A. . . . . . . . . . . . . . . . . . .University of South Carolina

Stanbridge, Eric J., Ph.D. . . . . . . . . . . . . . . . . . .University of California, Irvine

Stapleton, Sandra Joan, M.S. . . . . . . . . . . . . . . . .R2 Technology Inc.

Stein, C.A., M.D., Ph.D. . . . . . . . . . . . . . . . . . . .Montefiore Medical Center, Bronx, NY

Stein, Gary S., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Massachusetts Medical School, Worcester

Stein, John P., M.D. . . . . . . . . . . . . . . . . . . . . . .University of Southern California

Stern, David F., Ph.D. . . . . . . . . . . . . . . . . . . . . .Yale University

Sternfeld, Barbara, Ph.D. . . . . . . . . . . . . . . . . . . .Kaiser Foundation Research Institute

Stevens, Victoria L., Ph.D. . . . . . . . . . . . . . . . . . .American Cancer Society

Stoica, Adriana, Ph.D. . . . . . . . . . . . . . . . . . . . . .Georgetown University

Stokoe, David H., Ph.D. . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Stotts, R.C., Ph.D., R.N. . . . . . . . . . . . . . . . . . . .University of Tennessee Health Science Center

Strano, Michael S., Ph.D. . . . . . . . . . . . . . . . . . .University of Illinois, Urbana-Champaign

Strickland, Carolyn June, Ph.D., R.N. . . . . . . . . . .University of Washington

Strickler, Howard D., M.D. . . . . . . . . . . . . . . . . .Yeshiva University

Su, Ying-Hsiu, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Drexel University College of Medicine

Subramanian, Manny R., Ph.D. . . . . . . . . . . . . . .Best Medical International, Inc.

Sun, Duxin, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Glycomex Technologies, LLC

Sun, Luzhe, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, San Antonio

Sundaram, Sujatha, Ph.D. . . . . . . . . . . . . . . . . . .Virginia Commonwealth University

Suntharalingam, Nagalingam, Ph.D. . . . . . . . . . . .Thomas Jefferson University Hospital

Swaan, Peter W., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Swanson, Basil I., M.D., Ph.D. . . . . . . . . . . . . . . .University Of California, Los Alamos National Laboratory

Sweeney, Christopher J., M.D. . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Swenerton, Kenneth Douglas, M.D. . . . . . . . . . . .University of British Columbia

Szmacinski, Henryk, Ph.D. . . . . . . . . . . . . . . . . . .Microcosm, Inc.

Sznol, Mario, M.D. . . . . . . . . . . . . . . . . . . . . . . .Vion Pharmaceuticals, Inc.

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

142

T Tabb, Joel, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Agave Biosystems

Takayama, Shinichi, M.D., Ph.D. . . . . . . . . . . . . .Medical College of Georgia

Takayama, Shuichi, Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Takimoto, Chris H., M.D., Ph.D. . . . . . . . . . . . . .Cancer Therapy and Research Center

Talavera, Gregory A., M.D., Ph.D. . . . . . . . . . . . .San Diego State University

Tan, Wai-Yuan, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Memphis

Tang, Careen K., Ph.D. . . . . . . . . . . . . . . . . . . . .Georgetown University

Tang, Cha-Mei, Ph.D. . . . . . . . . . . . . . . . . . . . . .Creative Microtech, Inc.

Tanguay, Robert L., Ph.D. . . . . . . . . . . . . . . . . . .Columbia University Health Sciences Center

Tanjasiri, Sora P., Ph.D. . . . . . . . . . . . . . . . . . . .California State University, Fullerton

Tao, Lianhui, M.D., Ph.D. . . . . . . . . . . . . . . . . . .Ohio State University

Taylor, Ann G., R.N. . . . . . . . . . . . . . . . . . . . . . .Cornell University Medical Center

Taylor, Clive R., M.D., Ph.D. . . . . . . . . . . . . . . . .University of Southern California

Taylor, Jeremy Mg, Ph.D. . . . . . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Taylor, Richard E., Ph.D. . . . . . . . . . . . . . . . . . . .University of Notre Dame

Taylor, Russell H., Ph.D. . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Taylor, Wendell C., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, Houston

Tenforde, Thomas S., Ph.D. . . . . . . . . . . . . . . . . .National Council on Radiation Protection & Measurements

Teno, Joan M., M.D., . . . . . . . . . . . . . . . . . . . . .Brown University

Teschendorf, Bonnie, Ph.D. . . . . . . . . . . . . . . . . .American Cancer Society

Teufel-Shone, Nicolette I., Ph.D. . . . . . . . . . . . . . .University of Arizona

Tew, Kenneth D., Ph.D. . . . . . . . . . . . . . . . . . . . .Novelos Therapeutics, Inc.

Tewson, Timothy J., Ph.D. . . . . . . . . . . . . . . . . . .University of Iowa

Thomas, James P., M.D., Ph.D. . . . . . . . . . . . . . .University of Wisconsin, Madison

Thomas, Sara Moody, Ph.D. . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

Thomas, T.J., Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of Medicine and Dentistry of NJ-R.W. Johnson Medical School

Thompson, E.A., Ph.D. . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine Jacksonville

Thorp, Richard L. . . . . . . . . . . . . . . . . . . . . . . . .Multi-Media Systems, Inc.

Thorsen, Todd A., Ph.D. . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Thrall, Brian D., Ph.D. . . . . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratory

Threadgill, David W., Ph.D. . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Thundat, Thomas George, Ph.D. . . . . . . . . . . . . . .UT-Battelle, LLC-Oak Ridge National Laboratory

Timchalk, Charles A., Ph.D. . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratories

Tlsty, Thea D., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of California, San Francisco

Toburen, Larry H., Ph.D. . . . . . . . . . . . . . . . . . . .East Carolina University

Tollestrup, Kristine, Ph.D. . . . . . . . . . . . . . . . . . .University of New Mexico

Toretsky, Jeffrey A., M.D. . . . . . . . . . . . . . . . . . .Naviscan Pet Systems, Inc.

Toscano, William A., Ph.D. . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Tracy, J. Kathleen, Ph.D. . . . . . . . . . . . . . . . . . . .University of Maryland, Baltimore School of Medicine

Trask, Peter C., Ph.D. . . . . . . . . . . . . . . . . . . . . .Miriam Hospital

Trauth, Jeanette M., Ph.D. . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Traxler, Carol Bloomquest, Ph.D. . . . . . . . . . . . . .Gallaudet University

Treadway, Joseph A., Ph.D. . . . . . . . . . . . . . . . . .Quantum Dot Corporation

Triche, Timothy J., M.D., Ph.D. . . . . . . . . . . . . . .Novelix Pharmaceuticals, Inc.

True, Lawrence D., M.D. . . . . . . . . . . . . . . . . . . .University of Washington

Truitt, Robert L., Ph.D. . . . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

143

Tsao, Ming-Sound, M.D. . . . . . . . . . . . . . . . . . . .Princess Margaret Hospital

Tsui, Benjamin M., Ph.D. . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Tucker, Thomas C., Ph.D. . . . . . . . . . . . . . . . . . .University of Kentucky

Turchi, John J., Ph.D. . . . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Turker, Mitchell S., Ph.D. . . . . . . . . . . . . . . . . . . .Oregon Health and Science University

Turner, Leigh, Ph.D. . . . . . . . . . . . . . . . . . . . . . .McGill University

Tweardy, David J., M.D. . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Tycko, Benjamin, M.D., Ph.D. . . . . . . . . . . . . . . .Gordon Research Conferences

U Underwood, Willie, M.D., Ph.D. . . . . . . . . . . . . . .University of Michigan, Ann Arbor

Unger, Elizabeth R., M.D., Ph.D. . . . . . . . . . . . . .Centers for Disease Control and Prevention

Unger, Gretchen M., Ph.D. . . . . . . . . . . . . . . . . .Genesegues, Inc.

Urban, Nicole D., Ph.D. . . . . . . . . . . . . . . . . . . .Fred Hutchinson Cancer Research Center

V Vadaparampil, Susan T., Ph.D. . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Vaughan, William P., M.D. . . . . . . . . . . . . . . . . . .University of Alabama School of Medicine

Velie, Ellen M., Ph.D. . . . . . . . . . . . . . . . . . . . . .Michigan State University

Verlee, Donald, Ph.D. . . . . . . . . . . . . . . . . . . . . .Abbott Laboratories

Vicini, Paolo, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Washington

Vickers, Andrew J., Ph.D. . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Vieweg, Johannes W. G., M.D. . . . . . . . . . . . . . . .Duke University

Villanueva, Augusta M., Ph.D. . . . . . . . . . . . . . . .Drexel University

Villarreal, Roberto, M.D., Ph.D. . . . . . . . . . . . . . .University of Texas Health Science Center

Vincek, Vladimir, M.D., Ph.D. . . . . . . . . . . . . . . .University of Miami

Virnig, Beth A., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Minnesota, Twin Cities

Visuri, Steven R., Ph.D. . . . . . . . . . . . . . . . . . . . .Prodesse, Inc.

Vitkin, Alex, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .University of Toronto

Vogel, Carl-Wilhelm E., M.D., Ph.D. . . . . . . . . . . .University of Hawaii, Manoa

Vogelbaum, Michael A., M.D., Ph.D. . . . . . . . . . .Case Western Reserve University

Vogelzang, Nicholas J., M.D. . . . . . . . . . . . . . . . .University of Chicago Medical Center

Vogt, Peter K., Ph.D. . . . . . . . . . . . . . . . . . . . . .Scripps Research Institute

Vohra, Yogesh K., Ph.D. . . . . . . . . . . . . . . . . . . .University of Alabama, Birmingham

Voldman, Joel, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

Volkert, Wynn A., Ph.D. . . . . . . . . . . . . . . . . . . .University of Missouri, Columbia

Von Kalle, Christof, M.D., Ph.D. . . . . . . . . . . . . .Cincinnati Children’s Research Foundation

Vose, Julie M., M.D., Ph.D. . . . . . . . . . . . . . . . . .University of Nebraska Medical Center

Vuori, Kristiina, M.D., Ph.D. . . . . . . . . . . . . . . . .Burnham Institute

W Wachsman, William, M.D., Ph.D. . . . . . . . . . . . . .University of California, San Diego

Wade, Amy B., M.D. . . . . . . . . . . . . . . . . . . . . .University of Michigan

Waggoner, Alan S., Ph.D. . . . . . . . . . . . . . . . . . .Mellon Pitts Corporation

Wahba, Grace, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Wahl, Richard L., M.D. . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Wainwright, William H., Ph.D. . . . . . . . . . . . . . . .Wyeth Ayerst Research

Walborg, Earl F., Ph.D. . . . . . . . . . . . . . . . . . . . .Dermigen, Inc.

Waldman, Frederic M., M.D., Ph.D. . . . . . . . . . . .California Pacific Medical Center-Pacific Camp

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

144

Waldman, Scott A., M.D., Ph.D. . . . . . . . . . . . . .Thomas Jefferson University

Walker, Gilbert C., Ph.D. . . . . . . . . . . . . . . . . . . .University of Toronto

Waller, Edmund K., M.D., Ph.D. . . . . . . . . . . . . . .Emory University

Wallner, Paul E., D.O. . . . . . . . . . . . . . . . . . . . . .Food and Drug Administration

Walters, Karina L., Ph.D. . . . . . . . . . . . . . . . . . . .University of Washington

Wang, Binghe, M.D., Ph.D. . . . . . . . . . . . . . . . . .Johns Hopkins University

Wang, Kenneth K., M.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Wang, Peng George, Ph.D. . . . . . . . . . . . . . . . . .Ohio State University

Wang, Tao, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . .Medical College of Wisconsin

Wang, Yue J., M.D., Ph.D. . . . . . . . . . . . . . . . . .Virginia Polytechnic Institute and State University

Ward, John H., M.D. . . . . . . . . . . . . . . . . . . . . .University of Utah

Ward, Pamela, Ph.D. . . . . . . . . . . . . . . . . . . . . . .University of California, Irvine

Ward, Sandra E., Ph.D., R.N. . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Ware, Carl F., Ph.D. . . . . . . . . . . . . . . . . . . . . . .La Jolla Institute for Allergy and Immunology

Washington, Mary K., M.D., Ph.D. . . . . . . . . . . .Vanderbilt University

Weber, Michael J., Ph.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Weeks, Eric R., Ph.D. . . . . . . . . . . . . . . . . . . . . .Emory University

Wei, Wei-Zen, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Wayne State University

Wei, Yen, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .Drexel University

Weichert, Jamey P., M.D., Ph.D. . . . . . . . . . . . . .University of Wisconsin, Madison

Weier, Heinz-Ulrich G., Ph.D. . . . . . . . . . . . . . . . .Ernest Orlando Lawrence Berkley National Laboratory

Weinberg, Andrew D., Ph.D. . . . . . . . . . . . . . . . .Providence Portland Medical Center

Weinberg, David S., M.D., . . . . . . . . . . . . . . . . .Fox Chase Cancer Center

Weiner, Bryan J., Ph.D. . . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Weiner, George J., M.D. . . . . . . . . . . . . . . . . . . .University of Iowa

Weiss, Geoffrey R., M.D. . . . . . . . . . . . . . . . . . . .University of Virginia, Charlottesville

Weiss, Heidi, Ph.D. . . . . . . . . . . . . . . . . . . . . . . .Baylor College of Medicine

Weissfeld, Joel L., M.D. . . . . . . . . . . . . . . . . . . .University of Pittsburgh, Pittsburgh

Weissman, Sherman M., M.D. . . . . . . . . . . . . . . .Yale University

Weston, Brent W., M.D. . . . . . . . . . . . . . . . . . . .University of North Carolina, Chapel Hill

Westphall, Michael S., Ph.D. . . . . . . . . . . . . . . . .University of Wisconsin, Madison

Wheatley, Barnarese, M.P.H. . . . . . . . . . . . . . . . .Alameda County Medical Center

Wheatley, Margaret A., Ph.D. . . . . . . . . . . . . . . .Drexel University

White, Forest M., Ph.D. . . . . . . . . . . . . . . . . . . .Massachusetts Institute of Technology

White, John G., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Wisconsin, Madison

White, Lisa L., Ph.D. . . . . . . . . . . . . . . . . . . . . . .Rock Against Cancer

Whiteside, Theresa L., Ph.D. . . . . . . . . . . . . . . . .University of Pittsburgh

Wickstrom, Eric, Ph.D. . . . . . . . . . . . . . . . . . . . .Thomas Jefferson University

Wieder, Robert, M.D., Ph.D. . . . . . . . . . . . . . . . .University of Medicine and Dentistry of New Jersey

Wiener, Erik C., Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Pittsburgh

Wiernik, Peter H., M.D. . . . . . . . . . . . . . . . . . . .Our Lady of Mercy Medical Center

Wiggins, Charles L., Ph.D. . . . . . . . . . . . . . . . . . .The University of New Mexico

Wilburn, Louella S., M.S. . . . . . . . . . . . . . . . . . . .People Living With Cancer

Wilkie, Diana J., Ph.D., R.N. . . . . . . . . . . . . . . . .University of Illinois, Chicago

Willey, James C., M.D. . . . . . . . . . . . . . . . . . . . .Medical College of Ohio

Williams, Donna L., M.P.H. . . . . . . . . . . . . . . . . .Louisiana State University Health Science Center, New Orleans

Williams, Valerie S.L., Ph.D. . . . . . . . . . . . . . . . . .RTI Health Solutions

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

145

Williamson, John S., Ph.D. . . . . . . . . . . . . . . . . . .University of Mississippi

Williard, Paul G., Ph.D. . . . . . . . . . . . . . . . . . . . .Brown University

Willman, Cheryl L., M.D. . . . . . . . . . . . . . . . . . . .University of New Mexico

Wilson, Barbara A., Ph.D. . . . . . . . . . . . . . . . . . .Jackson State University

Wilson, Brian C., Ph.D. . . . . . . . . . . . . . . . . . . . .University of Toronto

Wilson, James M., M.D., Ph.D. . . . . . . . . . . . . . .University of Pennsylvania

Wilusz, Jeffrey, Ph.D. . . . . . . . . . . . . . . . . . . . . .PTC Therapeutics, Inc.

Winick, Naomi J., M.D. . . . . . . . . . . . . . . . . . . . .University of Texas SW Medical Center, Dallas

Wiseman, Robert W., Ph.D. . . . . . . . . . . . . . . . . .Michigan State University

Witherspoon, Yvonne, B.A. . . . . . . . . . . . . . . . . .Dana-Farber Cancer Institute

Witzig, Thomas E., M.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Wolinsky, Steven M., M.D. . . . . . . . . . . . . . . . . .Northwestern University

Woloschak, Gayle E., Ph.D. . . . . . . . . . . . . . . . . .Northwestern University

Wong, Franklin C., M.D., Ph.D. . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Wong, Gilbert Y., M.D. . . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Wood, Marie E., M.D. . . . . . . . . . . . . . . . . . . . . .University of Vermont and State Agricultural College

Woodle, Martin C., Ph.D. . . . . . . . . . . . . . . . . . .Intradigm Corporation

Woods, Virgil L., M.D. . . . . . . . . . . . . . . . . . . . .University of California, San Diego

Wooley, Karen L., Ph.D. . . . . . . . . . . . . . . . . . . .Washington University

Woolley, Adam T., Ph.D. . . . . . . . . . . . . . . . . . . .Brigham Young University

Woster, Patrick M., Ph.D. . . . . . . . . . . . . . . . . . .Wayne State University

Wriggers, Willy R., Ph.D. . . . . . . . . . . . . . . . . . .University of Texas Health Science Center, Houston

Wright, Daniel G., M.D. . . . . . . . . . . . . . . . . . . .National Institute of Diabetes and Digestive and Kidney Diseases

Wright, Kenneth L., Ph.D. . . . . . . . . . . . . . . . . . .H. Lee Moffitt Cancer Center and Research Institute

Wu, Albert W., M.D. . . . . . . . . . . . . . . . . . . . . . .Johns Hopkins University

Wu, Xifeng, M.D., Ph.D. . . . . . . . . . . . . . . . . . . .University of Texas M.D. Anderson Cancer Center

Y Yan, Lin, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . . .Protein Technologies International

Yang, Chung S., Ph.D. . . . . . . . . . . . . . . . . . . . .Rutgers the State University of New Jersey, New Brunswick

Yee, Douglas, M.D. . . . . . . . . . . . . . . . . . . . . . . .University of Minnesota

Yeung, Anthony T., Ph.D. . . . . . . . . . . . . . . . . . .Institute for Cancer Research

Yoon, Kyonggeun, Ph.D. . . . . . . . . . . . . . . . . . . .Thomas Jefferson University

Young, Charles Y., Ph.D. . . . . . . . . . . . . . . . . . . .Mayo Clinic College of Medicine, Rochester

Young, James F., Ph.D. . . . . . . . . . . . . . . . . . . . .Medimmune Inc.

Z Zahrbock, Cary A.C., MOTH . . . . . . . . . . . . . . . .United Behavioral Health

Zaider, Marco, Ph.D. . . . . . . . . . . . . . . . . . . . . . .Sloan-Kettering Institute for Cancer Research

Zangar, Richard C., Ph.D. . . . . . . . . . . . . . . . . . .Battelle Pacific Northwest Laboratories

Zanzonico, Pat B., Ph.D. . . . . . . . . . . . . . . . . . . .Memorial Sloan-Kettering Cancer Center

Zapka, Jane G., Ph.D. . . . . . . . . . . . . . . . . . . . . .Medical University of South Carolina

Zborowski, Maciej, Ph.D. . . . . . . . . . . . . . . . . . .Case Western Reserve University

Zebala, John A., M.D., Ph.D. . . . . . . . . . . . . . . .Syntrix Biosystems, Inc.

Zelterman, Daniel, Ph.D. . . . . . . . . . . . . . . . . . . .Yale Cancer Center

Zeltzer, Lonnie K., M.D. . . . . . . . . . . . . . . . . . . .University of California, Los Angeles

Zemel, Richard S., Ph.D. . . . . . . . . . . . . . . . . . . .University of Arizona

Zhan, Lin, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .University of Massachusetts, Lowell

Zhang, Jian-Ting, Ph.D. . . . . . . . . . . . . . . . . . . . .Indiana University-Purdue University, Indianapolis

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

146

Zhang, Peilin, M.D., Ph.D. . . . . . . . . . . . . . . . . .West Virginia University

Zhao, Shaying, Ph.D. . . . . . . . . . . . . . . . . . . . . .University of Georgia

Zharov, Vladimir P., Ph.D. . . . . . . . . . . . . . . . . . .University of Arkansas Medical Sciences Center, Little Rock

Zheng, Tongzhang, M.D., Ph.D. . . . . . . . . . . . . . .Yale University

Zheng, Wei, M.D., Ph.D. . . . . . . . . . . . . . . . . . . .Vanderbilt University

Zheng, Xiaofeng Steven, Ph.D. . . . . . . . . . . . . . . .University of Medicine and Dentistry of NJ-R.W. Johnson Medical School

Zheng, Yi, Ph.D. . . . . . . . . . . . . . . . . . . . . . . . . .Children’s Hospital Medical Center, Cincinnati

Zhou, Jin-Rong, Ph.D. . . . . . . . . . . . . . . . . . . . . .Beth Israel Deaconess Medical Center

Zuna, Rosemary E., M.D. . . . . . . . . . . . . . . . . . .University of Oklahoma Health Sciences Center

Total Number of D-3 Reviewers: 1,400

Appendix D-3: Consultants Serving on SEPs
NCI/DEA Annual Report 2005

147

Appendix E: NCI Grant Guidelines and Descriptions

Below is a brief description of NIH grants, contracts, and extramural policy notices. Additional

information about these and other administrative supplements to research grants, guidelines, study

section rosters, and information on the Center for Scientific Review, NIH, may be obtained by contacting the NIH Referral Office, Division of Research, or see NCI’s DEA Web page on Grants

Guidelines and Descriptions at http://deainfo.nci.nih.gov/ flash/awards.htm.

C Series: Research Construction Programs

C06 Research Facilities Construction Grants

To provide matching Federal funds, up to 75 percent, for construction or major remodeling

to create new research facilities. In addition to basic research laboratories, this may include,

under certain circumstances, animal facilities and/or limited clinical facilities where they are

an integral part of an overall research effort.

F Series: Fellowship Programs

F31 Predoctoral Individual National Research Service Award (NRSA)

To provide predoctoral individuals with supervised research training in specified health and

health-related areas leading toward a research degree (e.g., Ph.D.).

F31 Predoctoral Fellowship—Minority Students

A fellowship award that provides predoctoral minority students with supervised research

training in specified health and health-related areas leading toward the research degree (e.g.,

Ph.D.).

F31 Predoctoral Fellowship—Students with Disabilities

A fellowship award that provides predoctoral students with disabilities with supervised research training in specified health and health-related areas leading toward the research

degree (e.g., Ph.D.).

F32 National Research Service Award for Individual Postdoctoral Fellows

To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.

F33 National Research Service Award for Senior Fellows

To provide opportunities for experienced scientists to make major changes in the direction

of research careers, broaden scientific backgrounds, acquire new research capabilities,

enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Series: Career Development Programs

K01 The Howard Temin Award

An NCI-specific variant of the NIH Mentored Research Scientist Development Award that

is designed to provide research scientists with an additional period of sponsored research

experience as a way to gain expertise in a research area new to the applicant or in an area

that would demonstrably enhance the applicant’s scientific career.
NCI/DEA Annual Report 2005

148

K01 Mentored Career Development Award for Underrepresented Minorities

To support scientists committed to research who are in need of both advanced research training and additional experience.

K05 Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population 

Research

To support scientists qualified to pursue independent research that would extend the research

program of the sponsoring institution, or to direct an essential part of this program.

K07 Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award

To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the

population sciences. It supports up to 5 years of combined didactic and supervised (i.e.,

mentored) research experiences to acquire the methodological and theoretical research skills

needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in

the basic sciences, medicine, behavioral sciences, and public health. The K07 award has

been expanded from a scope limited to “preventive oncology” to include the entire spectrum

of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.

K08 Mentored Clinical Scientists Development Award

To provide the opportunity for promising medical scientists with demonstrated aptitude to

develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap

in specific shortage areas within U.S. health professions institutions.

K08 Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology

A specialized type of Mentored Clinical Scientist Developmental Awards (K08s) that support the development of outstanding clinical research scientists, with this type being

reserved for qualified individuals from under-represented minority groups. Both types of

K08 awards support periods of specialized study for clinically trained professionals who are

committed to careers in research and who have the potential to develop into independent

investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated

aptitudes who belong to under-represented minority groups to develop into independent

investigators, or for faculty members who belong to under-represented minority groups to

pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in

filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.

K12 Institutional Clinical Oncology Research Career Development Award

To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an

interdisciplinary research and development program.

K22 The NCI Transition Career Development Award for Underrepresented Minorities

To provide support to outstanding newly trained basic or clinical investigators to develop

their independent research skills through a two-phase program: an initial period involving

an intramural appointment at the NIH and a final period of support at an extramural instituAppendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

149

tion. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.

K22 The NCI Scholars Program

To provide an opportunity for outstanding new investigators to begin their independent

research careers, first within the special environment of the NCI and then at an institution of

their choice. Specifically, this Program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to

which they are recruited.

K23 Mentored Patient-Oriented Research Career Development Award

To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research

for clinically trained professionals who have the potential to develop into productive clinical investigators.

K23 Mentored Patient-Oriented Research Career Development Award for Underrepresented 

Minorities

To support the career development of investigators who have made a commitment to focus

their research on patient-oriented research. This mechanism provides support for a period of

supervised study and research for clinically trained professionals who have the potential to

develop into productive clinical investigators in patient-oriented research.

K24 Mid-Career Investigator Award in Patient-Oriented Research

To provide support for clinicians to allow them protected time to devote to patient-oriented

research and to act as mentors for beginning clinical investigators. The target candidates are

outstanding clinical scientists engaged in patient-oriented research who are within 15 years

of their specialty training, who can demonstrate the need for a period of intensive research

focus as a means of enhancing their clinical research careers, and who are committed to

mentoring the next generation of clinical investigators in patient-oriented research.

K25 Mentored Quantitative Research Career Development Award

This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the

necessary training and career development required to become involved in multidisciplinary

cancer research.

P Series: Research Program Projects and Centers

P01 Research Program Projects

To support multidisciplinary or multifaceted research programs that have a focused theme.

Each component project should be directly related to and contribute to the common theme.

P20 Exploratory Grants

To support planning for new programs, expansion or modification of existing resources, and

feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the

NIH. These exploratory studies may lead to specialized or comprehensive centers.

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

150

P30 Center Core Grants

To support shared use of resources and facilities for categorical research by investigators

from different disciplines who provide a multidisciplinary approach to a joint research

effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center’s component projects or Program Projects,

though funded independently from them. This support, by providing more accessible resources, is expected to assure greater productivity than that provided through the separate

projects and Program Projects.

P50 Specialized Center Grants

To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to

the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from

Program Project grants in that they are usually developed in response to an announcement

of the programmatic needs of an Institute or Division, and subsequently receive continuous

attention from its staff. Centers also may serve as regional or national resources for special

research purposes.

R Series: Research Projects

R01 Research Project

Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific

focus or objective in his or her area of interest and competence. Institutional sponsorship

assures the NIH that the institution will provide facilities necessary to conduct the research

and will be accountable for the grant funds. Applications are accepted for health-related

research and development in all areas within the scope of the NIH’s mission.

R03 Small Research Grants

Small grants provide research support, specifically limited in time and amount, for activities

such as pilot projects, testing of new techniques, or feasibility studies of innovative, highrisk research, which would provide a basis for more extended research.

R13 Conferences

The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation

with other organizations in supporting conferences rather than provision of sole support.

Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to

inquire in advance concerning possible interest on the part of an awarding Institute/Center

(IC), and to obtain more information on application procedures and costs.

R15 The NIH Academic Research Enhancement Awards (AREA)

To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions’

faculty members to develop new research projects or expand ongoing research activities in

health sciences and to encourage students to participate in the research activity. As funds are

anticipated to continue to be available each year, the NIH is now inviting applications for

AREA grants through a standing, ongoing Program Announcement.

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

151

R21 Exploratory/Developmental Grants

To encourage the development of new research activities in categorical program areas.

(Support generally is restricted in level of support and duration.)

R24 Resource-Related Research Projects

To support research projects that will enhance the capability of resources to serve biomedical research.

R25E Cancer Education Grant Program (CEGP)

A flexible, curriculum-driven program aimed at developing and sustaining innovative 

educational approaches that ultimately will have an impact on reducing cancer incidence,

mortality, and morbidity, as well as on improving the quality of life of cancer patients. The

CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of 

objectives ranging from short courses; to the development of new curricula in academic

institutions; to national forums and seminar series; to hands-on workshop experiences for

the continuing education of health care professionals, biomedical researchers, and the lay

community; to structured short-term research experiences designed to motivate high school,

college, medical, dental, and other health professional students to pursue careers in cancer

research. Education grants can focus on education activities before, during, and after the

completion of a doctoral level degree, as long as they address a need that is not fulfilled 

adequately by any other grant mechanism available at the NIH, and are dedicated to areas

of particular concern to the National Cancer Program.

R25T Cancer Education and Career Development Program

To support development and/or implementation of a program related to a category in one or

more of the areas of education, information, training, technical assistance, coordination, or

evaluation.

R33 Exploratory/Developmental Grants, Phase II

To provide a second phase for support of innovative exploratory and developmental research

activities initiated under the R21 mechanism. Although only R21 awardees are generally 

eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program

competency equivalent to that expected under R33.

R37 Method to Extend Research in Time (MERIT) Award

To provide long-term grant support to investigators whose research competence and 

productivity are distinctly superior and who are highly likely to continue to perform in an

outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or

members of the cognizant National Advisory Council/Board will identify candidates for the

MERIT Award during the course of review of competing research grant applications 

prepared and submitted in accordance with regular PHS requirements.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer

(STTR) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral

research area as described in the solicitations below. Support under the SBIR program is normally

provided for 6 months/$100,000 for Phase I, and 2 years/$500,000 for Phase II. However, applicants

may propose longer periods of time and greater amounts of funds necessary for completion of the

project.

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

152

R41 STTR Grants, Phase I

To support cooperative R&D projects between small business concerns and research institutions, limited in time and amount; to establish the technical merit and feasibility of ideas

that have potential for commercialization.

R42 STTR Grants, Phase II

To support indepth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.

R43 SBIR Grants, Phase I

To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.

R44 SBIR Grants, Phase II

To support indepth development of R&D ideas whose feasibility has been established in

Phase I that are likely to result in commercial products or services.

R55 James A. Shannon Director’s Awards; Guidelines

To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative

and creative approaches; and conduct other discrete projects that can demonstrate their

research capabilities and lend additional weight to their already meritorious applications.

R56 High-Priority, Short-Term Project Award

Beginning in FY2005, this grant will fund, for 1 or 2 years, high-priority new or competing

renewal R01 applications that fall just outside the limits of funding of the participating NIH

Institutes and Centers; recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins. (Investigators may not apply for an R56

grant.) 

S Series: Research-Related Programs

S06 Minority Biomedical Research Support (MBRS)

To strengthen the biomedical research and research training capability of ethnic minority

institutions, and thus establish a more favorable milieu for increasing the involvement of

minority faculty and students in biomedical research.

S07 Biomedical Research Support Grants (NCRR BRSG)

As an example of this funding mechanism, the NIH issued a Request for Applications (RFA)

in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support

for clinical research. Although there is considerable flexibility in the types of activities that

could be supported under the BRSG program, this RFA emphasized the importance of

efforts to enhance the protection of research subjects by means that will be sustained by the

recipient institution after the award period ends. Awardees are also required to collaborate

with other institutions conducting human subjects research and are not currently funded

under this program, to share educational resources, computer technologies, best practices,

etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it will be administered by the National Center for Research

Resources (NCRR).

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

153

S10 Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)

The National Center for Research Resources (NCRR) initiated its competitive Shared 

Instrumentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide

support for expensive state-of-the-art instruments utilized in both basic and clinical research.

This program is designed to meet the special problems of acquisition and updating of 

expensive shared-use instruments that are not generally available through other NIH 

funding mechanisms, such as the regular research project, program project, or center grant

programs. Applications for funds to design or to advance the design of new instruments are

not accepted. The objective of the program is to make available to institutions with a high

concentration of NIH-supported biomedical investigators expensive research instruments

that can only be justified on a shared-use basis and for which meritorious research projects

are described.

T Series: Training Programs

T15 Continuing Education Training Grants

To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with

new developments in the science and technology of the profession.

T32 NIH National Research Service Award—Institutional Research Training Grants

To enable institutions to make National Research Service Awards to individuals selected by

them for predoctoral and postdoctoral research training in specified shortage areas.

U Series: Cooperative Agreements

U01 Research Projects

To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.

U10 Cooperative Clinical Research—Cooperative Agreements

To support clinical evaluation of various methods of therapy and/or prevention in specific

disease areas. These represent cooperative programs between participating institutions and

Principal Investigators, and are usually conducted under established protocols.

U13 Conference—Cooperative Agreements

To coordinate, exchange, and disseminate information related to its program interests, an

NIH Institute or Center can use this type of award to provide funding and direction for

appropriate scientific conferences. These cooperative agreements allow the NCI to partner

with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National

Cancer Program.

U19 Research Program—Cooperative Agreements

To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often

long-term approach. 

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

154

U24 Resource-Related Research Projects—Cooperative Agreements

To support research projects contributing to improvement of the capability of resources to

serve biomedical research.

U54 Specialized Center—Cooperative Agreements

To support any part of the full range of research and development from very basic to 

clinical; may involve ancillary supportive activities such as protracted patient care necessary

to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from 

program projects in that they are usually developed in response to an announcement of the

programmatic needs of an Institute or Division and subsequently receive continual attention

from its staff. Centers may also serve as regional or national resources for special research

purposes, with assistance from staff of the funding component in identifying appropriate 

priority needs.

U56 Exploratory Grants—Cooperative Agreements

To support planning for new programs, expansion or modification of existing resources, and

feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the

NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during

performance of the research activities, as defined in the terms and conditions of award.

Appendix E: NCI Grant Guidelines and Descriptions
NCI/DEA Annual Report 2005

155

AACR American Association for Cancer Research

ACD Advisory Committee to the Director

AHRQ Agency for Healthcare Research and Quality

AISB Applied Information Systems Branch

ARA Awaiting Receipt of Application

AREA Academic Research Enhancement Award

BRSG Biomedical Research Support Grant

BSA Board of Scientific Advisors

BSC Board of Scientific Counselors

CaBIG Cancer Bioinformatics Grid

CAM Complementary and Alternative Medicine

CARRA Consumer Advocates in Research and 

Related Activities

CCR Center for Cancer Research

CCSG Cancer Center Support Grant

CD Career Development

CD Compact Disk

CDC Centers for Disease Control and Prevention

CEGP Cancer Education Grant Program

CIT Center for Information Technology

CM Committee Management

CMBB Comprehensive Minority Biomedical Branch

CMCR Centers for Medical Countermeasures 

Against Radiation

CMO Committee Management Office

CMS Centers for Medicare and Medicaid Services

CMUG Committee Management Users Group

CRCHD Center to Reduce Cancer Health Disparities

CSR Center for Scientific Review

CSS Cascading Style Sheet

CT Computed Tomography

CTEP Cancer Therapy Evaluation Program

CTWG Clinical Trials Working Group

DCB Division of Cancer Biology

DCCPS Division of Cancer Control and Population 

Sciences

DCEG Division of Cancer Epidemiology and Genetics

DCLG Director’s Consumer Liaison Group

DCP Division of Cancer Prevention

DCTD Division of Cancer Treatment and Diagnosis

DEA Division of Extramural Activities

DEAS Division of Extramural Activities Support

DHHS U.S. Department of Health and Human Services

DOD Department of Defense

ECARES Extramural Customer Assistance Request System

EDD Extramural Division Directors

EDRN Early Detection Research Network

EPMC Extramural Program Management Committee

eRA Electronic Research Administration

ESA Extramural Science Administrator

FACA Federal Advisory Committee Act

FDA U.S. Food and Drug Administration

FDG fluoro-2-deoxy-D-glucose

FLARE Fiscal Linked Analysis of Research Emphasis

FOA Funding Opportunity Announcements

FOP Financial Operating Plan

FY Fiscal Year

GSA General Services Administration

HHV Human Herpesvirus

HTLV Human T-Cell Lymphoma/Leukemia Virus

IC Institute/Center

ICMIC In Vivo Cellular and Molecular Imaging Center

IDeA Institutional Development Award

IMAT Innovative Technology for the Molecular Analysis

of Cancer

IMPAC Information for Management, Planning, 

Analysis, and Coordination—database

IRG Initial Review Group

IRM Information Resources Management

ISCS Information Systems and Computer Services

ISTB Information Services Technology Branch

Appendix F: Glossary of Acronyms
NCI/DEA Annual Report 2005

156

IT Information Technology

LOI Letter of Intent

KMDC Knowledge Management for Disease Coding

LRP Loan Repayment Program

MBRS Minority Biomedical Research Support

MERIT Method to Extend Research in Time

MION Monocrystalline Iron Oxide Nanoparticle

MRI Magnetic Resonance Images

NCAB National Cancer Advisory Board

NCCAM National Center for Complementary and

Alternative Medicine

NCDDG National Cooperative Drug Discovery Groups

NCI National Cancer Institute

NCRR National Center for Research Resources

NIAID National Institute of Allergy and 

Infectious Diseases

NIH National Institutes of Health

NLM National Library of Medicine

NOW NCI Online Workplace

NRSA National Research Service Award

NSF National Science Foundation

OCCAM Office of Cancer Complementary 

and Alternative Medicine

OCTR Office of Centers, Training and Resources

OD Office of the Director

OEA Office of Extramural Applications

OER Office of Extramural Research

OFACP Office of Federal Advisory Committee Policy

OLA Office of Liaison Activities

OPERA Office of Policy for Extramural Research 

Administration

ORRPC Office of Referral, Review, and Program 

Coordination

OSB Organ Systems Branch

OTIR Office of Technology and Industrial Relations

PA Program Announcement

PAR Reviewed Program Announcement

PCP President’s Cancer Panel

PCRB Program Coordination and Referral Branch

PET Positron Emission Tomography

PET-CT Positron Emission Tomography-Computed

Tomography

PHS Public Health Service (DHHS)

PRG Progress Review Group

RAEB Research Analysis and Evaluation Branch

R&D Research and Development

REAP Research Enhancement Awards Program

RFA Request for Applications

RFI Request for Information

RFP Request for Proposals

RO Referral Officer

RPC Review Policy Committee

RPDU Review Processing and Distribution Unit

RPG Research Project Grant

RPRB Research Programs Review Branch

RTRB Resources and Training Review Branch

SBIR Small Business Innovation Research

SBM Society of Behavioral Medicine

SEER Surveillance, Epidemiology, and End Results

SEP Special Emphasis Panel

SIC Special Interest Category

SIG Shared Instrumentation Grant

SOP Standard Operating Procedure

SPORE Specialized Program of Research Excellence

SRA Scientific Review Administrator

SREA Scientific Review and Evaluation Award

SRLB Special Review and Logistics Branch

STTR Small Business Technology Transfer Research

TAG Technical Advisory Group

T&E Training and Education

TGEN Translational Genomics Research Institute

TREC Transdisciplinary Research on Energetics 

and Cancer

TRWG Translational Research Working Group

UV Ultraviolet

Appendix F: Glossary of Acronyms
NCI/DEA Annual Report 2005

157

Appendix G: Cancer Information Sources on the Internet

NCI Web Site

The National Cancer Institute maintains a number of Web sites containing information about the

Institute and its programs. All NCI Web sites, including those designed to provide cancer-related

information to the general public and physicians, can be reached from the NCI home page

http://cancer.gov/.

DEA Web Sites

The following Web sites are maintained by the DEA to provide detailed information to researchers

and the public about NCI funding opportunities and the Advisory Boards and groups supported by

the DEA.

http://deainfo.nci.nih.gov/index.htm

DEA home page. Links to the individual DEA Web pages listed below; mission of the

Division; contact information for DEA staff.

Advisory Boards and Groups

http://deainfo.nci.nih.gov/advisory/Boards.htm

Links to the home pages of NCI’s Advisory Boards.

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm

Charter of the President’s Cancer Panel; meeting agendas; meeting minutes; annual reports.

http://deainfo.nci.nih.gov/advisory/ncab.htm

Charter of the National Cancer Advisory Board; members of subcommittees; meeting agendas.

http://deainfo.nci.nih.gov/advisory/ncabminmenu.htm

Full text of NCAB meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa.htm

Charter of the Board of Scientific Advisors; members of subcommittees; meeting agendas.

http://deainfo.nci.nih.gov/advisory/bsaminmenu.htm

Full text of BSA meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/bsaprgr.htm

Program Review Group reports.

http://deainfo.nci.nih.gov/advisory/bsc.htm

Charter of the Board of Scientific Counselors; members of subcommittees.

http://deainfo.nci.nih.gov/advisory/irg.htm

Charter of the Initial Review Group; members of subcommittees.

http://deainfo.nci.nih.gov/advisory/sep.htm

Charter of the Special Emphasis Panel; rosters of recent meetings.

http://deainfo.nci.nih.gov/advisory/joint.htm

Charter of the Advisory Committee to the Director; meeting schedules, agendas, and minutes; members of NCI Director’s Working Groups, Program Review Working Groups, and

Progress Review Working Groups.
NCI/DEA Annual Report 2005

158

http://deainfo.nci.nih.gov/flash/fum/training.htm

http://deainfo.nci.nih.gov/advisory/pog/progress/index.htm

Function and organization of Progress Review Groups; PRG reports and meeting schedules;

members of PRGs.

http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm

Charter of the NCI Director’s Consumer Liaison Group; meeting schedules, agendas, minutes, and meeting summaries.

Funding Opportunities

http://deainfo.nci.nih.gov/funding.htm

Comprehensive information about funding for cancer research; lists of active PAs and RFAs;

recently cleared concepts; grant policies and guidelines; downloadable application forms.

http://deainfo.nci.nih.gov/extra/pa/all_pa.htm

Active PAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/extra/rfa/index.htm

Active RFAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/grantspolicies/index.htm

Links to full-text NCI and NIH policies related to grants and grant review (e.g., Guidelines

on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions

to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative

Agreement Applications).

http://deainfo.nci.nih.gov/flash/awards.htm

Grants Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links to

PAs, RFAs, guidelines, and supplemental materials).

http://deais.nci.nih.gov/Query/Public/QueryForm

A visitor can search the database for information about research grant and contract awards

made by the National Cancer Institute. It includes awards for the current and past 5 fiscal

years. The Web site provides the ability to search the database in various ways, including a

text search of the project abstract and a search of the Special Interest Category (SIC) and

anatomic site codes assigned to the project. 

http://deainfo.nci.nih.gov/whatsnew/news.htm

Extramural events and updates.

NIH Web Sites

http://www.nih.gov

http://era.nih.gov/ElectronicReceipt/

http://grants1.nih.gov/grants/policy/policy.htm

http://grants.nih.gov/grants/guide/index.htm

http://grants.nih.gov/training/extramural.htm

Appendix G: Cancer Information Sources on the Internet
An electronic version of this document can be viewed and downloaded

from the Internet at http://deainfo.nci.nih.gov/
November 2006